Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 1 of 113 Clinical Trial Protocol  
Clinical Trial Protocol Number C-700-01
Title  A Phase 1/2, Open -Label, Multiple Ascending Dose Trial to 
Investigate the Safety, Tolerability, Pharmacokinetics, 
Biological, and Clinical Activity of AGEN2034 in Subjects 
with Metastatic or Locally Advanced Solid Tumors, with Expansion to Second Line Cervical Cancer  
Short Trial Name  [CONTACT_7609] 1/2 Study of AGEN2034 in Advanced Tumors  
Trial Phase  Phase 1/2  
Medical Monitor   
Sponsor  Agenus Inc.  
Original Protocol: 26 October 2016  
Amendment 1: 07 December 2016  
Amendment 2:  11 January 2017  
Amendment 3:  26 September 2017  
Amendment 4:  24 January 2019  
Amendment 5: 27 September 2019  
— Confident
ial —  
This document is the property of Agenus Inc. It is intended for restricted use only and may not be passed on, 
reproduced, published, or used in full or in part without the permission of Agenus.  
NCT #: [STUDY_ID_REMOVED]

Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491309] Blockade .............................................................................................21  
1.1.2.  AGEN2034  .................................................................................................................22  
[IP_ADDRESS].  Summary of Preclinical Data  ......................................................................................22  
[IP_ADDRESS].  Summary of Clinical Data  ..........................................................................................24  
1.1.3.  Safety of Nivolumab  ...................................................................................................24  
[IP_ADDRESS].  Common Adverse Reactions of Nivolumab ...............................................................24  
[IP_ADDRESS].  Notable Immune -Mediated Adverse Reactions of Nivolumab ..................................25  
1.2. Rationale for Dose Selection  ......................................................................................25  
1.2.1.  Starting Dose in Phase 1  .............................................................................................25  
1.2.2.  Dose in Phase 2  ...........................................................................................................27  
1.3. Rationale for Expansion Cohort .................................................................................28  
1.4. Rationale for Biomarker Assessment  .........................................................................29  
1.4.1.  Biomarkers in Phase 1 ................................................................................................29  
1.4.2.  Biomarkers in Phase 2 ................................................................................................29  
1.4.3.  Assessment of PD -L1 Expression in Tumors .............................................................29  
2. OBJECTIVES, ENDPOINTS, AND BENEFIT/RISK ..............................................30  
2.1. Objectives and Endpoints ...........................................................................................30  
2.1.1.  Phase 1  ........................................................................................................................30  
2.1.2.  Phase 2  ........................................................................................................................31  
2.2. Overall Risk/Benefit Assessment ...............................................................................32  
3. INVESTIGATIONAL PLAN  .....................................................................................33  
3.1. Phase 1 (Part A): Dose Escalation  ..............................................................................33  
3.1.1.  Dose -Limiting Toxicity  ..............................................................................................35  
3.1.2.  Stoppi[INVESTIGATOR_304988]........................................................................................36  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 3 of 113 3.1.3.  Backfill Expansion Enrollment for Each Dose Level Cohort in the Phase 1 .............36  
3.2. Phase 2: Dose Expansion Phase .................................................................................[ADDRESS_491310] ..............................................................................46  
5.2. Packaging and Labeling  ..............................................................................................47  
5.3. Storage and Dispensing ..............................................................................................47  
5.4. Dosage and Administration ........................................................................................48  
5.4.1.  AGEN2034  .................................................................................................................48  
[IP_ADDRESS].  Treatment Regimen  ....................................................................................................48  
5.4.2.  Premedication  .............................................................................................................48  
5.4.3.  Treatment of Infusion Related Reactions ...................................................................48  
5.4.4.  Dose Modifications and Treatment Delay  ..................................................................52  
[IP_ADDRESS].  Dose Reductions .........................................................................................................52  
[IP_ADDRESS].  Treatment Delay  .........................................................................................................52  
5.4.5.  Treatment Beyond Disease Progression .....................................................................53  
5.5. Concomitant Treatments  .............................................................................................54  
5.5.1.  Acceptable Concomitant Medications  ........................................................................54  
[IP_ADDRESS].  Rescue Medications and Supportive Care ..................................................................54  
5.5.2.  Prohibited and/or Restricted Treatments  ....................................................................55  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 4 of 113 5.5.3.  Other Restrictions and Precautions .............................................................................56  
5.6. Management of Immune- related Adverse Events  ......................................................56  
5.6.1.  Dermatological Immune -related Adverse Events  .......................................................57  
5.6.2.  Gastrointestinal Immune -related Adverse Events  ......................................................58  
5.6.3.  Pulmonary Immune -related Adverse Events  ..............................................................59  
5.6.4.  Hepatic Immune -related Adverse Events  ...................................................................60  
5.6.5.  Endocrine Immune -related Adverse Events  ...............................................................61  
5.6.6.  Renal Immune -related Adverse Events  ......................................................................62  
5.6.7.  Neurological Immune -related Adverse Events  ...........................................................63  
6. TRIAL ASSESSMENTS AN D PROCEDURES  .......................................................64  
6.1. Phase 1 Schedules of Assessments and Procedures ...................................................64  
6.2. Phase 2 Schedule of Assessments and Procedures  .....................................................70  
6.3. Visit Requirements  .....................................................................................................75  
6.3.1.  Screening  ....................................................................................................................75  
6.3.2.  Treatment Phase  ..........................................................................................................75  
6.3.3.  End-of-Treatment Visits  .............................................................................................75  
[IP_ADDRESS].  Discontinuation Visit  ..................................................................................................75  
[IP_ADDRESS].  Safety Follow -up Visit ................................................................................................75  
6.3.4.  Follow-up Phase .........................................................................................................75  
[IP_ADDRESS].  Follow- up Visits  .........................................................................................................76  
[IP_ADDRESS].  Survival Follow-up (Phase 2 only) .............................................................................76  
6.4. Trial Procedures  ..........................................................................................................76  
6.4.1.  Administrative Procedures ..........................................................................................76  
[IP_ADDRESS].  Informed Consent .......................................................................................................76  
[IP_ADDRESS].  General Informed Consent ..........................................................................................76  
[IP_ADDRESS].  Consent for Pharmacogenomics Assessment (optional) .............................................77  
[IP_ADDRESS].  Review of Inclusion and Exclusion Criteria ...............................................................77  
[IP_ADDRESS].  Emergency Med ical Support and Subject Card ..........................................................77  
[IP_ADDRESS].  Medical History  ..........................................................................................................78  
[IP_ADDRESS].  Review of Baseline Symptoms  ...................................................................................78  
[IP_ADDRESS].  Review of Prior and Concomitant Medications ..........................................................78  
[IP_ADDRESS].  Cancer Disease Details and Prior Treatment  ..............................................................78  
[IP_ADDRESS].  Assignment of Subject Trial Number  .........................................................................79  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 5 of 113 [IP_ADDRESS].  Trial Compliance  ........................................................................................................79  
6.4.2.  Tissue Collection and Tumor Biomarker Assessment ................................................80  
[IP_ADDRESS].  Tissue Collection  ........................................................................................................80  
[IP_ADDRESS].  PD-L1 Expression Assessment ...................................................................................81  
[IP_ADDRESS].  HPV Assessment  ........................................................................................................81  
6.4.3.  Clinical Assessments and Procedures  .........................................................................81  
[IP_ADDRESS].  Review of Adverse Events ..........................................................................................81  
[IP_ADDRESS].  Physical Examination  .................................................................................................82  
[IP_ADDRESS].  Vital Signs, Height and Weight ..................................................................................82  
[IP_ADDRESS].  12-lead Electrocardiogram ..........................................................................................82  
[IP_ADDRESS].  Expanded Electrocardiogram Evaluation (in selected sites only) ..............................82  
[IP_ADDRESS].  Eastern Cooperative Oncology Group Performance ..................................................83  
6.4.4.  Imaging Assessments ..................................................................................................83  
[IP_ADDRESS].  Tumor Imaging ...........................................................................................................83  
[IP_ADDRESS].  Brain Imaging .............................................................................................................83  
[IP_ADDRESS].  Response Assessment  .................................................................................................84  
6.4.5.  Pharmacokinetic, Pharmacodynamic, Genetic, and Other Assessments  ....................85  
[IP_ADDRESS].  Pharmacokinetic Assessments  ....................................................................................85  
[IP_ADDRESS].  Immunogenicity Assessment ......................................................................................85  
[IP_ADDRESS].  Blood Biomarker Assessments ...................................................................................85  
[IP_ADDRESS].  Pharmacogenomics Assessments (Optional)  ..............................................................87  
6.4.6.  Local Laboratory Tests  ...............................................................................................87  
7. ADVERSE EVENTS ..................................................................................................89  
7.1. Adverse Event Definitions ..........................................................................................89  
7.1.1.  Adverse Event  .............................................................................................................89  
7.1.2.  Abnormal Laboratory Findings and Other Abnormal Investigational 
Findings ......................................................................................................................90  
7.1.3.  Adverse Drug Reaction  ...............................................................................................90  
7.1.4.  Serious Adverse Event ................................................................................................90  
7.1.5.  Events That Do Not Meet the Definition of an SAE ..................................................90  
7.1.6.  Events not to be Considered as AEs/SAEs .................................................................91  
7.1.7.  AE/SAEs Observed in Association with Disease Progression ...................................[ADDRESS_491311] for Safety Monitoring  ..........................91  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 6 of 113 7.2. Methods of Recording and Assessing Adverse Events ..............................................92  
7.2.1.  Definition of the Adverse Event Reporting Period .....................................................92  
7.2.2.  Procedure for Reporting SAEs / AESIs ......................................................................92  
[IP_ADDRESS].  Serious Adverse Events ..............................................................................................92  
[IP_ADDRESS].  Adverse Events of Special Interest  .............................................................................93  
[IP_ADDRESS].  Safety Reporting to Health Authorities, Independent Ethics Committees/ 
Institutional Review Boards, and Investigators ..........................................................93  
7.3. Monitoring of Subjects with Adverse Events .............................................................94  
7.4. Pregnancy and In Utero Drug Exposure .....................................................................94  
7.5. AGEN2034 Overdose .................................................................................................95  
8. STATISTICAL CONSIDERATIONS  .......................................................................95  
8.1. Sample Size  ................................................................................................................95  
8.1.1.  Phase 1  ........................................................................................................................95  
8.1.2.  Phase 2  ........................................................................................................................95  
8.2. Analysis Sets  ...............................................................................................................96  
8.3. Description of Statistical Analyses  .............................................................................96  
8.3.1.  General Considerations ...............................................................................................96  
8.3.2.  Analysis of Primary Endpoints ...................................................................................97  
[IP_ADDRESS].  In Phase 1: Dose- limiting Toxicity  .............................................................................97  
[IP_ADDRESS].  In Phase 2: Objective Response Rate .........................................................................97  
8.3.3.  Analysis of Secondary Endpoints ...............................................................................97  
[IP_ADDRESS].  Efficacy Parameters  ....................................................................................................97  
[IP_ADDRESS].  Pharmacokinetic Parameters  .......................................................................................98  
[IP_ADDRESS].  Immunogenicity  ..........................................................................................................98  
[IP_ADDRESS].  Exploratory Biomarkers ..............................................................................................98  
8.3.4.  Safety Analyses  ..........................................................................................................98  
[IP_ADDRESS].  Adverse Events  ...........................................................................................................99  
[IP_ADDRESS].  Laboratory Variables  ..................................................................................................99  
[IP_ADDRESS].  Physical Examination, Vital Signs, and Electrocardiogram  .......................................99  
8.3.5.  Interim and Final Analysis ..........................................................................................99  
9. TRIAL GOVERNANCE AND OVERSIGHT  .........................................................100  
9.1. Safety Monitoring Committee  ..................................................................................100  
9.2. Independent Endpoint Review Committee ...............................................................100  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 7 of 113 9.3. Independent Data Monitoring Committee (IDMC) ..................................................[ADDRESS_491312]  ........................................................103  
10.6.  Clinical Trial Insurance and Compensation to Subjects ...........................................104  
10.7.  Health Authorities  .....................................................................................................104  
11. TRIAL MANAGEMENT  .........................................................................................104  
11.1.  Sponsor and Trial Administrative Structure  .............................................................104  
11.2.  Investigational Sites  ..................................................................................................104  
11.3.  Trial Coordination/Monitoring .................................................................................104  
11.4.  Data Collection  .........................................................................................................105  
11.5.  Investigator Site File and Archiving  .........................................................................105  
11.6.  Monitoring, Quality Assurance and Inspection by [CONTACT_391458]  ....................105  
11.7.  Publication Policy  .....................................................................................................106  
11.7.1.  Clinical Trial Report .................................................................................................106  
11.7.2.  Publications ...............................................................................................................106  
12. REFERENCES  .........................................................................................................107  
APPENDIX 1.  .................. EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE 
SCALE  ......................................................................................................................110  
APPENDIX 2.  ........................ SIGNATURE [CONTACT_391526]  .......................................................................................................................111  
 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491313] OF TABLES  
Table 1: AGEN2034 Starting Dose Calculations ..........................................................................26  
Table 2: Phase 1 Dosing Regimens ...............................................................................................48  
Table 3: AGEN2034 Infusion Related Reaction Management Guidelines ...................................51  
Table 4: Dermatological Immune -related Adverse Event Management Algorithm  ......................57  
Table 5: Gastrointestina l Immune -related Adverse Event Management Algorithm  .....................58  
Table 6: Pulmonary Immune-related Adverse Event Management Algorithm .............................59  
Table 7: Hepatic Immune -related Adverse Event Management Algorithm ..................................60  
Table 8: Endocrine Immune-related Adverse Event Management Algorithm ..............................61  
Table 9: Renal Immune-related Adverse Event Management Algorithm .....................................62  
Table 10: Neurological Immun e-related Adverse Event Management Algorithm  ........................63  
Table 11:  Phase 1 Part A1 — Schedule of Assessments and Procedures ...................................64  
Table 12:  Phase 1 Part  A2 — Schedule of Assessments and Procedures ...................................67  
Table 13:  Phase 2 — Schedule of Assessments and Procedures  ................................................71  
Table 14:  Phase 2 — Blood Sampling for Pharmacokinetic, Pharmacodynamic, 
Genetic, and Other Assessments  .................................................................................74  
Table 15: Required Local Laboratory Panel Tests  ........................................................................[ADDRESS_491314] OF FIGURES  
Figure 1: In vitro  Comparability of AGEN2034 and Nivolumab ..................................................23  
Figure 2: Phase 1 Dose Escalation Schematic  ...............................................................................35  
 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491315] Term  Explanation  
ACTH  adrenocorticotropic hormone  
ADA  anti-drug antibody; in this trial, antibody against AGEN2034  
ADL  activities of daily living  
ADR  adverse drug reaction  
AE adverse event  
AESI  adverse event of special interest  
AJCC -[ADDRESS_491316]  aspartate aminotransferase  
AUC  area under the drug concentration -time curve  
AUC 0-∞  area under the drug concentration -time curve from time of dosing (0  h) 
extrapolated to infinity  
AUC 0-t  area under the drug concentration -time curve from time of dosing (0  h) to 
time t (typi[INVESTIGATOR_391431])  
AUC (t1-t2)-ss  area under the drug concentration -time curve within the time span t1 to time 
t2 at steady -state 
BOR  best overall response  
BUN  blood urea nitrogen  
C Celsius  
CI confidence interval  
Cmax  maximum drug concentration observed postdose  
CNS  central nervous system  
CR complete response  
CRO  contract research organization  
CRP  C-reactive protein  
CT  computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTLA -4 cytotoxic T lymphocyte antigen -4 
dL deciliter  
DLT  dose-limiting toxicity  
DNA  deoxyribonucleic acid  
DOR  duration of response  
EC 50 half-maximal effective concentration  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
FDA  [LOCATION_002] Food and Drug Administration  
FFPE  formalin -fixed paraffin embedded  
FSH follicle -stimulating hormone  
g gram  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
h hour(s)  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
ICF informed consent form  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491317] Term  Explanation  
ICH International Council for Harmonisation (of Technical Requirements for 
Pharmaceuticals for Human Use)  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IERC  Independent Endpoint Review Committee  
IgG4  immunoglobulin G4  
IgG4κ  immunoglobulin G4 antibodies with immunoglobulin kappa light chains  
IL interleukin  
IMP investigational medicinal product  
INR international normalized ratio  
irAE  immune -related adverse event  
IRB Institutional Review Board  
IULN  institutional upper limit of normal  
IV intravenous  
kg kilogram  
L liter 
lb pound  
LDH  lactate dehydrogenase  
LFT liver function test  
λz  terminal elimination rate constant  
m month  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
µg microgram  
mg milligram  
min minute  
mL milliliter  
mm millimeter  
mM millimolar  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
nM nanomolar  
NSAID  nonsteroidal anti-inflammatory drug  
NSCLC  non–small -cell lung cancer  
ORR  objective response rate  
OS overall survival  
PBMC  peripheral blood mononuclear cell  
PD pharmacodynamic, or progressive disease  
PD-1 programmed cell death protein 1  
PD-L1/-L2 ligand 1 or 2 of programmed cell death protein 1  
PFS progression -free survival  
PK pharmacokinetic(s)  
PO oral, or by [CONTACT_391459]  
q each, every  
Q calendar quarter  
RBC  red blood cell  
RCC  renal cell carcinoma  
RECIST 1.1  Response Evaluation Criteria in Solid Tumors version 1.1  
RNA  ribonucleic acid  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491318] Term  Explanation  
SAE  serious adverse event  
SAP statistical analysis plan  
SD stable disease  
SEA  Staphylococcus  enterotoxin A  
SGOT  serum glutamic oxaloacetic transaminase  
SGPT  serum glutamic pyruvic transaminase  
SHP-1/-2 Src homology region 2 domain –containing phosphatase [ADDRESS_491319]  upper limit of normal  
V visit 
wk week(s)  
WBC  white blood cell  
 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 12 of 113 SYNOPSIS  
Trial Title  A Phase 1 / 2, Open -Label, Multiple Ascending Dose Trial to Investigate the Safety, 
Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in 
Subjects with Metastatic or Locally Advanced Solid Tumors, with Expansion to Second 
Line Cervical Cancer  
Trial Number  C-700-[ADDRESS_491320], Lexington, MA [ZIP_CODE], [LOCATION_003]  
Phase  1 / 2 
Trial Centers/  
Countries  Phase 1: approximately 10- 15 enrolling centers globally 
Phase 2: approximately [ADDRESS_491321] in: 2Q [ADDRESS_491322] out: 2Q 2022  
Objectives  Phase  1: 
Primary Objective  
 • To assess the safety and tolerability of AGEN2034 in subjects with metastatic and/or locally advanced solid tumors  
Secondary Objectives  
• To characterize the AGEN2034 pharmacokinetic (PK) profile 
• To correlate AGEN2034 exposure with target occupancy  
• To evaluate the immunogenicity of AGEN2034 and correlate it to exposure 
Exploratory Objectives  
• 
• To explore the association of programmed cell death protein 1 – ligand 1 (PD -L1) 
expression with clinical responses  
Phase  2: 
Primary Objective  
 • To assess objective response rate (ORR) according to RECIST 1.1 as determined 
by [CONTACT_391460] (IERC)  
Secondary Objectives 
• To assess the safety and tolerability of AGEN2034 in subjects with metastatic and/or locally advanced solid tumors  
• To characterize the AGEN2034 PK profile 
• To evaluate the immunogenicity of AGEN2034 and correlate it to exposure 
• To assess ORR according to RECIST 1.1 as determined by [CONTACT_1697]  
• To assess duration of response (DOR), disease control rate (DCR), duration of stable disease (SD), time to response, and progression -free survival (PFS) time per 
RECIST 1.1  
• To assess overall survival (OS) rate  
• To assess OS time  
Exploratory Objectives  
• 
• To explore the association of programmed cell death protein 1 – ligand 1 (PD -L1) 
expression with clinical outcomes  

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 13 of 113 Endpoints  Phase 1: 
Primary Endpoints  
• Occurrence of dose -limiting toxicities (DLTs) in subjects in dose escalation during 
the first 21 days of treatment  
• Frequency, severity, and duration of treatment -emergent AEs (TEAEs) and 
laboratory abnormalities using the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) v4.03.  
Secondary Endpoints  
• AGEN2034 PK parameters which may include (but are not limited to) maximum drug concentration observed postdose at steady -state (C
max-ss), mini mum observed 
concentration at steady -state (C min-ss), area under the drug concentration -time curve 
within time span t1 to t2 at steady -state (AUC (t1-t2)-ss ), area under the drug 
concentration -time curve from time zero to time t (AUC (0-t)), area under the d rug 
concentration -time curve from time zero to infinity (AUC (0-∞)), time to maximum 
observed concentration (t max), terminal disposition rate constant (λ z), terminal 
elimination half -life (t 1/2), systemic clearance (CL), and volume of distribution (Vd)  
• Receptor occupancy on circulating T cells measured [ADDRESS_491323] dose and 
immediately prior to the 2nd dose 
• Receptor occupancy saturation levels correlated with AGEN2034 PK exposure metrics  
• Antidrug antibody (ADA) concentrations and correlation with AGEN2034 PK exposure metrics  
Exploratory Endpoints  
• 
• • 
• Baseline expression of PD -L1 
Phase  2: 
Primary Endpoint  
 • Confirmed ORR per RECIST 1.1, as determined by [CONTACT_391461], in the analysis 
population  
Secondary Endpoints  
• Frequency, severity, and duration of TEAEs and laboratory abnormalities, using NCI CTCAE v4.03  
 • AGEN2034 PK parameters which may include (but are not limited to) maximum drug concentration observed postdose at steady -state (C
max-ss), minimum observed 
concentration at steady -state (C min-ss), area under the drug concentration -time cu rve 
within time span t1 to t2 at steady -state (AUC (τ1-τ2)-ss ), area under the drug 
concentration -time curve from time zero to time t (AUC (0-t)), area under the drug 
concentration -time curve from time zero to infinity (AUC (0-∞)), time to maximum 
observed co ncentration (t max), terminal disposition rate constant (λ z), terminal 
elimination half -life (t 1/2), systemic clearance (CL), and volume of distribution (Vd)  
• ADA concentrations and correlation with AGEN2034 PK exposure metrics  
• Confirmed ORR per RECIST 1 .1, as determined by [CONTACT_2413]  
• DOR per RECIST 1.1, as determined by [CONTACT_391462], defined as time from first observation of response to first observation of documented disease 
progression (or death within [ADDRESS_491324] tumor asses sment). Subjects 

Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491325] tumor 
assessment.  
• DCR, defined as proportion of subjects with complete response (CR), partial 
response (PR), or stable disease (SD) for at least 12 weeks  
• Duratio n of SD, measured from the start of treatment until the criteria for 
progression are met, taking as reference the smallest measurements recorded since the treatment started, including baseline measurements  
• Time to response, defined as the time from the f irst dose date to first observation of 
confirmed response  
• PFS time, defined as time from first treatment administration to first observation of 
documented disease progression (or death within [ADDRESS_491326] tumor 
assessment), per RECIST 1.1, as determi ned by [CONTACT_391462]. Subjects 
without an event at analysis cutoff date will be censored on date of last tumor assessment.  
• Median OS and OS rate  
• OS time, defined as time from start of treatment to death. For subjects who are still alive at time of data cutoff for trial analysis or who are lost to follow -up, survival 
will be censored at the last recorded date that the subject is known to be alive as of the cutoff date for analysis  
Exploratory Endpoints  
• 
• 
• Baseline expression of PD -L1 association with clinical outcomes  
Trial Design and Plan  This is a 2 -part trial: a Phase 1, open -label, dose -escalation trial in subjects with 
metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to 
evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum -based treatment regimen.  
Phase 1: Dose Escalation  
Phase [ADDRESS_491327] 3+3 dose escalation with the following escalating dose levels and schedules:  
 Part A1: 1, 3, and 10 mg/kg administered every 2 weeks  
 Part A2: 6  and 10 mg/kg administered every [ADDRESS_491328] will stay on the dose level and schedule assigned at trial entry. Subjects 
will receive AGEN2034 for a maximum of 24 months or until progression, 
unacceptable toxicity, or any criterion for stoppi[INVESTIGATOR_391432].  
A Safety Monitoring Committee (SMC) will assess safety; decide on dose- escalation 
and opening of backfill enrollment; define the recommended Phase 2 dose (RP2D); and 
determine opening of the Phase [ADDRESS_491329] of each cohort will be observed for 16 days (i.e., ≥  48 hours 
after second dose) for occurrence of DLT before the second subject is administered trial medication. Thereafter, within each cohort, consecutively enrolled subject s may initiate 
treatment ≥  [ADDRESS_491330] initiated treatment. Dose escalation 
will continue until the maximum tolerated dose (MTD) is reached or the maximum 
planned dose level (10.0 mg/kg) is shown to be safe. The MTD is defined  as the dose 
below which ≥  2 DLTs are observed. 
Once Part A1 is completed, enrollment to Part A2 will begin. If <  2 DLTs are observed 
in Part A1 at the maximum planned dose of 10 mg/kg every 2 weeks, open enrollment 
to Part A2 will begin with enrollment of 10 subjects at 6 mg/kg every 3 weeks, followed 

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 15 of 113 by [CONTACT_391463] 10 subjects at 10 mg/kg every 3  weeks. If ≥ [ADDRESS_491331] 3+3 dose escalation 
will continue with Part A2 where consecutively enrolled subjects in dose escalation m ay 
initiate treatment ≥  [ADDRESS_491332] initiated treatment.  
For cohorts in dose escalation, concurrent with the 3+[ADDRESS_491333] 10 subjects. Subjects enrolled to backfill cohorts may be enrolled 
simultaneously, without sequential dosing (i.e., not required to wait 48 hours between 2 subjects). These additional subjects at each dose level will have the purpose of 
gene rating additional safety, PK, and receptor occupancy data, and will not undergo 
formal DLT observation.  
Phase 2: Dose Expansion  
To further characterize safety and efficacy, subjects with recurrent, unresectable, or metastatic cervical cancer will be enroll ed in Phase  2 and receive the RP2D of 
AGEN2034 (3 mg/kg every 2 weeks) for a maximum of 24 months or until progression, 
unacceptable toxicity, or any criterion for stoppi[INVESTIGATOR_391433].  
An SMC will assess safety, and an Independent Data Monitoring Committee (IDMC) 
will evaluate safety and efficacy. 
Number of Subjects (Planned)  Phase 1 (Parts A1 and A2):  Approximately 50 subjects; final sample size may vary 
depending on the total number of dose levels to be tested, and subject replacement for 
DLT evaluation, if applicable 
Phase 2:  Approximately 150 subjects with recurrent, unresectable, or metastatic 
cervical cancer.  
Trial Eligibility  Inclusion Criteria:  
1. Voluntarily agree to participate by [CONTACT_109348]. Participation in 
pharmacogenomics testing is optional.  
2. Be ≥ 18 years of age.  
3. Diagnosis and prior systemic treatment:  
a. Phase 1: Have a histologically or cytologically confirmed diagnosis of a 
metastatic or locally advanced solid tu mor for which no standard therapy is 
available or standard therapy has failed.  
b. Phase 2:  
I.  Have (1) a histologically or cytologically confirmed diagnosis of 
squamous -cell carcinoma, adenosquamous carcinoma, or adenocarcinoma 
of the cervix, and (2) metastatic, locally advanced, and/or unresectable disease at the time of enrollment. Histologic confirmation of the original primary tumor is required via pathology report. 
 Note:  The following cervical tumors are not eligible: minimal 
deviation/adenoma malig num, gastric type adenocarcinoma, clear cell 
carcinoma, and mesonephric carcinoma.  
II.  Has cervical cancer and has relapsed after a platinum -based treatment (first 
line) regimen for advanced (recurrent, unresectable, or metastatic) disease;  
 Note:  Subje ct receiving chemotherapy concurrently with primary radiation 
(e.g., weekly cisplatin) or subject receiving adjuvant chemotherapy following completion of radiation therapy (e.g., paclitaxel and carboplatin for ≤ 4 cycles) and progressed within [ADDRESS_491334]- line 
treatment.  
4. Measurable disease – based on investigator assessment  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 16 of 113 a. Phase 1: Have objective evidence of disease; the presence of measurable 
disease is not required. 
b. Phase 2: Have measurable disease on imaging based on RECIST version 1.1.  
 Note:  Subjects must have at least one "target lesion" to be used to assess 
response, as defined by [CONTACT_44993] 1.1. Tumors within a previously 
irradiated field will be designated as "non -target" lesions unless progression is 
documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.  
       Note:  Measurable disease by [CONTACT_393] 1.[ADDRESS_491335] 3 months and an Eastern Cooperative Oncology Group (ECOG) performance status of [ADDRESS_491336] adequate organ function as indicated by [CONTACT_132725]:  
a. Adequate hematological function defined by [CONTACT_28763] (ANC) 
≥ 1.5 x 10
9/L, platelet count ≥ 100 x 109/L, and stable hemo globin ≥ 8 g/dL 
(without transfusions within [ADDRESS_491337] dose).  
b. Adequate hepatic function based by a total bilirubin level ≤ 1.5  x the 
institutional upper limit of normal (IULN), aspartate aminotransferase (AST) 
level ≤ 2.[ADDRESS_491338], alanine aminotransferase (ALT) level ≤ 2.[ADDRESS_491339], and alkaline phosphatase ≤ 2.[ADDRESS_491340].  
c. Adequate renal function defined as creatinine ≤ 1.[ADDRESS_491341] OR calculated 
creatinine clearance ≥ 50 mL/min for subjects with creatinine levels > 1.[ADDRESS_491342] (if no local guidelin e is available, creatinine clearance should be 
calculated using the Cockcroft -Gault Method).  
d. Adequate coagulation defined by [CONTACT_365187] (INR) or prothrombin time ≤ 1.[ADDRESS_491343] (unless the subject is receiving anticoagulant 
therapy); and activated partial thromboplastin time (aPTT) ≤ 1.[ADDRESS_491344] 
(unless the subject is receiving anticoagulant therapy)  
7. Other than the cancer for which the subject is enrolled, have no history of prior malignancy, with the exceptio n of basal cell carcinoma of the skin, superficial 
bladder cancer, squamous -cell carcinoma of the skin, or has undergone potentially 
curative therapy with no evidence of that disease recurrence for [ADDRESS_491345] provide a sufficient and adequate formalin -fixed paraffin 
embedded (FFPE) tumor tissue sample preferably from the most recent biopsy of a tumor lesion, collected either at the time of or after the diagnosis of advanced or metastatic disease has been made AND from a site not previously irradiated. If no tumor tissue is available, a fresh biopsy will be required.  
 Note: Tissue from needle or excisional biopsy or from resection is required.  
9. Female subjects must have a negative serum pregnancy test at screening (within 
[ADDRESS_491346] dose of study drug) if of childbearing potential or be of non-
child bearing potential. Non -childbearing potential is defined as (by [CONTACT_73550]):  
a. ≥ 45 years of age and has not menstruated fo r greater than 1 year, 
b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a follicle -stimulating hormone (FSH) value in the postmenopausal range upon 
pretrial (screening) evaluation,  
c. Whose status is post hysterectomy, oophorectomy or tubal ligation.  
10. If of childbearing potential, female subjects must be willing to use 2 highly 
effective methods (defined in the informed consent form [ICF]) throughout the 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491347] dose  of study 
drug.  
 Note:  Abstinence is acceptable if this is the established and preferred contraception 
for the subject. 
11. Male subjects with a female partner(s) of child -bearing potential must agree to use 
2 highly effective methods (defined in the ICF) throughout the trial starting with the 
screening visit through [ADDRESS_491348] agree to use a condom; no additional method of contraception is required for the pregnant partner.  
 Note: Abstinence is acceptable if this is the established and preferred contraception 
for the subject. 
12. Is willing and able to comply with the requirements of the protocol.  
Exclusion Criteria:  
1. Is currently participating and receiving study therapy or has participated in a study 
of an investigational agent and received study therapy or used an investigation device within [ADDRESS_491349] dose of study drug  defined as:  
a. Received systemic cytotoxic chemotherapy or biological therapy within [ADDRESS_491350] dose. 
3. Has received prior therapy with: 
a. Any antibody/drug targeting T -cell co -regulatory proteins (immune 
checkpoints) such as anti –PD-1, anti –PD-L1, or anti –cytotoxic T -lymphocyte 
antigen 4 (CTLA -4) antibodies  
b. For Phase 2: > 1 systemic treatment regimen for the advanced (recurrent, 
unresectable, or metastatic) cervical cancer for which the subject is considered for the study 
 Note:  In Phase 1, prior treatment with a CTLA- 4 antibody is permissible for 
subjects with metastatic melanoma.  
4. Has persisting toxicity related to prior thera py of NCI CTCAE Grade > 1 severity.  
 Note:  Sensory neuropathy or alopecia of Grade ≤ 2 is acceptable.  
5. Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, 
and/or surgical resection).  
6. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI CTCAE version 4.03 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma.  
7. Is receiving systemic corticosteroid ≤ [ADDRESS_491351] dose of trial treatment or receiving any other form of systemic immunosuppressive medication (corticosteroid use on study for management of immune -related adverse events, 
and/or a premedication for IV contrast allergies/reactions is allowed). Subjects who are receiving daily corticosteroid replacement therapy are an exception to this rule. Examples of permitted therapy are daily prednisone at doses of 5 to 7.5 mg or 
equivalent hydrocortisone dose, and steroid therapy ad ministered by [CONTACT_12523][INVESTIGATOR_2855], 
intraocular, intranasal, and/or inhalation routes.  
8. Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous 
meningitis identified either on the baseline brain imaging obtained during the screening period OR i dentified prior to consent.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 18 of 113  Note: Subjects with history of brain metastases that have been treated may 
participate provided they show evidence of stable supra- tentorial lesions at 
screening (based on 2 sets of brain images, performed ≥ 4 weeks apart, and 
obtained after the brain metastases treatment). In addition, any neurologic 
symptoms that developed either as a result of the brain metastases or their treatment 
must have resolved or be minimal and be expected as sequelae from treated lesions. For individ uals who received steroids as part of brain metastases treatment, steroids 
must be discontinued ≥ [ADDRESS_491352] dose of study drug.  
9. Has active or history of autoimmune disease that has required systemic treatment within 2 years of the start of t rial treatment (i.e., with use of disease modifying 
agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not c onsidered a form of systemic treatment.  
 Note: Subjects with diabetes type 1, vitiligo, psoriasis, hypo -, or hyperthyroid 
disease not requiring immunosuppressive treatment are eligible.  
10. Has had an allogeneic tissue/solid organ transplant.  
11. Has or ha d interstitial lung disease (ILD) OR has had a history of pneumonitis that 
has required oral or IV corticosteroids.  
12. Has an active infection requiring intravenous systemic therapy.  
13. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 ant ibodies).  
14. Has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is 
defined as a known positive HBsAg result. Active Hepatitis C is defined by a 
known positive Hep C Ab result and known quantitative HCV RNA results greater than t he lower limits of detection of the assay.  
15. Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months before enrollment, unstable angina, congestive heart failure (New Yo rk Heart Association class ≥ II), 
or serious uncontrolled cardiac arrhythmia requiring medication.  
16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the s ubject’s 
participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_12980].  
17. Has known psychiatric or substance abuse disorders that would interfere with cooperati on with the requirements of the trial.  
18. Is, at the time of signing informed consent, a regular user (including “recreational use”) of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).  
19. Is legally  incapacitated or has limited legal capacity.  
20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through [ADDRESS_491353] dose of study drug.  
Dosage and Administration  AGEN2034 is an IgG4 antibody designed to block PD -1. 
Dose Levels  
 Phase  1: Part A1: 1, 3, and 10 mg/kg IV every 2 weeks   
    Part A2: 6 and 10 mg/kg IV every 3 weeks  
 Phase  2: 3 mg/kg IV every 2 weeks  
Administration  
 AGEN2034 will be administered IV over 60 minutes ( -10/+20 min)  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491354] dose 
of study treatment.  
The overall trial duration is expected to be approximately 63 months.  
Schedule of Visits and Assessments  Screening Period (Phase 1 and Phase 2)  
Screening assessments will be conducted within [ADDRESS_491355] treatment dose, with associated evaluations and procedures. 
Treatment Phase (Phase 1 and Phase 2) The treatment phase is divided into 2 -week (Phases 1 and 2) or 3 -week (Phase  1) cycles 
with associated evaluations and procedures that must be performed at specific time 
points. Each cycle begins with the administration of AGEN2034. Subjects will be 
treated for up to [ADDRESS_491356] dose until disease progression or a new line of therapy is initiated. 
End-of-Treatment (Phase 1 and Phase 2)  
Discontinuation Visit and Safety Follow -up Visit:  
All subjects who discontinue the trial treatment prematurely for an AE should have a 
full safety evaluation at the time of discontinuation (Discontinuation Visit).  
A mandatory Safety Follow -up Visit should be scheduled [ADDRESS_491357]. Subjects with an AE of Grade >  [ADDRESS_491358]. Subjects with an adverse drug reaction (ADR) ongoing at the Safety Follow -up Visit must be followed up until the ADR resolves, becomes stable, or is 
considered not clinically significant by [CONTACT_737].  
Follow -up Phase (Phase 1 and Phase 2)  
Subjects who discontinue treatment will be followed for up to 12 months (Phase  1) or 
24 months (Phase  2) after the last dose of study drug or until death, withdrawal of 
consent, or becoming lost to follow -up.  
Follow -up Vi sits 
Visits with associated evaluations and procedures will occur every [ADDRESS_491359] dose of study drug or until disease progression and/or start 
of a new line of therapy. Tumor assessments will continue every [ADDRESS_491360] dose 
until discontinuation of study drug. 
Survival Follow -up (Phase 2 only)  
Subjects in Phase 2 who present with progressive disease and/or start a new line of 
therapy will be contact[CONTACT_12090] [ADDRESS_491361] dose of study drug.  
Statistical Considerations:  The total sample size is expected to be approximately 200 subjects: [ADDRESS_491362] deviation, median, and range; categorical variables will be summarized using counts and percentages.  
Phase 1:  
The sample size of approximately 50  subjects was determined by [CONTACT_391464].  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 20 of 113 Phase 2:  
The primary endpoint of Phase 2, ORR, will be estimated as the binomial proportion of 
patients with confirmed partial or complete best overall response per RECIST 1.1, as 
determined by [CONTACT_391461], and will be reported with two -sided, 95% Wilson score 
confiden ce interval  (CI).  
With 150 patients in the final analysis, the power to exclude an ORR of 5% by [CONTACT_391465] 95% two -sided Wilson score CI is 92.2% and 96.2% , assuming  a true ORR  
of 12% and 13%, respectively. The sample size will provide ≥ 77% p robability to observe 
an AE with and underlying rate of ≥ 1%. 
Interim analys es will be performed to a ssess the safety and efficacy (using the ORR and 
selected secondary efficacy endpoints) when (1) data are available for approximately [ADDRESS_491363] 3 months and (2) approximately [ADDRESS_491364] the 
overall type I error.  A non- binding futility analysis may be performed using methods 
described in the statistical analysis plan. Additional interim analyses for safety and 
efficacy assessment may performed. 
Statistics for continuous variables may include means, medians, ranges, and appropriate 
measures of variability . Statistics for the binary endpoint will be summarized with 
counts and frequencies , and statistics for time -to-event data will be summarized with 
median , 95% CI , etc., as appropriate.   
 
 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491365] shown that a tumor’s ability to evade the immune system can determine outcome. This has led to the development of therapi[INVESTIGATOR_391434] l andscape of modern oncology. Researchers have dissected numerous regulatory 
pathways that are exploited by [CONTACT_391466].  
The programmed cell death -1 (PD -1) and cytotoxic T lymphocyte associated antigen-4 
(CTLA -4) proteins are the most extensively studied negative regulatory receptors, and whose 
pathways are the target of multiple therapi[INVESTIGATOR_014] ( Buchbinder & Desai 2016; 
Sharma & Allison  2015; Topalian et al 2015). Inhibition of the PD-[ADDRESS_491366] led to a number of regulatory approvals across the globe for single agents and 
combinations in various indications including melanoma, non- small cell lung cancer (NSCLC), 
renal cell carcinoma, head and neck cancers, Hodgkin lymphoma, and micro- satellite 
instability -high (MSI
HI) cancers. This protocol will study the PD-[ADDRESS_491367] Blockade 
The importance of immune surveillance in controlling outgrowth of neoplastic transformation is 
well described and consistent with a correlation between prevalence of tumor- infiltrating 
lymphocytes in cancer tissues and favorable prognosis in various malignancies ( Disis 2010). 
Tumors can nevertheless evade recognition and destruction by [CONTACT_391467]- expressed molecules that naturally mediate immune suppression 
(Topalian  et al 2015). In this context, the PD-[ADDRESS_491368] has emerged as a 
significant mode by [CONTACT_391468] ( Postow et al 2015).  
PD-1, or CD279, is a member of the immunoglobulin superf amily (IgSF) that negatively 
regulates T -cell responses to maintain peripheral tolerance and immune homeostasis 
(Zha et al 2004). A range of T -cell subsets, including activated T effector cells, memory T cells, 
regulatory T cells, and T follicular helper c ells, express PD -1. PD-1 is rapi[INVESTIGATOR_391435] T 
cells activated via their T -cell receptor (TCR). Under conditions of persistent antigenic exposure, 
such as in chronic pathogenic infections or within the tumor microenvironment, PD-1 expression can be s ustained on antigen- specific T cells, leading to a state of dysfunction commonly referred 
to as T -cell exhaustion ( Barber et al 2006 ). 
PD-1 signaling is mediated by 2 ligands: PD -1 ligand 1 (PD-L1 or CD274) and PD-1 ligand 2 
(PD- L2 or CD273) ( Latchman et al 2001). PD -L1 is expressed on the cell surface of a range of 
immune and non- immune cell types, including antigen -presenting cells (APCs) and tumor cells. 
Upon binding to PD-L1 or PD-L2, PD- 1 signaling in T cells can potently attenuate TCR 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 22 of 113 signaling, resu lting in diminished cytokine and proliferative responses, reduced T effector cell 
cytolytic activity, and impaired central memory T -cell differentiation ( Allie et al 2011 ). Proximal 
to ligand binding, PD-1 recruits Src homology region 2 domain–containing phosphatase (SHP)–1 
and SHP-2 proteins to an immunoreceptor tyrosine-based inhibitory motif and an 
immunoreceptor tyrosine- based switch motif within its intracellular domain ( Chemnitz et al 
2004). This impairs phosphorylation of several key kinase proteins, including zeta chain –
associated protein kinase 70, phosphatidylinositol 3-kinase, protein kinase B, casein kinase 2, and protein kinase C theta, thereby [CONTACT_391469] 
(Yokosuka et al 2012 ). 
Inhibition of the PD -[ADDRESS_491369] by [CONTACT_391470]-ligand interactions has been 
demonstrated to improve clinical outcome in a range of malignancies. The therapeutic benefit of such a blockade in the treatment of subjects with cervical cancer is under investigation. 
1.1.2. AGEN 2034 
AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed 
to block PD- 1 from interacting with its ligand PD -L1 and PD-L2 in a manner comparable to 
nivolumab. 
[IP_ADDRESS]. Summary of Preclinical Data 
The utility of PD -1 as a therapeutic antibody target in human cancer has been well characterized. 
A human immunoglobulin G4 antibody with immunoglobulin kappa light chains (IgG4κ) 
monoclonal antibody directed against PD-1 (nivolumab, Opdivo
®) has been evaluated in 
thousands of patients covering a range of IV doses, from 0.1 mg/kg to 20 mg/kg 
(Topalian  et al, 2015). AGEN2034 is physicochemically comparable to nivolumab (anti- PD-1 
specific IgG4 antibodies with Igκ light chains) and a side -by-side in vitro pharmacological 
characterization of AGEN2034 and nivolumab demonstrated that these two antibodies were functionally comparable. More specifically both antibodies: 1) bind human PD-1 with 
subnanomolar affinities (KD 0.14 nM for AGEN2034 and 0.12 nM for nivolumab) and have comparable relative cellular binding affinities to human T cells expressing PD -1 (EC
50 
0.025 µg/mL for AGEN2034 and 0.03 µg/mL for nivolumab) ( Figure 1 A); 2) potently block the 
binding of PD-L1 to PD- 1 (IC 50 0.03 µg/mL for both antibodies) ( Figure 1 B); and 3) augment 
the activation of recombinant PD-1 expressing and primary human T cells ( Figure 1 C-D). 
AGEN2034 toxicity was assessed in a 4- week good laboratory practices (GLP) repeat dose study 
in cynomolgus monkeys and in a human tissue cross reactivity study. Details of these studies can be found in the Investigator’s Brochure. Briefly, in the 4- week GLP repeat dose study, 
AGEN2034 was dosed by [CONTACT_391471] 0 (vehicle), 40 and 300 mg/kg on Study Days 1, 8, 15, 22 and 29, to 3 male and 3 female animals in the control and low dose groups and 5 male and 5 female animals in the high dose group. The dosing period was followed by a 
4-week non-dosing period for 2 males and 2 females each in the vehicle and 300 mg/kg dose 
groups. Standard study endpoints, plus electrocardiogram (ECG), ophthalmic, and cardiovascular assessments, were included.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 23 of 113 Figure 1: In vitro  Comparability of AGEN2034 and Nivolumab 
 
Head -to-head evaluat ion of AGEN2034 ( black ), commercial nivolumab ( gray), or IgG4 isotype antibody ( white ) 
for: (A) - antibody binding to PD -1+ CD4+ T cells in cultures of Staphylococcus  enterotoxin A (SEA) -stimulated 
human peripheral blood mononuclear cells (PBMCs); (B) - antibody -mediated blockade for PD -1 binding to PD -L1; 
(C) - inhibition of PD -1:PD -L1 signaling in a T -cell reporter assay; and (D) - T cell –induced IL -2 release in SEA -
stimulated PBMC cultures. On the x -axis, log converted antibody concentration (log µg/mL) are shown. Data shown 
are representative of 2 independent experiments.  
 
In this study, AGEN2034 demonstrated biphasic distribution after IV bolus dose administration 
and serum AGEN2034 concentrations increased in a manner commensurate with the increase in 
dose. There were no apparent differences in the exposure or disposition of AGEN2034 between 
male and female monkeys. The estimated mean half -life was 12.4 days in the recovery phase, 
and it is anticipated that steady -state conditions might be achieved in about 5 to 9 weeks. Anti-
drug antibodies as a measure of immunogenicity of AGEN2034 in monkeys were assessed and revealed positive results at an incidence of 30 percent. Full toxicokinetic details are included in the AGEN2034 Investigator’s Brochure. 
The no- observed - adverse-effect level (NOAEL) of AGEN2034 from the 4- week cynomolgus 
monkey toxicity study is 40 mg/kg. Histopathology findings at 300 mg/kg included 
vascul ar/perivascular inflammation in a variety of tissues. The collective histology, IHC, PK and 
anti-drug antibody (ADA) data are consistent with an immune- mediated vasculitis caused by 
[CONTACT_391472] a proportion of monkeys given 300 mg/kg AGEN2034. ADA is a recognized 
phenomenon in non- human primate studies as it relates to the antigenicity of an administered 
humanized antibody and these types of events are typi[INVESTIGATOR_391436] ( Frazier et al 2015 ; Ponce et al  2009; Rojko et al 2014). Other treatment -
related findings in the 4 -week study were consistent with pharmacodynamic effects including 
changes in lymphoid cellularity in the spleen (increased at ≥  40 mg/kg) and thymus (decreased at 
300 mg/kg) and an increas e in mononuclear cell infiltration in the brain (≥  40 mg/kg). These 
findings related to some changes in organ weights that showed a trend towards recovery 
following the 4- week non -dosing phase. Cytokine measurements from the 4- week toxicity study 

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 24 of 113 in cynomolgus monkeys and from an in vitro cytokine release assay in human whole blood 
revealed no findings that are considered related to cytokine release syndrome.  
A human tissue cross- reactivity GLP study was completed using cryosections from a full panel 
of normal human adult tissues at two concentrations (15 and 30 µg/mL AGEN2034). 
AGEN2034 - specific membrane and/or cytoplasmic staining was observed in cells of splenic 
white pulp and tonsillar germinal centers. This is consistent with the expected membrane staining 
pattern of PD-1 on a subset of T lymphocytes. 
For detailed information on preclinical characterization, manufacturing and administration of 
AGEN2034, please refer to the AGEN2034 Investigator’s Brochure. 
[IP_ADDRESS]. Summary of Clinical Data 
There are no existing safety data for AGEN2034, as this study will support its first human 
administration.  
The best indication of the safety profile of AGEN2034 is expected to be the safety profile of nivolumab (Opdivo
®), as specified in its prescribing information (Opdivo® 2017).  
Per Amendment 4, this study would further support safety and efficacy data utilizing the expansion cohort of subjects with cervical cancer.  
1.1.3. Safety of Nivolumab 
The following safety information is based on data from 7 clinical trials in which 2,166 subj ects 
received nivolumab as a single agent for treatment of unresectable or metastatic melanoma, metastatic NSCLC, advanced renal cell carcinoma (RCC), and classical Hodgkin’s lymphoma (cHL). Across all trials, nivolumab treatment was discontinued in 4% to 16% of subjects and 
delayed in 23% to 44% of subjects because of toxicities. Serious adverse reactions occurred in 
21% to 47% of subjects. Fatal adverse reactions were also observed. 
[IP_ADDRESS]. Common Adverse Reactions of Nivolumab 
Adverse reactions observed in more than 20% of subjects treated with nivolumab in clinical trials included (Opdivo
® 2015): 
• In melanoma: Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, and nausea. 
• In metastatic NSCLC: Fatigue, musculoskeletal pain, decreased appetite, cough, and constipation.  
• In advanced RCC: Asthenic conditions (decreased activity, fatigue, and malaise), cough, nausea, rash, dyspnea, diarrhea, constipation, decreased appetite, back pain, and arthralgia.  
• In cHL: Fatigue, upper respi[INVESTIGATOR_1092], pyrexia, diarrhea, and cough. 
The most frequent severe or serious reactions, occurring in more than 2% of patients, included: 
• In melanoma:  
− Pretreated (n = 268): 2%–5% abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 25 of 113 − Untreated (n = 206): 2%–4% gamma- glutamyl transferase (GGT) increase, 
diarrhea, musculoskeletal pain, increased alanine aminotransferase (ALT), 
increased aspartate aminotransferase (AST), increased alkaline phosphatase, and increased bilirubin. 
− Nivolumab-only arm of combination study (n = 313): 2%–5% diarrhea, increased ALT, increased AST, hyponatremia, increased alkaline phosphatase, anemia, and lymphopenia (4.3%); and increased lipase (9%). 
• In NSCLC (n = 287): >2% serious pneumonia, pulmonary embolism, d yspnea, 
pleural effusion, and respi[INVESTIGATOR_1399]. 
• In RCC (n = 287): >2% serious acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia.  
• In cHL (n = 263): >1% serious infusion-related reaction, pneumonia, pleural effusion, 
pyrexia, r ash, and pneumonitis. 
[IP_ADDRESS]. Notable Immune -Mediated Adverse Reactions of Nivolumab 
Immune-mediated conditions are defined as adverse reactions requiring the use of 
corticosteroids, with no clear alternate etiology. The most common immune -mediated reactions 
assoc iated with nivolumab include pneumonitis (including interstitial lung disease), colitis, 
hepatitis, encephalitis, nephritis and/or renal dysfunction, rash, and endocrinopathies such as hypophysitis, adrenal insufficiency, thyroid disorders, and type 1 diab etes mellitus. The majority 
of events were moderate or mild; however, severe events were observed, including fatal cases of 
pneumonitis, fatal limbic encephalitis, and toxic epi[INVESTIGATOR_194]. The onset time of these 
events is highly variable, ranging from within [ADDRESS_491370] dose to more than 2 years after 
initiation of therapy. In many cases, the events resolved with corticosteroid treatment, and occasional event recurrence was observed after re-initiation of nivolumab therapy. 
In fewer than 1% of patients, the following clinically significant immune -mediated adverse 
reactions occurred: uveitis, iritis, pancreatitis, facial and abducens nerve paresis, demyelination, 
polymyalgia rheumatica, autoimmune neuropathy, Guillain-Barré syndrome, hypopi[INVESTIGATOR_297], 
systemic inflammatory response syndrome, gastritis, duodenitis, sarcoidosis, motor dysfunction, 
vasculitis, and myasthenic syndrome. 
1.2. Rationale for Dose Selection  
1.2.1. Starting Dose in Phase 1 
The NOAEL of AGEN2034 from the 4 -week cynomolgus monkey toxicity study was 40 mg/kg 
(see Section  [IP_ADDRESS]). This dose and serum AGEN2034 concentrations were used in the 
calculations below for the safe starting dose. 
For the clinical trial, the starting dose of 1 mg/kg was selected based on the results of 2 complementary approaches:  
• Nonclinical safety: human equivalent dose (HED) projections based on the NOAEL of 40 mg/kg from the 4 -week GLP toxicity stu dy in cynomolgus monkey 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 26 of 113 • Biological effects and efficacy: AGEN2034 is biologically active in several in vitro 
assays, including: 1) inhibition of PD-1 binding to PD- L1/PD -L2; 2) promotion of 
TCR signaling in a T cell –based reporter gene assay; 3) increase o f T-cell IL -2 
production; and 4) increase in T-cell proliferation under conditions of immune suppression. 
Two regulatory guidelines can be used for determination of the human starting dose of AGEN2034, starting from the NOAEL:  
• International Council for Harmonisation (ICH) S9 “Nonclinical Evaluation for Anticancer Pharmaceuticals” ( Food and Drug Administration 2010) provides 
2 methods to determine a safe starting dose:  
− HED based on average serum AGEN2034 concentrations from the cynomolgus monkey study and a 10x safety factor are derived per the guidance in Section IIIA of ICH S9. 
− The highest non-severely toxic dose (HNSTD) in mg/kg from non-rodent studies and a 6x safety factor are derived from Section V, Note 2 of ICH S9. 
• In addition, the maximum recommended starting dose (MRSD), the HED based on the NOAEL dose and a 10x safety factor, is derived from the [LOCATION_002] Food and Drug Administration (FDA) Guidance for Industry “Estimating the Maximum Safe 
Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers” 
(Food and Drug Administration Center for Drug Evaluation and Research 2005).  
• An additional 2-fold safety factor is included in each calculation to conservatively compensate for the observed < 2- fold difference of cellular bin ding affinity to human 
PD-1 as compared to cynomolgus monkey PD-1. 
 
Table 1: AGEN2034 Starting Dose Calculations 
AGEN2034 Dose From 4- Week 
Cynomolgus Monkey Study(1) HED 
(ICH  S9 IIIA)(2) HNSTD  
(ICH  S9 V Note  2)(3) MRSD 
(FDA  VC3)(4) 
40 mg/kg (NOAEL)  0.9 mg/kg  3.3 mg/kg  2.0 mg/kg  
300 mg/kg  8 mg/kg  25 mg/kg  15 mg/kg  
Abbreviations: FDA: Food and Drug Administration; HED: human equivalent dose; HNSTD: highest non -severely 
toxic dose; ICH: International Council for Harmonisation; MRSD: maximum recommended starting dose; NOAEL: 
no-observed -adverse -effect level.  
1 All calculations include an additional 2 -fold safety factor to conservatively compensate for binding affinity 
difference.  
2 Based on cynomolgus monkey AGEN2034 C avg: 40 mg/kg C avg = 488 μg/mL; HED calculation using a 2,500 mL 
human blood volume and 70 kg human body weight.  
3 Based on an HNSTD value calculated as 1/6 of the mg/kg dose.  
4 Food and Drug Administration, Center for Drug Evaluation and Researc h, 2005.  
 
Collectively, these guidance documents indicate a safe clinical starting dose within the 1 to 
3 mg/kg range based on the NOAEL of 40 mg/kg. If the 300 mg/kg dose is considered 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 27 of 113 appropriate for human safe dose calculations, this would provide an ev en greater level of safety 
cover, between 8 to 25 mg/kg, for a clinical starting dose.  
There is no cross- species reactivity to rodent PD -[ADDRESS_491371] demonstrated that AGEN2034 exhibits a pharmacological 
profile consistent with antagonism of the PD -1/PD- L1 interaction. These results indicate the 
estimated minimum anticipated biological effect level (MABEL) at EC 10 is approximately 
7.3 x 10-4 mg/kg; at EC 50 is 6.6 x 10-3 mg/kg; and at EC 90 is 0.17 mg/kg. It is anticipated that 
administration of 1  mg/kg AGEN2034 every [ADDRESS_491372] shown clinical activity of this class and an overall acceptable safety profile, leading to regulatory approval for these drugs as a treatment of several malignancies.  
In conclusion, the proposed safe starting dose of AGEN2034 is 1 mg/kg administered every [ADDRESS_491373] treatment 
and for which no established therapy is available. 
1.2.2. Dose in Phase 2  
The choice of the Phase 2 dose was based on clinical data from the Phase 1 portion of this trial, 
evaluatin g AGEN2034 as monotherapy. Supportive clinical responses are also available from 
publications of similar -mechanism competitor nivolumab (anti PD -1; Opdivo
®) as monotherapy 
since AGEN2034 has been shown to be functionally comparable to nivolumab. 
Dosing for Phase 1 was guided by [CONTACT_391473] (PK), preclinical pharmacology, 
and comparisons to published results of nivolumab as monotherapy. 
In Phase 1, a partial response was reported ( Drescher et al 2018 ) in the 3 mg/kg every 2  weeks 
(q2wk) coho rt that later was designated a complete response. Preliminary PK analysis of Phase 1 
data suggests an AGEN2034 terminal half-life of approximately 10 days. Therefore, dosing 
AGEN2034 q2wk results in only a 25% increase in accumulation ratio compared to eve ry 
3 weeks. AGEN2034 dosed at 3 and 10 mg/kg q2wk resulted in average plasma AGEN2034 
concentrations (C avg) of 20 and 67 µg/mL, respectively (corresponding to 1.30 and 1.80 µg/mL 
when log-transformed). When these log- transformed values are compared with receptor 
occupancy and IL-2 AGEN2034 concentration-response profiles, the AGEN2034 C avg values are 
clearly on the flat saturated part of the dose- response curves for these key pharmacodynamic 
parameters. Therefore, no additional benefit is expected for AGEN2 034 doses greater than 
3 mg/kg q2wk. 
Since limited clinical efficacy information is available from the ongoing evaluations, the primary 
decisions for the recommended Phase 2 dose (RP2D) of AGEN2034 were based on (1) the complete response experienced with t he 3 mg/kg q2wk dose in Phase 1, and (2) favorable 
comparison of attained clinical C
avg to key preclinical pharmacodynamic evaluations. Therefore, 
3 mg/kg q2wk was the dose and regimen selected as RP2D for evaluation in Phase 2 of this trial. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 28 of 113 1.3. Rationale for  Expansion Cohort  
Subjects with unresectable or metastatic cervical cancer with disease progression after a 
platinum-based treatment regimen will be enrolled in an expansion cohort. This population has a 
high unmet need for effective therapy, and there is a strong rationale for the use of a PD -1 
therapeutic antibody.  
It is estimated that 12,800 new cases of cervical cancer will be diagnosed in the US in 2017, with 4,200 deaths attributable to this malignancy ( Siegel et al 2017 ). More widely, cervical cancer  is 
the [ADDRESS_491374] common cause of cancer death for women worldwide ( Torre et al 2015 ). Human 
papi[INVESTIGATOR_27509] (HPV) vaccination is expected to reduce the incidence of cervical cancer over time, however vaccination rates in female adolescents remain below 50% in many parts of the 
US (Reagan -Steiner et al 2016) and unresectable or metastatic disease is likely to remain an 
important health concern. The current standard of care for the first- line treatment of recurrent or 
metastatic cervical cancer is pl atinum doublet chemotherapy with or without bevacizumab 
(National Comprehensive Cancer Network 2016; Tewari et al 2014 ). While a number of agents 
may be utilized in clinical practice for the second -line treatment of cervical cancer currently, 
none can be r egarded as definitive with proven survival benefit; therefore, clinical trials are often 
recommended for such individuals ( Borcoman & Le Tourneau 2017).  
The use of checkpoint protein blockade in the treatment of cervical cancer is supported by [CONTACT_391474]- L1 expression in cancers with viral etiology, including cervical cancer 
(Schumacher & Schreiber 2015; Mezache et al 2015 ). The upregulation of PD-1 and PD- L1 was 
also shown to correlate with impaired immunity in high -risk HPV -related cervical cancer 
(Yang  et al 2013 ). Furthermore, initial trials of PD -[ADDRESS_491375]- line therapy, received pembrolizumab at a 
dose of 10 mg/kg IV every 2 weeks. Four subjects (17%) had a Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) partial response with a median duration of response of 
26 weeks ( Frenel et al 2016 ). The safety profile of pembrolizumab was consistent with that 
observed in trials in other tumor types. In the KEYNOTE-[ADDRESS_491376] been treated regardless of 
PD-L1 biomarker status. The ORR in the PD-L1 positive cohort (81 subjects) was 16% including 
3 subjects with complete response. None of the 17 subjects with PD -L1 negative c ancers 
responded. Again many of the responses were shown to be durable ( Chung et al 2018). 
Pembrolizumab was approved by [CONTACT_391475] 2018 for patients with recurrent or 
metastatic cervical cancer with disease progression on or after chemotherapy who se tumors 
express PD -L1 (CPS ≥  1) as determined by [CONTACT_13247] -approved test ( Food and Drug 
Administration 2018). Finally, nivolumab has been studied in a trial of subjects with virus-associated cancers including [ADDRESS_491377] had a complete 
response and 4 subjects had partial response for an overall response rate of 26%. In the study 
population as a whole the response rate was higher in HPV positive cancers (28.6%) than in 
cancers with unknown HPV status (10.0%) ( Hollebecque et al 2017). These findings of clinical 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491378] -line therapy.  
1.4. Rationale for Biomarker Assessment  
1.4.1. Biomarkers in Phase 1  
When the study started, due to limited understanding of the biological activities induced by [CONTACT_391476]2034 in cancer subjects, there was no certainty that the doses examined will be associated 
with relevant antitumor immune activities. As a consequence, the study will serve to: evaluate 
receptor occupancy at different dose levels; investigate the mechanism of action of the drug by 
[CONTACT_391477]; and evaluate potential predictive/prognostic 
biomarker candidates related to the drug and/or cancer (e.g., level of PD-L1 tumor expression, 
HPV status).  
1.4.2. Biomarkers in Phase 2  
Phase 2 of the study will continue to investigate the mechanism of action of the drug by 
[CONTACT_391477]; will monitor  
as a non -invasive reflection of the tumor burden; will evaluate potential predictive/prognostic 
biomarker candidates related to the drug and/or cancer (e.g., level of PD-L1 tumor expression, 
HPV status).  
1.4.3. Assessment of PD -L1 Expression in Tumors 
PD-L1 expression has been associated with response to PD-1. In treatment naive NSCLC, a 
PD-L1 expression level of ≥  50% tumor proportion score (TPS) as a companion diagnostic for 
treatment with pembrolizumab was evaluated and is now approved. 
There is limited data available on PD -L1 expression in cervical cancer, particularly in subjects 
with metastatic disease who have relapsed after initial therapy. In a recent publication by [CONTACT_391478] ( 2017), 34% of subjects with cervical cancer were PD -L1 positive. On June 12, 2018, the 
US Food and Drug Administration approved pembrolizumab for patients with recurrent or 
metastatic cervical cancer with disease progression on or after chemotherapy whose tumors 
express PD -L1 (CPS ≥ 1) as determined by [CONTACT_13247] -approved test (Food and Drug 
Administration 2018). In KEYNOTE -158, [ADDRESS_491379] been treated regardless of PD- L1 
biomarker status. The response rate in the 81 PD-L1 positive cancers was 16% including 
3 subjects with complete response ( Chung et al 2018).  
In this study, the hypothesis is that subjects with  positive PD -L1 expression may have improved 
anti-tumor response, therefore tumor tissue is required for subjects in trial Phase 2. This is an 
exploratory biomarker that, in the future, may help to determine the patients who will best respond to PD-1 inhibition.  

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 30 of 113 2. OBJECTIVES, ENDPOINTS, AND BENEFIT/RISK  
2.1. Objectives and Endpoints  
The objectives and associated endpoints for Phase 1 and Phase 2 are shown in Section  2.1.1 and 
Section  2.1.2, respectively .  
2.1.1. Phase 1  
 Objective  Endpoint  
Primary  • To assess the safety and tolerability 
of AGEN2034 in subjects with 
metastatic and/or locally advanced solid tumors  • Occurrence of DLTs in subjects in dose 
escalation during the first 21 days of treatment  
• Frequency, severity, and duration of treatment -
emergent adverse events (TEAEs) and 
laboratory abnormalities using the National 
Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE) v4.03.  
Secondary  • To characterize the AGEN2034 
pharmacokinetic (PK) profile  • AGEN2034 PK parameters which may include 
(but are not limited to) maximum drug 
concentration  observed postdose  at steady -state 
(Cmax-ss), minimum observed concentration at 
steady -state (C min-ss), area under the  drug 
concentration -time curve within time span t1 to 
t2 at steady -state (AUC (t1-t2)-ss ), area under the 
drug concentration -time curve from time zero to 
time t (AUC (0-t)), area under the drug 
concentration -time curve from time zero to 
infinity  (AUC (0-∞)), time to maximum observed 
concentration (t max), terminal disposition rate 
constant (λ z), terminal elimination half -life (t 1/2), 
systemic clearance (CL), and volume of 
distribution (Vd)  
 • To correlate AGEN2034 exposure with target occupancy  • Receptor occupancy on circulating T cells measured [ADDRESS_491380] dose and 
immediately prior to the 2nd dose 
• Receptor occupancy saturation levels correlated 
with AGEN2034 PK exposure metrics  
 • To evaluate the immunogenicity of 
AGEN2034 and correlate it to 
exposure  • Antidrug antibody (ADA) concentrations and 
correlation with AGEN2034 PK exposure 
metrics  
Exploratory  
 • To explore the association of programmed cell death protein 1 – 
ligand 1 (PD -L1) expression with 
clinical responses  • Baseline expression of PD -L1  
 
  

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 31 of 113 2.1.2. Phase 2  
 Objective  Endpoint  
Primary  • To assess objective response rate 
(ORR) according to RECIST  1.1 as 
determined by [CONTACT_391460] (IERC)  • Confirmed ORR per RECIST 1.1, as determined 
by [CONTACT_391461], in the analysis population  
Secondary  • To assess the safety and tolerability of AGEN2034 in subjects with metastatic and/or locally advanced solid tumors  • Frequency, severity, and duration of TEAEs and laboratory abnormalities, using NCI CTCAE 
v4.03.  
 • To characterize the AGEN2034 PK profile  • AGEN2034 PK parameters which may include (but are not limited to) maximum drug 
concentration  observed postdose  at steady -state 
(C
max-ss), minimum observed concentration at 
steady-state (C min-ss), area under the drug 
concentration -time curve within time span t1 to 
t2 at steady -state (AUC (τ1-τ2)-ss ), area under the 
drug concentration -time curve from time zero to 
time t (AUC (0-t)), area under the drug 
concentration -time curve from time zero to 
infinity (AUC (0-∞)), time to maximum observed 
concentration (t max), terminal disposition rate 
constant (λ z), terminal elimination half -life (t 1/2), 
systemic clearance (CL), and volume of distribution (Vd)  
 • To evaluate the immunogenicity of AGEN2034 and correlate it to exposure  • ADA concentrations and correlation with AGEN2034 PK exposure metrics  
 • To assess objective response rate (ORR) according to RECIST  1.1 as 
determined by [CONTACT_1697]  • Confirmed ORR per RECIST 1.1, as determined by [CONTACT_2413]  
 • To assess duration of response (DOR), disease control rate (DCR), duration of stable disease (SD), time to response, and progression- free survival (PFS) 
time per RECIST 1.1  • DOR per RECIST 1.1, as determined by [CONTACT_391462], defin ed as time from first 
observation of response to first observation of documented disease progression (or death within [ADDRESS_491381] tumor assessment). Subjects without an event at analysis cutoff date will be censored on date of last tumor assessment . 
• DCR, defined as proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD) for at least 12  weeks  
• Duration of SD, measured from the start of 
treatment until the criteria for progression are 
met, taking as reference t he smallest 
measurements recorded since the treatment started, including baseline measurements.  
• Time to response, defined as the time from the first dose date to first observation of confirmed response.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 32 of 113  Objective  Endpoint  
Secondary 
(continued)   • PFS time, defined as time from first treatment 
administration to first observation of documented disease progression (or death within [ADDRESS_491382] tumor assessment), per RECIST 1.1, as determined by [CONTACT_391462]. Subjects without an event at analysis cutoff date 
will be censored on date of last tumor 
assessment.  
 • To assess overall survival (OS) rate  • Median OS and OS rate  
 • To assess OS time  • OS time, defined as time from start of treatment to death. For subjects who are still alive at time of data cutoff for trial analysis or who are lost to 
follow -up, survival will be censored at the last 
recorded date that the subject is known to be alive as of the cutoff date for analysis  
Exploratory  
 • To explore the association of 
programmed cell death protein 1 – 
ligand  1 (PD -L1) expressio n with 
clinical outcomes  • Baseline expression of PD -L1 association with 
clinical outcomes  
 
2.2. Overall Risk/Benefit Assessment  
The risk -benefit relationship has been carefully considered in the planning of this trial. Based on 
preclinical and clinical data available to date, the conduct of the trial is considered safe and 
reasonable using the dose and schedule of AGEN2034 as speci fied for Phase  1, Cohort 1 in this 
clinical trial protocol.  
A Safety Monitoring Committee (SMC) in Phase 1 and an Independent Data Monitoring Committee (IDMC) in Phase 2 are planned for ongoing assessment of the risk-benefit ratio. The trial shall be disc ontinued in the event of any new findings that indicate a relevant deterioration 
of the risk -benefit relationship and would render continuation of the trial unjustifiable. The risks 
of exposure to AGEN2034 include: 
• Infusion- related reactions.  
• Increase in i mmune- related adverse events (irAEs), which constitute a unique 
spectrum of AEs that occur via activation of the subject’s immune system and that can sometimes lead to serious and even fatal events ( Boutros et al 2016; 
Kumar  et al 2017; Weber et al 2012 ). 
Infusion- related reactions are a risk inherent to administration of any recombinant protein to 
humans. The incidence of immunogenicity and the character or severity of immunogenicity- 
induced side effects cannot be predicted by [CONTACT_391479] a much stronger immune-response in rodents or non-human primates 

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 33 of 113 than in humans. However, for AGEN2034, clinical signs of hypersensitivity were not observed 
in pi[INVESTIGATOR_2268] 4 -week IV repeat -dose toxicity studies conducted in cynomolgus monkeys (a primate 
species closer to human). There were also no findings in an in vitro cytokine release assay in 
human whole blood. 
Immune- related AEs are events that are drug -related and can be explained by [CONTACT_391480]. Relevant clinical safety experience has 
been generated with several PD -[ADDRESS_491383]–blocking monoclonal antibodies and with the 
combination with CTLA-4 agents ( Ott et al 2017 ; Boutros et al 2016; Kumar et al 2017).  
For the reasons noted previously, it is anticipated that the safety profile of nivolumab will provide a good estimate for the safety and tolerability of AGEN2034. Overall, the safety profile 
for nivolumab, which blocks the PD-1/PD- L1 axis at the same level as does AGEN2034, is 
acceptable in the context of treatment of subjects with advanced malignancies. Nevertheless, 
occurrence of AEs, especially irAEs, will be carefully monitored. 
A direct benefit is usually considered unlikely for participants in a Phase [ADDRESS_491384] 
relapsed after a platinum -based treatment regimen. There is no regimen with proven clini cal 
benefit currently available to these subjects and the treatment with PD -1 blockade provides an 
opportunity to improve on the response rates observed with chemotherapy. 
Overall, the risk -benefit ratio of the proposed treatment with AGEN2034 is considered positive, 
and to further manage the potential for added risk, in this trial there will be pro -active monitoring 
for immunogenicity and pro- active management of immune related AEs.  
3. INVESTIGATIONAL PLAN  
This is a 2 -part trial: a Phase 1, open-label, dose- escalation trial in subjects with metastatic or 
locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in 
subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum -based treatment regimen.  
3.1. Phase 1 (Part A): Dose Escalation  
Phase 1 (Part A) of the study will consist of a standard 3+3 dose escalation with the following escalating dose levels and schedules:  
• Part A1: 1, 3, and 10 mg/kg administered ever y 2 weeks  
• Part A2: 6 and 10 mg/kg administered every [ADDRESS_491385] of each cohort will be observed for 16 days (i.e., ≥  48 hours after 
second dose) for occurrence of dose- limiting toxicity (DLT) before the second subject is 
administered trial medication. Thereafter, within each cohort in the dose escalation phase of Part A1, consecutively enrolled subjects may initiate treatment ≥  48 hours after the prior enrolled 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491386] initiated treatment. Dose escalation will continue until the M TD is reached or the 
maximum planned dose level (10.0 mg/kg) is shown to be safe. The MTD is defined as the dose 
below which ≥  2 DLTs are observed.  
Once Part A1 is completed, enrollment for Part A2 will begin: 
• If < 2 DLTs are observed in dose escalation at  the 10 mg/kg every 2  weeks dose level 
in Part  A1, open enrollment will begin for Part A2 at the 6 mg/kg every 3  weeks dose 
level; enrollment of these subjects does not to have to be sequential (that is, a wait of 48 hours between 2 subjects is not required). Once 10 subjects at the 6 mg/kg dose level have completed, open enrollment will begin for Part A2 at the 10 mg/kg every 
3 weeks dose level; enrollment of these subjects does not to have to be sequential 
(that is, a wait of 48 hours between 2 subjects is not required). 
• If ≥ 2 DLTs are observed in dose escalation at the 10 mg/kg every [ADDRESS_491387] 3 + 3 dose escalation will continue with Part A2. Within each 
dose level cohort, consecutively enrolled subjects may initiate treatment ≥  [ADDRESS_491388] initiated treatment. Dose escalation will continue until 
the MTD is reached or the maximum planned dose level for Part A2 (10.0 mg/kg every 3 weeks) is shown to be safe. 
Each subject will stay on the do se level and schedule assigned at trial entry. Subjects will receive 
AGEN2034 for a maximum of 24 months or until disease progression, unacceptable toxicity, or 
any criterion for stoppi[INVESTIGATOR_391433]. 
The DLT observation period for the dose escalation portion of Phase 1 (Parts A1 and A2) is the 
first [ADDRESS_491389] reached the end of the DLT evaluation period. See Section  9.1 for a description of the 
SMC.  
The dose escalation criteria are as follows:  
• For each dose level, DLTs are assessed during the first 21 days. The criteria for moving from one dose level to another do not allow escalation to the next cohort in cases in which ≥  1 of 3 or ≥  2 of 6 subjects in a dose- level cohort experience DLT.  
• If 1 of 3 subjects in a cohort experiences a DLT, this cohort will be expanded to 6 subjects.  
• The MTD is defined as the highest dose at which < 2 of 6 subjects experience a DLT. 
Thus, the MTD cohort should accrue a total of ≥  6 subjects.  
A schematic of dose escalation is presented in  Figure 2. 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 35 of 113 Figure 2: Phase 1 Dose Escalation Schematic 
 
 
 
 
 
DLT: dose limiting toxicity; MTD: maximum tolerated dose  
 
It is conceptually acceptable to de- escalate to an intermediate, not pre-defined and not 
previously- studied dose level, if evaluation of toxicity at such a dose is desired. If this approach 
is taken, 3 new subjects should be enrolled at the new intermediate dose, and the aforementioned 
rules should be used to determine further enrollment at this dose level. 
The decision to expand a cohort to 6 subjects, to de-escalate and/or to open enrollment to the 
Dose Expansion Phase will be made by [CONTACT_391481] a 
cohort in dose escalation have reached the end of the DLT evaluation period. 
3.1.1. Dose -Limiting Toxicity  
In this trial, a DLT is defined as any treatment- related toxicity that is NCI CTCAE Grade ≥  3, 
confirmed by [CONTACT_391482], and that occurs during the 
first 3 weeks of AGEN2034 treatment in the dose escalation portion of the trial (DLT evaluation period) for all dose cohorts and for all subjects with data used for implementing the dose-
escalation algorithm for determination of MTD. Additional subjects enrolled in the dose 
escalation phase will have AEs collected but will not have a specific DLT observation period. 
The SMC recognizes that in the absence of prior human experience with AGEN203 4, a 
conservative approach will need to be adopted in ascribing the relevance of treatment- related 
toxicity to drug. Treatment- related serious adverse events (SAEs) will be ascribed as related to  
Starting  Dose  
 
Treat  3 subjects,
Assess DLT after 3 weeks  
 
Escalate  to next dose
level 
 
Determine
MTD  
MTD/maximum  dose
to be confirmed  on
total of 6 subjects  
 
Determine
MTD  
0 of 3 
Number  
of DLTs  
≥ 2 of 3 
No 
1 of 3 
Max 
dose per
protocol  
? 
Treat  additional  3 subjects,  
Assess DLT after 3 weeks  
 
1 of 3 
Yes 
≤ 1 of 6 
Number  
of DLTs  
 ≥ 2 of 6 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 36 of 113 drug except where a clear relationship to the underlying dis ease or recognized co -morbidities is 
evident. 
Exceptions to this DLT definition include: 
• Grade 3 infusion-related reactions resolving within 6 hours and controlled with 
medical management.  
• Transient (≤  6 hours) Grade 3 flu-like symptoms or fever, which are controlled with 
medical management.  
• Transient (≤  24 hours) Grade 3 fatigue, local reactions, headache, nausea, or emesis 
that resolves to grade ≤  1. 
• Grade [ADDRESS_491390] (ALT, AST, or GGT) increase 
that resolves to grade ≤  1 in < 7 days after medical management (e.g., 
immunosuppressant treatment) has been initiated. 
• Single laboratory values out of normal range that are unlikely related to trial 
treatment according to the investigator, do not have any clinical correlate, a nd resolve 
to grade ≤  1 within 7 days with adequate medical management.  
• Tumor flare phenomenon, defined as local pain, irritation, or rash localized at sites of known or suspected tumor. 
Any DLT will immediately lead to permanent withdrawal of AGEN2034.  
3.1.2. Stoppi[INVESTIGATOR_391437]. 
Should >  33% subjects on any dose level experience toxicities that meet DLT criteria but occur 
after the DLT observation period or in subjects not included in the DLT analysis set, enrollment 
will be held and the occurrences will be thoroughly evaluated by [CONTACT_942]. The SMC will 
then make recommendations to re-open enrollment or to initiate other changes in study conduct 
(such as prot ocol amendments).  
If there is a subject death within [ADDRESS_491391]’s disease progression, the trial will be put on hold to accrual and treatment held for 
subjects on study. The SMC will evaluate the cause of the event and recommend the appropriate change in study conduct. If the event is determined to be related to AGEN2034, then a study 
amendment and/or other corrective action plan will be established. If the event is determined not 
to be related to the AGEN2034, then the study will re-open to accrual and subjects on study will resume treatment.  
3.1.3. Backfill Expansion Enrollment for Each Dose Level Cohort in the Phase 1 
Concurrent with the 3+[ADDRESS_491392] 10 subjects: 
• Part A1:  
− Once the safety of the 1 mg/kg dose is established, enrollment for the 3 mg/kg dose cohort will begin. When accrual of first 3 subjects in the 3mg/kg cohort is 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 37 of 113 paused for the 21-day safety assessment and DLT observation, enrollment of 
≤ 7 subjects to backfill the 1 mg/kg cohort may begin.  
− When the safety of the 3 mg/kg dose has been established, enrollment for the 10 mg/kg dose cohort will begin. When accrual for the 10 mg/kg dose cohort is paused for safety assessment and DLT observation, enrollment of ≤  7 subjects to 
backfill the 3 mg/kg dose level can begin. 
Note:  Enrollment of 10 subjects to the 1 mg/kg dose level must be completed 
before additional subjec ts can be enrolled to backfill the 3  mg/kg dose level. 
− When the safety of the 10 mg/kg dose has been established, ≤ 4 subjects may be 
enrolled at the same dose level, for a total of 10 subjects at 10 mg/kg. 
Note:  Enrollment of 10 subjects to the 1 and 3 mg/kg dose levels must be 
completed before additional subjects can be enrolled to backfill the 10 mg/kg dose 
level.  
• Part A2:  
− Backfill for Part A2 will be considered if ≥ 2 DLTs are observed in dose escalation at the 10 mg/kg every 2 -weeks dose level in Part A1 and dose 
escalation continues with Part A2. Backfill of Part A2 will proceed as follows: 
▪ When the safety of the 6 mg/kg dose has been established, enrollment for the 
10 mg/kg dose cohort will begin. When accrual for the 10 mg/kg dose cohort is 
paused for safety assessment and DLT observation, enrollment of ≤  7 subjects to 
backfill the 6  mg/kg dose level can begin. 
▪ When the safety of the 10  mg/kg dose has been established, ≤  4 subjects may be 
enrolled at the same dose level, for a total of 10 subjects  at 10  mg/kg.  
Note: Enrollment of 10 subjects to the 6 mg/kg dose level must be completed 
before additional subjects can be enrolled to backfill the 10 mg/kg dose level. 
Backfill expansion enrollment of subjects for each cohort does not to have to be seque ntial (that 
is, a wait of 48 hours between 2 subjects is not required). Subjects enrolled to backfill each dose 
level cohort will have the purpose of generating additional safety, PK, and receptor occupancy data, and will not undergo formal DLT observation. 
3.2. Phase 2: Dose Expansion Phase  
There is no approved standard of care for second line treatment of advanced or metastatic cervical cancer. As such, these subjects would be eligible for the Phase 1 portion of the study; 
therefore, the SMC may decide to open enrollment to the expansion cohorts of this trial at a dose 
level that has been found to be safe and is expected to be active.  
The following expansion cohort will be enrolled: recurrent, unresectable, or metastatic cervical 
cancer.  
Enrollment of subjects for expansion cohort does not to have to be sequential (i.e., a wait of 
48 hours between 2 subjects is not required). Subjects will receive AGEN2034 for a maximum of 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 38 of 113 24 months or until disease progression, unacceptable toxicity, or any criterion for stoppi[INVESTIGATOR_391438]. 
The SMC will continue to evaluate safety on an ongoing basis for the Phase 2. Additionally, for 
the Phase 2 portion of the study, an IDMC will be established to evaluate safety and efficacy. 
3.3. Plann ed Number of Subjects  
3.3.1. Enrollment Targets  
The planned number of subjects for this trial is: 
• Phase 1 (Parts A1 and A2): approximately 50 subjects. 
• Phase 2: approximately 150 subjects with recurrent, unresectable and/or metastatic cervical cancer.  
The final s ample size may vary depending on the total number of dose levels tested, and subject 
replacement for DLT evaluations. 
3.3.2. Subject Replacement Strategy  
In Phase 1, subjects who do not complete the DLT observation period defined in Section  3.[ADDRESS_491393] dose of study drug. 
The overall trial duration is expected to be approximately 63 months:  
• First subject in: Q 2 2017 
• Last subject out (after follow-up): Q2 [ADDRESS_491394] planned dose of study drug. 
3.6. Medical Care of Subjects  After End of Trial  
At the end of the protocol-specified periods of active study therapy, the Sponsor will not 
continue to supply study drug to subjects/investigators unless the Sponsor chooses to extend the 
study. The investigator should ensure that the s ubject receives appropriate standard of care to 
treat the condition under study. 
Upon withdrawal from trial treatment, subjects may receive the care upon which they and their 
physicians agree. Subjects will be followed for survival and AEs as specified in Section  6. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 39 of 113 4. SELECTION OF TRIAL P OPULATION 
4.1. Target Population  
Phase 1 (Parts A1 and A2): 
Male and female subjects over the age of [ADDRESS_491395] therapy has failed. 
Phase 2:  
Female subjects over the age of 18 years with recurrent and/or metastatic cervical cancer who 
have relapsed after a platinum- based treatment regimen for advanced (recurrent, unresectable, or 
metastatic) disease.  
After the interim analyses, subsequent enrollment of subjects may be based on biomarker 
enrichment (including  but not limited to PD -L1 expression). In such cases, tumor tissue must be 
positive for the selected entry biomarker prior to subject enrollment. 
4.2. Inclusion Criteria 
For inclusion in the trial, all of the following inclusion criteria must be fulfilled as no waivers 
will be permitted: 
1. Voluntarily agree to pa rticipate by [CONTACT_109348]. Participation in 
pharmacogenomics testing is optional. 
2. Be ≥  18 years of age. 
3. Diagnosis and prior systemic treatment: 
a. Phase 1:  Have a histologically or cytologically confirmed diagnosis of a metastatic or 
locall y advanced solid tumor for which no standard therapy is available or standard 
therapy has failed.  
b. Phase 2:   
I.  Have (1) a histologically or cytologically confirmed diagnosis of squamous- cell 
carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cer vix, and 
(2) metastatic, locally advanced, and/or unresectable disease at the time of 
enrollment. Histologic confirmation of the original primary tumor is required via pathology report. 
Note:  The following cervical tumors are not eligible: minimal deviatio n/adenoma 
malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric 
carcinoma.  
II.  Has cervical cancer and has relapsed after a platinum -based treatment (first line) 
regimen for advanced (recurrent, unresectable, or metastatic) disease;  
 Note : Subject receiving chemotherapy concurrently with primary radiation (e.g., 
weekly cisplatin) or  subject receiving adjuvant chemotherapy following 
completion of radiation therapy (e.g., paclitaxel and carboplatin for ≤  4 cycles) 
and progressed within [ADDRESS_491396] line treatment.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 40 of 113 4. Measurable disease – based on investigator assessment  
a. Phase 1:  Have objective evidence of disease; the presence of measurable disease is 
not required. 
b. Phase 2:  Have measurable disease on imaging based on RECIST version 1.1. 
Note:  Subje cts must have at least one "target lesion" to be used to assess response, as 
defined by [CONTACT_44993] 1.1. Tumors within a previously irradiated field will be 
designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.  
Note:  Measurable disease by [CONTACT_393] 1.[ADDRESS_491397] 3 months and an Eastern Cooperative Oncology Group 
(ECOG) performance status of [ADDRESS_491398] adequate organ function as indicated by [CONTACT_132725]: 
a. Adequate hematological function defined by [CONTACT_28763] (ANC) ≥  1.5 x 
10
9/L, platelet count ≥ 100 x 109/L, and stable hemoglobin ≥ 8 g/dL (without 
transfusions within [ADDRESS_491399] dose). 
b. Adequate hepatic function based by a total bilirubin leve l ≤ 1.5 x the institutional 
upper limit of normal (IULN), aspartate aminotransferase (AST) level ≤ 2.[ADDRESS_491400], 
alanine aminotransferase (ALT) level ≤ 2.[ADDRESS_491401], and alkaline phosphatase ≤ 2.[ADDRESS_491402].  
c. Adequate renal function defined as creatinine ≤ 1.[ADDRESS_491403] OR  calculated creatinine 
clearance ≥  50 mL/min for subjects with creatinine levels > 1.[ADDRESS_491404] (if no local 
guideline is available, creatinine clearance should be calculated using the Cockcroft -
Gault Method). 
d. Adequate coagulation defined by [CONTACT_365187] (INR) or prothrombin time ≤ 1.[ADDRESS_491405] (unless the subject is receiving anticoagulant therapy); and activated partial thromboplastin time (aPTT) ≤  1.[ADDRESS_491406] (unless the subject is 
receiving anticoagulant therapy)  
7. Other than the cancer for which the subject is enrolled, have no history of prior 
malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder 
cancer, squamous-cell carcinoma of the skin, or has undergone potentially curative 
therapy with no evidence of that disease recurrence for [ADDRESS_491407] provide a sufficient and adequate formalin- fixed paraffin 
embedded (FFPE) tumor tissue sample preferably from the most recent biopsy of a tumor lesion, collected either at the time of or after the diagnosis of advanced or metastatic 
disease has been made AND from a site not previously irradiated. If no tumor tissue is 
available, a fresh biopsy will be req uired. (See Section  [IP_ADDRESS] for details.) 
Note:  Tissue from needle or excisional biopsy or from resection is required. 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491408] at screening (within [ADDRESS_491409] dose of study drug) if of childbearing potential or be of non- child bearing 
potential. Non-childbearing potential is defined as (by [CONTACT_73534]): 
a. ≥ 45 years of age and has not menstruated for greater than 1 year, 
b. Amenorrheic for <  2 years without a hysterectomy and oophorectomy and a follicle-
stimulating hormone (FSH) value in the postmenopausal range upon pretrial 
(screening) evaluation, 
c. Whose status is post hysterectomy, oophorectomy or tubal ligation. 
10. If of childbearing potential, female subjects must be willing to use 2 highly effective 
methods (defined in the informed consent form [ICF]) throughout the study, starting with 
the screening visit through [ADDRESS_491410] dose of study drug. 
Note:  Abstinence is acceptable if this is the established and preferred contraception for 
the subject.  
11. Male subjects with a female partner(s) of child -bearing potential must agree to use 
2 highly effective methods (defined in the ICF) throughout the trial starting with the 
screening visit through [ADDRESS_491411] agree to use a condom; no additional method of contraception is required for the preg nant partner.  
Note:  Abstinence is acceptable if this is the established and preferred contraception for 
the subject.  
12. Is willing and able to comply with the requirements of the protocol. 
4.3. Exclusion Criteria  
The subject must be excluded from participating in the trial if the subject:  
1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within [ADDRESS_491412] dose of study drug defined as:  
a. Received systemic cytotoxic chemotherapy or biological therapy within  [ADDRESS_491413] dose. 
3. Has received prior therapy with:  
a. Any antibody/drug targeting T- cell co -regulatory proteins (immune checkpoints) such 
as anti –PD-1, anti–PD -L1, or anti–cytotoxic T -lymphocyte antigen 4 (CTLA- 4) 
antibodies 
b. For Phase 2: >  [ADDRESS_491414] emic treatment regimen for the advanced (recurrent, 
unresectable, or metastatic) cervical cancer for which the subject is considered for the 
study 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 42 of 113 Note:  In Phase 1, prior treatment with a CTLA-4 antibody is permissible for subjects 
with metastatic melanoma . 
4. Has persisting toxicity related to prior therapy of NCI CTCAE Grade >  1 severity.  
Note:  Sensory neuropathy or alopecia of Grade ≤  2 is acceptable.  
5. Is expected to require any other form of systemic or localized antineoplastic therapy 
while on trial (including maintenance therapy with another agent, radiation therapy, 
and/or surgical resection).  
6. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (National Cancer Institute Common Terminology Criteria for Adverse Events ver sion 
4.03 [NCI CTCAE] Grade ≥  3), any history of anaphylaxis, or uncontrolled asthma. 
7. Is receiving systemic corticosteroid ≤ [ADDRESS_491415] dose of trial treatment or receiving any other form of systemic immunosuppressive medication (corticoster oid use 
on study for management of immune-related adverse events, and/or a premedication for 
IV contrast allergies/reactions is allowed). Subjects who are receiving daily corticosteroid 
replacement therapy are an exception to this rule. Examples of permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose, and steroid therapy administered by [CONTACT_12523][INVESTIGATOR_2855], intraocular, intranasal, and/or inhalation routes. 
8. Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period OR identified prior to consent. 
Note:  Subjects with history of brain metastases that have been treated may participate 
provided they show evidence of stable supra-tentorial lesions at screening (based on 
2 sets of brain images, performed ≥  4 weeks apart, and obtained after the brain metastases 
treatment). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be minimal and be expected as sequelae from treated lesions. For individuals who received steroids as part of brain metastases treatment, steroids must be discontinued ≥  [ADDRESS_491416] ive or history of autoimmune disease that has required systemic treatment within 
2 years of the start of trial treatment (i.e., with use of disease modifying agents, 
corticosteroids or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, 
insulin , or physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_12978], etc.) is not considered a form of systemic treatment. 
Note:  Subjects with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid disease not 
requiring immunos uppressive treatment are eligible.  
10. Has had an allogeneic tissue/solid organ transplant. 
11. Has or had interstitial lung disease (ILD) OR has had a history of pneumonitis that has 
required oral or IV corticosteroids. 
12. Has an active infection requiring intravenous systemic therapy.  
13. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 43 of 113 14. Has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is defined 
as a known positive HBsAg result. Active Hepatitis C is defined by a known positive 
Hep C Ab result and known quantitative HCV RNA results greater than the lower limits 
of detection of the assay. 
15. Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months before enrollment, unstable angina, congestive heart failure ([LOCATION_001] Heart Association class ≥  II), or serious 
uncontrolled cardiac arrhythmia requiring medication. 
16. Has a history or current evidence of any condition, therapy, or laboratory a bnormality 
that might confound the results of the trial, interfere with the subject’s participation for 
the full duration of the trial, or is not in the best interest of the subject to participate, in 
the opi[INVESTIGATOR_12980]. 
17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.  
18. Is, at the time of signing informed consent, a regular user (including “recreational use”) of any illicit drugs or had a recent history (within the last year) of substance abuse 
(including alcohol). 
19. Is legally incapacitated or has limited legal capacity.  
20. Is pregnant or breastfeeding or expecting to conceive or father children within the 
projected duration of the trial, starting with the screening visit through [ADDRESS_491417] be withdrawn in the event of any of the following: 
• Occurrence of an event that would have been considered an exclusion criterion prior to 
enrollment, that is clinically relevant and affects the subject’s safety, and if discontinuation is considered necessary by [CONTACT_1755]/or Sponsor. 
• Radiological disease progression, defined by [CONTACT_393] 1.1 as defined in Section  [IP_ADDRESS], 
unless the subject is considered to derive clinical benefit from the treatment by [CONTACT_093], is clinically stable and there is agreement with the Sponsor ( Section  5.4.5).  
  Clinical stability is defined by:  
− Absence of new symptoms and signs indicating clinically significant disease  
progression 
− No decline in ECOG performance status. 
− Absence of rapid progression of disease or progressive tumor at critical 
anatomical sites (e.g. , cord compression) requiring urgent alternative medical 
intervention. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 44 of 113 • Note: For Phase 2, tumor assessments should be performed every 6 weeks (± 3 days) 
from first treatment dose until discontinuation of treatment, regardless of reason for 
discontinuation. This includes patients who are being treated past disease progression. Clinical disease progression, in the absence of radiologic progression on the basis of 
RECIST 1.1 , including 1 or more of the following: 
− signs and/or symptoms of consistent with clinica lly significant progression of 
disease, including worsening of laboratory values, appearance of new 
lesion/worsening of the lesion best seen clinically, etc.  
− decline in ECOG performance status  
− tumor progression at critical anatomical sites that requires ur gent medical 
intervention (e.g., CNS metastasis with potential for cord progression)  
− initiation of chronic opi[INVESTIGATOR_858], or initiation of chemotherapy or new antineoplastic therapy, palliative radiation therapy, or surgery 
• Any Grade 2 drug -related uveitis or ey e pain or blurred vision that does not respond to 
topi[INVESTIGATOR_20308] 1 severity within 2 weeks OR requires systemic treatment; 
• Any Grade ≥ 2 drug -related pneumonitis or interstitial lung disease that does not resolve 
to dose dela y and systemic corticosteroids (also see Pulmonary Immune Related Adverse 
Event Management Algorithm [ Section  5.6.3 ]); 
• Any Grade 2 or 3 drug -related toxicity that does not resolve in ≤ 6 weeks;  
• Any Grade 3 drug -related bronchospasm, hypersensitivity reaction, or infusion- related 
reaction, regardless of duration; with the exception of Grade 3 infusion- related reactions 
resolving within 6 hours and controlled with medical management; 
• Any Grade 3 non-skin, drug- related AE lasting > 7 days, with the following exceptions 
for uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic toxicity, hypersensitivity reactions, infusion reactions, endocrinopathies, and laboratory abnormalities: 
− Grade 3 drug -related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic toxicity, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation; 
− Grade 3 drug -related endocrinopathies adequately controlled with only 
physiologic hormone replacement do not require discontinuation; 
− Grade 3 drug -related laboratory abnormalities do not require treatment 
discontinuation except: 
▪ Grade 3 drug -related thrombocytopenia > 7 da ys or associated with bleeding 
requires discontinuation; 
▪ Any drug -related liver function test (LFT) abnormality that meets the 
following criteria require discontinuation (also see hepatic immune -related AE 
management algorithm [ Table 7 ]): 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 45 of 113 ► AST or ALT > [ADDRESS_491418];  
► Total bilirubin > [ADDRESS_491419];  
► Concurrent AST or ALT > [ADDRESS_491420] AND total bilirubin > [ADDRESS_491421];  
• Any Grade 4 drug -related AE or laboratory abnormality, except for the following events, 
which do not require discontinuation: 
− Grade 4 neutropenia <7 days; 
− Grade 4 lymphopenia or leukopenia; 
− Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corre cted with supplementation/appropriate management 
within 72 hours after their onset; 
• Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the subject with continued treatment; 
• Tumor flare phenomenon, defined as local pain, irritation, or rash localized at sites of 
known or suspected tumor does not require treatment discontinuation. 
• Any requirement for ≥  10 mg per day of prednisone (or equivalent) for >  6 weeks; 
• Any recurrence of a Grade 3 or 4 drug -related toxicity;  
• Dose delay which results in no AGEN2034 dosing for more than 6 weeks. 
• Occurrence of AEs, resulting in discontinuation of trial drug that is desired or considered 
necessary by [CONTACT_1755]/or the subject (if applicable). 
• Occurrence of pregnancy (if applicable).  
• Use of a non-permitted concomitant drug, as defined in Section  5.5.2, in whi ch the 
predefined consequence is withdrawal from study drug (Sponsor may be contact[CONTACT_391483]).  
• Noncompliance for non- medical reasons ( Section  [IP_ADDRESS]) 
4.4.2. Withdrawal from the Trial 
Subjects are free to discontinue the trial at any time without giving their reasons. A subject must 
be withdrawn in the event of any of the following: 
• Withdrawal of the subject’s consent. 
• Participation in any other therapeutic trial during the treatment duration of this trial.  
If a subject has failed to attend scheduled trial assessments, the investigator must determine the reasons and the circumstances as completely and accurately as possible.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 46 of 113 In case of premature withdrawal from the trial, the investigations scheduled for the 
Discontinuation Visit should be performed ( Section  6.1) if possible, with focus on the most 
relevant assessments. In any case, the appropriate electronic case report form (eCRF) section 
must be completed. 
4.4.3. Premature Discontinuation of the Trial 
The entire trial may be discontinued prematurely in the event of any of the following: 
• New information leading to unfavorable risk-benefit judgement of AGEN2034, e.g., due 
to: 
- Occurrence of significant previously unknown adverse reactions, or unexpectedly 
high intensity or incidence of known adverse reactions. 
- Other unfavorable safety findings. 
Note: Evidence of inefficacy may arise from this trial or from other trials of 
AGEN2034, and unfavorable safety findings may arise from clinical or non- clinical 
examinations (e.g., toxicology). 
• Sponsor’s decision that continuation of the trial is unjustifiable for medical or ethical 
reasons.  
• Poor enrollment of subjects, making completion of the trial within an acceptable 
timeframe unlikely.  
• Discontinuation of development of AGEN2034. 
Health authorities and Independent Ethics Committees (IECs)/Institutional Review Boards 
(IRBs) will be informed about trial discontinuation in accordance with applicable regulations.  
The entire trial may be terminated or suspended upon request of health authorities. 
5. STUDY DRUGS AND TREATMENT  
5.1. Investigational Medicinal Product  
The investigational medicinal product (IMP), also known as study drug, is AGEN2034, a novel, 
fully human monoclonal IgG4 antibody designed to block PD-1.  
AGEN2034 drug product is supplied as a sterile, single-use solution for IV injection in a 2 mL or 
10 mL glass vial. AGEN2034 should be stored in a refrigerator at 2°C to 8°C. 
Each drug product 2 mL vial contains a withdrawable volume of 1 mL with 50 mg AGEN2034 
at a nominal concentration of 50 mg/mL formulated in  
. Each drug product 10 mL vial contains a withdrawable volume of 
5 mL with 50 mg AGEN2034 at a nominal concentration of 10 mg/mL formulated in  
. 

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 47 of 113 Please refer to the current version of the Investigator’s Brochure and/or Pharmacy Manual for 
complete storage, handling, dispensing, and infusion information for AGEN2034. 
5.2. Packaging and Labeling  
Study drug packaging and labeling w ill be in accordance with applicable local regulatory 
requirements and applicable Good Manufacturing Practice guidelines. The following information 
will be pre -printed on the vial: vial contents, storage conditions, and lot number. The label will 
also cont ain a statement to conform with FDA Investigational New Drug (IND) requirements as 
follows: 
“Caution: New Drug - Limited by [CONTACT_192321].”  
All study drug must be kept in a secure place under appropriate storage conditions. The sponsor 
or its representatives must be granted access on reasonable request to check drug storage, 
dispensing procedures, and accountability records. Refer to the Pharmacy Manual for additional 
details.  
5.3. Storage and Dispensing  
The product storage manager should ensure that study drugs are stored in accordance with the environmental conditions (temperature, light, and humidity) as determined in the Pharmacy 
Manual. If concerns regarding the quality or appearance of the study drug arise, the study drug 
should not be dispensed and Sponsor should be contact[CONTACT_15608]. 
Study drug documentation must be maintained including all processes required to ensure drug is 
accurately administered. This includes documentation of drug storage, administration and, as 
applicable, s torage temperatures, reconstitution, and use of required processes (e.g., required 
diluents, administration sets).  
AGEN2034 will be shipped in transport cool containers (2°C to 8°C) that are monitored with temperature control devices.  
AGEN2034 drug product must be stored at 2°C to 8°C until use, with a temperature log 
maintained daily. All medication boxes supplied to each study center must be stored carefully, 
safely, and separately from other drugs.  
For application in this trial, AGEN2034 drug product must be diluted with 0.9% saline solution 
(sodium chloride injection). Detailed information on infusion bags and medical devices to be 
used for preparation of dilutions and subsequent administration is provided in the Pharmacy Manual.  
Once the vial is punctured, the AGEN2034 drug product must be diluted into appropriate volume of 0.9% saline solution in an infusion bag immediately. Infusion from the bag should begin within 24 hours of vial puncture when the bag is stored either at room temperature or at 5°C 
± 3°C (refrigerated conditions). 
Any unused portion of solution should be discarded in biohazard waste disposal, with final 
disposal by [CONTACT_148423]. 
Please refer to the current version of the Investigator’s Brochure and/or Pharmacy Manual for 
complete storage, handling, dispensing, and infusion information for AGEN2034. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 48 of 113 5.4. Dosage and Administration  
5.4.1. AGEN2034 
AGEN2034 infusions should be administered within 60 minutes (-10/+20 min) using an infusion 
pump. A central catheter is not required for infusion; however, if a subject has a central venous 
catheter in place, it is recommended that it be used for the infusion. Once the infusion is completed, all remaining drug solution in the line should be administered according to institutional guidelines for saline flushing.  
[IP_ADDRESS]. Treatment Regimen  
In Phase 1, the dose levels and schedules shown in  Table 2 will be studied.  
Table 2: Phase 1 Dosing Regimens 
Part and Agent  Dose  Schedule  Duration of Treatment 
Part A1: Dose Level 1     
 AGEN2034 1 mg/kg IV1 Every 2 weeks  Up to 24 months  
Part A1: Dose Level 2     
 AGEN2034 3 mg/kg IV1 Every 2 weeks  Up to 24 months  
Part A1: Dose Level 3     
 AGEN2034 10 mg/kg IV1 Every 2 weeks  Up to 24 months  
Part A2: Dose Level 1     
 AGEN2034 6 mg/kg IV1 Every 3 weeks  Up to 24 months  
Part A2: Dose Level 2     
 AGEN2034 10 mg/kg IV1 Every 3 weeks  Up to 24 months  
1 Infusion time is 60  minutes ( -10/+20 min)  
 
In Phase 2, all subjects will receive AGEN2034 at a dose of 3 mg/kg IV over 60 minutes 
(-10/+20 min) every [ADDRESS_491422] meets criteria to remain on therapy.  
5.4.2. Premedication  
Premedication should not be administered routinely prior to dosi ng of drugs. See  Section  5.4.3 
for subsequent premedication recommendations following AGEN2034-related infusion reactions.  
5.4.3. Treatment of Infusion Related Reactions  
Acute infusion reactions (which can include cytokine release syndrome, angioedema, or anaphylaxis) are different from allergic/hypersensitive reactions, although some of the manifestations are common to both AEs. Signs and symptoms usually develop during or shortly 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 49 of 113 after drug infusion and generally resolve completely within 24 hours of completion of infusion. 
Signs/symptoms may include: allergic reaction/hypersensitivity (including drug fever); arthralgia 
(joint pain); bronchospasm; cough; di zziness; dyspnea (shortness of breath); fatigue (asthenia, 
lethargy, malaise); headache; hypertension; hypotension; myalgia (muscle pain); nausea; 
pruritus/itching; rash/desquamation; rigors/chills; sweating (diaphoresis); tachycardia; tumor 
pain (onset or exacerbation of tumor pain due to treatment); urticaria (hives, welts, wheals); vomiting.  
For an individual subjects, once the AGEN2034 infusion rate has been decreased by 50% or interrupted due to an infusion- related reaction, it must remain decreased fo r all subsequent 
infusions to that subject. If the subject has a second infusion- related reaction that is Grade ≥  [ADDRESS_491423] be recorded. 
Should infusion reaction be considered a significant safety issue by [CONTACT_4484], the SMC might 
decide to recommend premedication with an antihistamine and acetaminophen approximately 30 
to 60 minutes before each dose of AGEN2034 (e.g., 25–50 mg diphenhydramine, 500–650 mg 
paracetamol IV or oral equivalent acetaminophen). This regimen may be modified based on local treatment standards and guidelines, as appropriate. 
Table [ADDRESS_491424] likely in the hour after completion of the infusion, and immune rel ated AEs, 
before leaving the study site. This will include instructions on when and how to return for 
immune mediated toxicities associated with PD -1 blockade.  
Once the AGEN2034 infusion rate has been decreased by 50% or interrupted due to an infusion- related reaction, it must remain decreased for all subsequent infusions. If the subject has a second 
infusion- related reaction that is Grade ≥  [ADDRESS_491425] be recorded. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 50 of 113 Should infusion reaction be considered a significant safety issue by [CONTACT_4484], the SMC might 
decide to recommend premedication with an antihistamine and acetaminophen approximately 
30 to 60 minutes before each dose of AGEN2034 (e.g., 25-50 mg diphenhydramine, 500-650 mg paracetamol IV or oral equivalent acetaminophen). This regimen may be modified based on local treatment standards and guidelines, as appropriate. 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 51 of 113 Table 3: AGEN2034 Infusion Related Reaction Management Guidelines 
 
CTCAE  Grade   
Treatment  Premedication  at 
Subsequent  Dose  
 Grade  1: 
Mild reaction; infusion  
interruption  not 
indicated; intervention 
  Increase  monitoring  of vital signs  as 
medically  indicated  until the subject is 
deemed  medically  stable  in the opi[INVESTIGATOR_8574].  None.  
Grade  2: 
Requires  infusion interruption 
but responds  promptly  to 
symptomatic  treatment 
(e.g.,  antihistamines,  
nonsteroidal anti -inflammatories  
[NSAIDS], narcotics, IV fluids);  
prophylactic  medications  
indicated  for ≤ 24 hours.  Stop infusion  and monitor  symptoms.  
Additional appropriate  medical  therapy  
may include  but is not limited  to the 
following:  
• IV fluids  
• Antihistamines  
• NSAIDS  
• Acetaminophen  
• Narcotics  
Increase monitoring of vital signs  as 
medically  indicated  until the subject is 
deemed  medically  stable  in the opi[INVESTIGATOR_151733].  
If symptoms  resolve  within  1 hour of 
stoppi[INVESTIGATOR_13056],  the infusion may be 
restarted  at 50% of the original infusion  
rate. Otherwise,  dose administration  will be 
held until symptoms  resolve,  and the  
subject  should  be premedicated  for the next 
scheduled  dose.  
Subjects  who develop  Grade  [ADDRESS_491426]  may be pre-medicated 
1.5 hours  (± 30 minutes)  prior  to 
infusion with the following:  
• Diphenhydramine  50 mg 
PO (or equivalent dose of  
antihistamine).  
• Acetaminophen  500-1000 
mg PO (or equivalent dose 
of antipyretic).  
Grades  3 or 4 
 
Grade  3: 
Prolonged (i.e., not rapi[INVESTIGATOR_391439]/or  brief  
interruption  of infusion);  
recurrence  of symptoms  
following  initial 
improvement;  hospi[INVESTIGATOR_391440] (e.g.,  renal 
impairment,  pulmonary  
infiltrates).  
 
Grade  4: 
Life-threatening; pressor  or 
ventilatory  support 
indicated.  Stop infusion.  
Additional appropriate  medical  therapy  
may include  but is not limited  to: 
• IV fluids  
• Antihistamines  
• NSAIDS  
• Acetaminophen  
• Narcotics  
• Oxygen 
• Pressors  
• Corticosteroids  
• Epi[INVESTIGATOR_391441].  
Hospi[INVESTIGATOR_144094].  
Subject is permanently discontinued  
from  further  study  drug administration.  No subsequent dosing. 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 52 of 113 5.4.4. Dose Modifications and Treatment Delay  
[IP_ADDRESS]. Dose Reductions  
No AGNE2034 dose reduction or escalation is allowed. Each subject will stay on the dose 
levels assigned in the trial unless treatment needs to be stopped.  
[IP_ADDRESS]. Treatment Delay  
[IP_ADDRESS].1. Criteria for Treatment Delay  
AGEN2034 administration should be delayed for the following: 
• Any Grade ≥ 2 non-skin, drug-related AE with the following exceptions: 
− Do not delay treatment for Grade ≥ 2 Fatigue and laboratory abnormalities except 
for: 
▪ Delay dosing for Grade ≥ 2 serum creatinine (more than 1.5x baseline) toxicity  
▪ If a subject has a baseline AST, ALT, or  total bilirubin that is within normal 
limits, delay dosing for drug -related Grade ≥ 2 toxicity;  
• Any Grade ≥ 3 skin drug- related AE or suspected Stevens -Johnson syndrome (SJS) or 
toxic epi[INVESTIGATOR_194] (TEN)  
• Any Grade ≥ [ADDRESS_491427], ALT, or total bilirubin: 
− Grade 3 lymphopenia does not require a dose delay. 
− If a subject has a baseline AST, ALT, or total bilirubin that is within normal 
limits, delay dosing for drug -related Grade ≥ 2 toxicity.  
− If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity 
range, delay dosing for drug- related Grade ≥ 3 toxicity.  
• Any AE, laboratory abnormality, or inter-current illness which, in the judgment of the 
investigator, warrants delaying the dose of study drug. 
Subjects receiving AGEN2034 who have drug- related toxicities that meet the criteria for dose 
delay should have treatment delayed until retreatment criteria are met.  
[IP_ADDRESS].2. Criteria to Resume Treatment  
Subjects may resume treatment with AGEN2034 when drug- related AE(s) resolve(s) to Grade 1 
or baseline value, with the following exceptions: 
• Subjects may resume treatment in the presence of Grade 2 fatigue.  
• Subjects who have not experienced a Grade 3 drug- related skin AE may resume 
treatment in the presence of Grade 2 skin toxicity.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 53 of 113 • Subjects with baseline Grade [ADDRESS_491428]/ALT or total bilirubin who require dose delays 
for reasons other than a 2- Grade shift in AST/ALT or total bilirubin may resume 
treatment in the presence of Grade [ADDRESS_491429]/ALT or total bilirubin.  
− Subjects with combined Grade [ADDRESS_491430]/ALT AND total bilirubin values meeting 
discontinuation parameters ( Section  4.4.1) should have treatment permanently 
discontinued. 
• Drug -related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline 
before treatment is resumed.  
• Drug -related endocrinothapi[INVESTIGATOR_391442].  
• Subjects who received systemic corticosteroids for management of any drug- related 
toxicity must be off corticosteroids or have tapered down to an equivalent dose of 
prednisone ≤  10 mg/day.  
5.4.5. Treatment Beyond Disease Progression  
Subjects  will be permitted, with the Sponsor’s approval, to continue with treatment beyond 
initial RECIST 1.1 defined progressive disease (PD) as long as they meet the following criteria:  
• Investigator- assessed clinical benefit from the treatment;  
• Is clinically sta ble (see definition in Section  4.4.1); 
• Subject is tolerating study drug; and  
• There is agreement with the sponsor. 
The assessment of clinical benefit  should take into account whether the subject is clinically 
deteriorating and unlikely to receive further benefit from continued treatment. The following criteria need to be taken into consideration:  
• Absence of clinical symptoms and signs (including worsen ing of laboratory values) 
indicating disease progression. 
• No decline in ECOG performance status. 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention.  
Subjects should discontinue study therapy upon evidence of further progression, defined as an 
additional 10% or greater increase in tumor burden from time of initial progression (including all 
target lesions and new measurable lesions ). 
Imaging is required every 6 weeks (±  3 days) for those subjects with PD who remain on 
AGEN2034 until treatment is discontinued. 
At the time of initial progression, new lesions are considered measurable if the longest diameter 
is ≥ 10 mm (except for path ological lymph nodes, which must have a short axis of ≥  15 mm). 
Any new lesion considered non- measurable at the time of initial progression may become 
measurable and therefore included in the tumor burden measurement if the longest diameter 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 54 of 113 increases to ≥  10 mm (except for pathological lymph nodes, which must have an increase in 
short axis to ≥  15 mm). 
5.5. Concomitant Treatments 
5.5.1. Acceptable Concomitant Medications  
All treatments that the investigator considers necessary for a subject’s welfare may be 
administere d at the discretion of the investigator in keepi[INVESTIGATOR_12983]. All concomitant medication will be recorded on the eCRF including all prescription, over-the-counter (OTC), herbal supplements, and IV medications and fluids. If 
changes occur during the trial period, documentation of drug dosage, frequency, route, and date will also be included on the eCRF. 
Palliative and supportive care is permitted during the course of the trial for underlying medical 
conditions and management of symptoms.  
Surgery for tumor control or symptom management is not permitted during the study. Palliative radiotherapy is permitted to a single lesion if considered medically necessary by [CONTACT_391484] a RECIST 1.1- defined target lesion and treatment is NOT 
administered for tumor control. Trial therapy should be held during the course of palliative radiotherapy and should be resumed no earlier than the next scheduled administration of trial therapy. The specifics of the radiation treatment, including the location, will be recorded. 
All concomitant medications received within [ADDRESS_491431] dose of trial treatment through the Safety Follow-up Visit should be recorded. 
[IP_ADDRESS]. Rescue Medications and Supportive Care  
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_110525].  
For guidelines for continuing treatment with AGEN2034, see Section  [IP_ADDRESS].2. 
• Diarrhea: Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus). In 
symptomatic subjects, infectious etiologies should be ruled out, and if symptoms are 
persistent and/or severe, endoscopic evaluation should be considered. All subjects who experience diarrhea should be advised to drink liberal quantities of clear fluids. 
If sufficient oral fluid intake is not feasible, fluid and electrolytes should be 
substituted via IV infusion. 
• Anemia: Transfusions and/or erythropoietin may be utilized as clinically  indicated for 
the treatment of anemia, but should be clearly noted as concurrent medications. Consider a potential immunologic etiology.  
• Neutropenia: Prophylactic use of colony- stimulating factors including Granulocyte 
Colony- Stimulating Factor (G -CSF), PEGylated G -CSF or Granulocyte Macrophage 
Colony- Stimulating Factor GM CSF is not allowed in this trial. Therapeutic use of 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 55 of 113 G-CSF is allo wed in subjects with Grade 3 -4 febrile neutropenia. Consider a potential 
immunologic etiology.  
• Thrombocytopenia: Transfusion of platelets may be used if clinically indicated. 
Immune thrombocytopenia purpura (ITP) should be ruled out before initiation of platelet transfusion.  
• Anti-infectives: Subjects with a documented infectious complication should receive 
oral or IV antibiotics or other anti-infective agents as considered appropriate by [CONTACT_391485] a given infectious condition, according to standard 
institutional practice.  
• Adverse event with a potential immunologic etiology (irAE): identification, evaluation and management of adverse experiences of a potential immunologic etiology. Depending on the type and severity of an irAE, oral or int ravenous 
treatment with a corticosteroid should be considered, in addition to appropriate symptomatic treatment of a given condition (see Section  5.6 for management 
algorithms). These are also considered AEs of special interest (AESI) and should be reported to the Sponsor per Section  [IP_ADDRESS]. 
5.5.2. Proh ibited and/or Restricted Treatments  
As stated in the exclusion criteria ( Section  4.3), subjects must not have had chemotherapy, 
radiotherapy (other than palliative bone- directed radiotherapy, as described in Section  5.5.1), 
major surgery, or received another investigational agent within 28 days b efore the start of study 
treatment.  
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_391443]:  
• Immunotherapy not specified in this protocol. 
• Chemotherapy.  
• Investigational agents o ther than AGEN2034. 
• Surgery for symptom management or tumor control. 
• Growth factors (granulocyte colony-stimulating factor or granulocyte macrophage colony- stimulating factor). Exception: Erythropoietin and darbepoietin alpha may be 
prescribed at the investigator’s discretion. Therapeutic use of G- CSF is allowed in 
subjects with Grade 3 or 4 febrile neutropenia. 
• Radiation therapy for tumor control. 
• Glucocorticoids for any purpose other than to modulate symptoms from an irAE, or 
for use as a pre-medication in subjects with a known history of an IV contrast allergy 
administered as part of computed tomography (CT) radiography. 
Note: Replacement doses of corticosteroids (for example, prednisone 5-7.5 mg daily) are permitted while on study.  
Note: Use of inhaled or topi[INVESTIGATOR_391444].  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 56 of 113 • Bisphosphonates and/or receptor activator of nuclear factor kappa-B ligand (RANKL) 
inhibitor therapi[INVESTIGATOR_391445]. These therapi[INVESTIGATOR_391446].  
• Subjects who, in the assessment by [CONTACT_093], require the use of any of the aforementioned treatments for clinical management should be removed from the trial.  
• Subjects may receive other medications that the investigator deems to be medically necessary.  
• Medications listed in the Exclusion Criteria are prohibited in this trial.  
• There are no prohibited therapi[INVESTIGATOR_3927]- Treatment Follow -up Phase 
5.5.3. Other Restrictions and Precautions  
The following non-drug therapi[INVESTIGATOR_391447] (and within 28 days before the start of trial treatment):  
• Major surgery (excluding prior diagnostic biopsy). 
• Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or that 
are known to potentially interfere with major organ function (e.g., hypericin). 
• Subjects should not abuse alcohol or other drugs during the study. 
5.6. Management of Immune -related Adverse Even ts  
Immuno-oncology agents such as AGEN2034 are associated with irAEs. Early recognition and management of irAEs may mitigate severe toxicity. Investigators should also monitor subjects closely for potential irAEs, which may manifest at the earliest after weeks of treatment. Such 
events may consist of persistent rash, diarrhea, colitis, autoimmune hepatitis, pneumonitis, encephalitis, arthritis, glomerulonephritis, cardiomyopathy, or uveitis and other inflammatory eye conditions. 
Management Algorithms have been developed to assist investigators in assessing and managing 
the following groups of irAEs: Gastrointestinal, Pulmonary, Dermatological, Renal, Hepatic, Neurological, and Endocrine among others. 
Adverse events (both non-serious and serious) associated with drug exposure and consistent with 
an immune phenomenon may represent an immunologic etiology. These immune related AEs may be predicted based on the nature of the study drugs, their mechanism of action, and reported 
experience with immunotherapi[INVESTIGATOR_156134] t have a similar mechanism of action. An irAE can occur 
shortly after the first dose or several months after the last dose of study drug. Particular attention 
should be paid to AEs that may be suggestive of potential irAEs as outlined below. 
Immune- related  AEs are considered are considered AESIs and should be reported to the Sponsor 
per Section  [IP_ADDRESS]. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 57 of 113 5.6.1. Dermatological Immune- related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. 
 
Table 4: Dermatological Immune- related Adverse Event Management Algorithm  
Dermatological Immune -related Adverse Events  
Grade  of Rash  
(NCI CTCAE  v4.03)   
Management   
Follow -Up 
Grade  1–2 
Covering ≤30%  body  surface 
area.  • Symptomatic  therapy  (e.g., 
antihistamines,  topi[INVESTIGATOR_80114]).  
• Continue  AGEN2034  therapy  
per protocol.  • If persists  >1 to 2 weeks  or recurs:  
Consider  skin biopsy.  
• Delay  AGEN2034 therapy.  
• Consider  0.5–1 mg/kg/day  
methylprednisolone  IV or oral 
equivalent. Once  improving,  taper  
corticosteroids  over at least 1 month;  
consider  prophylactic  antibiotics  for 
opportunistic  infections; and resume 
AGEN2034  therapy  per protocol.  
• If worsens:  treat as Grade  3–4. 
Grade  3–4 
Covering >30%  body  surface  
area; life- threatening  
consequences.  • Delay  or discontinue  
AGEN2034  therapy  per 
protocol.  
• Consider  skin biopsy.  
• Dermatology consult  
• 1–2 mg/kg/day  
methylprednisolone  IV or IV 
equivalent.  • If improves  to Grade  1: taper  
corticosteroids  over at least 1 month;  
add prophylactic  antibiotics  for 
opportunistic  infections.  
• Resume  AGEN2034  therapy  per 
protocol.  
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 58 of 113 5.6.2. Gastrointestinal Immune -related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy. Opi[INVESTIGATOR_858]/narcotics may mask symptoms of perforation. Infliximab should not be 
used in cases of perforation or sepsis.  
 
Table 5: Gastrointestinal Immune -related Adverse Event Management Algorithm  
Gastrointestinal Immune -related Adverse Events  
Severity of Diarrhea/Colitis  
(NCI CTCAE  v4.03)  Management  Follow -Up 
Grade  1 
Diarrhea: <4 stools/day  over 
baseline.  
Colitis: asymptomatic.  • Continue  AGEN2034  therapy  
per protocol.  
• Symptomatic  treatment • Close  monitoring for worsening  
symptoms.  
• Educate  subject to report worsening 
immediately.  
• Consider  symptomatic  treatment  
including hydration,  electrolyte 
replacement, dietary  changes  (e.g. 
American  Dietetic  Association  colitis  
diet),  and loperamide  
• If worsens:  treat as Grade  2 or 3–4. 
Grade  2 
Diarrhea: 4–6 stools  per day 
over baseline;  IV fluids  
indicated  <24 h; not interfering  
with activities  of daily  living  
(ADL).  
Colitis: abdominal pain;  blood  
in stool  • Delay  AGEN2034  therapy  
per protocol.  
• Symptomatic  treatment.  • If improves  to Grade 1: resume  
AGEN2034  therapy  per protocol.  
• If persists  >5 to 7 days  or recurs:  0.5–
1 mg/kg/day  methylprednisolone  or 
equivalent.  
• When symptoms  improve  to Grade  1, 
taper  corticosteroids  over at least 
1 month;  consider  prophylactic  
antibiotics  for opportunistic  infections; 
resume  AGEN2034  therapy  per 
protocol.  
• If worsens  or persists  >3 to 5 days with 
oral corticosteroids: treat as Grade  3–4. 
Grade  3 to 4 
Diarrhea  (Grade  3): ≥7 stools  
per day over baseline;  
incontinence;  IV fluids  ≥24 h;  
interfering  with ADL.  
Colitis  (Grade  3): severe 
abdominal pain, medical  
intervention  indicated,  
peritoneal signs.  
Grade  4: life-threatening,  
perforation  • Discontinue  AGEN2034  
therapy  per protocol.  
• 1–2 mg/kg/day  
methylprednisolone  IV or 
equivalent.  
• Add prophylactic  antibiotics  
for opportunistic  infections.  
• Consider  lower  endoscopy.  • If improves:  continue  corticosteroids  
until Grade  1, then taper  over at least 1 
month.  
• If persists  >3 to 5 days,  or recurs  after 
improvement: add infliximab  5 mg/kg 
(if no contraindication).  
Note : infliximab  should not be used in 
cases  of perforation  or sepsis.  
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 59 of 113 5.6.3. Pulmonary Immune -related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. Evaluate with imaging and pulmonary consultation. 
 
Table 6: Pulmonary Immune -related Adverse Event Management Algorithm  
Pulmonary  Immune -related Adverse Events  
Grade  of Pneumonitis 
(NCI  CTCAE  v4.03)  Management  Follow -Up 
Grade  1 
Radiographic  changes  only.  • Consider  delay  of 
AGEN2034  therapy  per 
protocol.  
• Monitor  for symptoms  every  
2–3 days.  
• Consider  pulmonary  and 
infectious  disease  consults.  • Re-image  every  ≥3 weeks.  
• If worsens:  treat as Grade  2 or Grade  
3–4. 
Grade  2 
Mild to  moderate new 
symptoms  • Delay  AGEN2034  therapy  
per protocol.  
• Pulmonary and infectious  
disease  consults.  
• Monitor  symptoms  daily; 
consider  hospi[INVESTIGATOR_059].  
• 1 mg/kg/day  
methylprednisolone  IV or 
oral equivalent.  
• Consider  bronchoscopy,  lung 
biopsy.  • Re-image  every  1–3 days.  
• If improves:  when  symptoms  return  to 
near baseline, taper  corticosteroids  over 
at least 1 month,  then resume  
AGEN2034  therapy  per protocol, and  
consider  prophylactic  antibiotics.  
• If not improving after 2 weeks  or 
worsening: treat as Grade  3–4. 
Grade  3–4 
Severe new symptoms; new/  
worsening hypoxia; life - 
threatening.  • Discontinue  AGEN2034  
therapy  per protocol.  
• Hospi[INVESTIGATOR_18552].  
• Pulmonary and infectious  
disease  consults.  
• 2–4 mg/kg/day  
methylprednisolone  IV or IV 
equivalent.  
• Add prophylactic  antibiotics  
for opportunistic  infections.  
• Consider  bronchoscopy,  lung 
biopsy.  • If improves  to baseline:  taper  
corticosteroids  over at least 6 weeks.  
• If not improving  after  48 hours  or 
worsening: add additional 
immunosuppression (e.g.,  infliximab,  
cyclophosphamide,  IV 
immunoglobulin,  mycophenolate  
mofetil).  
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 60 of 113 5.6.4. Hepatic Immune -related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. Consider imaging for obstruction. 
 
Table 7: Hepatic Immune -related Adverse Event Management Algorithm  
Hepatic  Immune -related Adverse Events  
Grade  of Liver  Test Elevation  
(NCI CTCAE  v4.03)   
Management   
Follow -Up 
Grade  [ADDRESS_491432]  or ALT  >ULN  to [ADDRESS_491433]  
and/or  total bilirubin  >ULN  to 
1.[ADDRESS_491434].  • Continue  AGEN2034  therapy  
per protocol.  • Continue  liver function  tests (LFT)  
monitoring  per protocol.  
• If worsens:  treat as Grade  2 or Grade  
3–4. 
Grade  [ADDRESS_491435]  or ALT  >3 to ≤[ADDRESS_491436]  
and/or  total bilirubin  >1.5 to 
≤[ADDRESS_491437].  • Delay  AGEN2034  therapy  
per protocol.  
• Increase frequency of 
monitoring  to every  
3 days.  
• If subject has concurrent AST  
or ALT  > [ADDRESS_491438]  AND  
total bilirubin  > [ADDRESS_491439],  
Discontinue  AGEN2034  
therapy  per protocol.  • If returns  to baseline:  resume  routine  
monitoring; resume  AGEN2034 
therapy  per protocol.  
• If elevations  persist  >5 to 7 days  or 
worsen: 0.5–1 mg/kg/day 
methylprednisolone  IV or oral 
equivalent. When LFT returns  to Grade  
[ADDRESS_491440] 1 month,  consider  prophylactic  
antibiotics  for opportunistic  infections,  
and resume  AGEN2034  therapy  per 
protocol.  
Grade  3–[ADDRESS_491441]  or ALT  >[ADDRESS_491442]  and/or  
total bilirubin  >[ADDRESS_491443].  • Discontinue  AGEN2034  
therapy  per protocol.  
• Increase frequency of 
monitoring  to every  
1–2 days.  
• 1–2 mg/kg/day  
methylprednisolone  IV or 
oral equivalent*.  
• Add prophylactic  antibiotics  
for opportunistic  infections.  
• Consult gastroenterology.  
• Consider  obtaining MRI/CT  
scan of liver and liver biopsy  
if clinically  warranted.  • If returns  to Grade  2: taper  
corticosteroids  over at least 1 month.  
• If does not improve  in > 3 to 5 days,  
worsens  or rebounds:  add 
mycophenolate  mofetil 1 g twice  daily.  
If no response  within  an additional 
3-5 days,  consider  other  
immunosuppressants  per local 
guidelines.  
*The  recommended  starting  dose for Grade  4 hepatitis  is 2 mg/kg/day  methylprednisolone  IV. 
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 61 of 113 5.6.5. Endocrine Immune -related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. Consider visual field testing, endocrinology consultation, and 
imaging.  
 
Table 8: Endocrine Immune -related Adverse Event Management Algorithm  
Endocrine  Immune -related  Adverse Events  
Endocrine  Disorder Management  Follow -Up 
Asymptomatic  
thyroid -stimulating 
hormone ( TSH)  
abnormality  • Continue  AGEN2034  therapy  per protocol.  
• If TSH < 0.5 x lower  limit of normal (LLN)  or TSH > [ADDRESS_491444],  or 
consistently out of range  in 2 subsequent  measurements: include  free 
thyroxine  (fT4) at subsequent  cycles  as clinically indicated; consider  
endocrinology consult.  
Symptomatic  endocrinopathy  • Evaluate  endocrine  function.  
• Consider  pi[INVESTIGATOR_362908]. 
• Symptomatic  with 
abnormal  lab/pi[INVESTIGATOR_391448]:  delay  AGEN2034 
therapy  per protocol;  
1-2 mg/kg/day  
methylprednisolone  IV or 
oral equivalent; initiate  
appropriate  hormone  therapy.  
• No abnormal lab/ pi[INVESTIGATOR_391449]:  repeat labs in 
1-3 wk/MRI  in 1 month.  • If improves  (with  or without  
hormone  replacement):  taper  
corticosteroids  over at least month  and 
consider  prophylactic  antibiotics  for 
opportunistic  infections.  
• Resume  AGEN2034  therapy  per 
protocol.  
• Subjects  with adrenal insufficiency  may 
need  to continue  corticosteroids  with 
mineralocorticoid  component.  
Suspi[INVESTIGATOR_391450]  
(e.g.,  severe dehydration,  
hypotension,  shock out of 
proportion  to current  illness)  • Delay  or discontinue  AGEN2034  therapy per protocol.  
• Rule  out sepsis.  
• Stress  dose of IV corticosteroids  with mineralocorticoid activity.  
• IV fluids.  
• Consult endocrinologist.  
• If adrenal  crisis  ruled  out, treat as  above  for symptomatic  endocrinopathy.  
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 62 of 113 5.6.6. Renal Immune -related Adverse Events  
Rule out non-inflammatory causes, if non- inflamma tory cause is identified, treat accordingly and 
continue therapy per protocol. 
 
Table 9: Renal Immune -related Adverse Event Management Algorithm  
Renal  Immune -related Adverse Events  
Grade  of Creatinine  Elevation  
(NCI CTCAE  v4.03)  Management  Follow -Up 
Grade  1 
Creatinine  > upper  limit of normal  
(ULN)  and >  than baseline  but ≤ 
1.5x baseline.  • Continue  AGEN2034  
therapy  per protocol.  
• Monitor  creatinine  weekly  • If returns  to baseline:  resume  routine  
creatinine  monitoring per protocol.  
• If worsens:  treat as Grade  2 or Grade  
3–4. 
Grade  2-3 
Creatinine  > 1.5x baseline  to ≤ 6x 
ULN.  • Delay  AGEN2034  therapy  
per protocol.  
• Monitor  creatinine  every  2- 
3 days 
• 0.5 to 1.0 mg/kg/day  
methylprednisolone  IV or 
oral equivalent.  
• Consider  renal  biopsy  • If returns  to Grade  1: taper  
corticosteroids  over at least 1 month,  
consider  prophylactic  antibiotics  for 
opportunistic  infections,  and resume 
AGEN2034  therapy  and routine  
creatinine  monitoring per protocol.  
• If elevations  persist  > 7 days or worsen:  
treat as Grade  4. 
Grade  4 
Creatinine  > 6x ULN.  • Discontinue  AGEN2034  
therapy  per protocol.  
• Monitor  creatinine  daily.  
• 1.0 to 2.0 mg/kg/day  
methylprednisolone  IV or 
IV equivalent.  
• Consult  nephrologist.  
• Consider  renal  biopsy  • If returns  to Grade  1: taper  
corticosteroids  over at least 1 month  
and add prophylactic  antibiotics  for 
opportunistic  infections.  
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 63 of 113 5.6.7. Neurological Immune- related Adverse Events  
Rule out non-inflammatory causes, if non- inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. 
 
Table 10: Neurological Immune- related Adverse Event Management Algorithm  
Neurological Immune -related Adverse Events  
Grade  of Neurological  Toxicity  
(NCI CTCAE  v4.03)  Management  Follow -Up 
Grade  1 
Asymptomatic  or mild symptoms;  
intervention  not indicated.  • Continue  AGEN2034  
therapy  per protocol.  • Continue  to monitor subject.  
• If worsens:  treat as Grade  2 or Grade  
3–4. 
Grade  2 
Moderate  symptoms;  Limiting  
instrumental activities  of daily  life 
(ADL).  • Delay  AGEN2034  therapy  
per protocol.  
• Treat symptoms  per local  
guidelines.  
• Consider  0.5 to 
1.0 mg/kg/day  
methylprednisolone  IV or 
oral equivalent.  • If returns  to baseline:  resume  
AGEN2034  therapy  per protocol.  
• If worsens : treat as Grade  3-4. 
Grade  3-4 
Severe symptoms;  Limiting  self- 
care activities  of daily  life; Life- 
threatening.  • Discontinue  AGEN2034  
therapy  per protocol.  
• Obtain  neurology consult.  
• Treat symptoms  per local  
guidelines.  
• 1.0 to 2.0 mg/kg/day  
methylprednisolone  IV or 
IV equivalent.  
• Add prophylactic  
antibiotics  for opportunistic  
infections.  • If improves  to Grade 2: taper  
corticosteroids  over at least 1month.  
• If worsens or atypi[INVESTIGATOR_31790]:  
consider  IV immunoglobulin or other  
immunosuppressive  therapi[INVESTIGATOR_391451].  
 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 64 of 113 6. TRIAL ASSESSMENTS AND PROCEDURES  
6.1. Phase  1 Schedules of Assessments and Procedures  
The assessments and procedures to be performed in Phase 1 are shown in Table 11 for Part  A1 and in Table 12 for PartA2.  
Table 11: Phase  1 Part A1 — Schedule of Assessments and Procedures  
 Screening  Treatment  Phase  (2-week  cycles)  End of Treatment  Follow -up1 
   
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4 
Visits  Schedule  (days)   [ADDRESS_491445] visit 
Schedule  Window  (days)  2  −3/+1   −3/+1   −3/+1 −3/+1 ≤ 7 ± 7 ± 7 ± 7 ± 7 
Administrative  Procedures  <-42 days  
Informed  consent  X              
Review  of inclusion  / exclusion  criteria  X X             
Issue  Emergency  Medical  Support  and Subject  
Card  X              
Review  of medical  history  and demographics  X              
Review  of baseline  symptoms  X X             
Review  of prior  and concomitant  medications  X X X X X X X X X X X X X X 
Cancer  disease  details  and prior  treatment  X              
Subsequent  antineoplastic  therapy  status           X X X X X 
Clinical  Procedures  / Assessments  <-7 days  
Review  AEs3  X X X X X X X X X X X X X 
Full Physical  Examination  X         X     
Focused  Physical  Examination   X     X X X  X X X X 
Vital  Signs  and Weight  X X     X X X X X X X X 
12-lead ECG4 X X   X   X  X X    
ECOG  Performance  Status  X X X X X X X X X X X X X X 
Imaging  Assessments5 <-21 days  
Tumor  Imaging  X Every  6 weeks (±3 days)  from  first dose until discontinuation of study drug .  
Brain  Imaging  X              
Continued on next page  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 65 of 113  Screening  Treatment  Phase  (2-week  cycles)  End of Treatment  Follow -up1 
   
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4 
Visits  Schedule  (days)   [ADDRESS_491446] visit 
Schedule  Window  (days)  2  −3/+1   −3/+1   −3/+1 −3/+1 ≤ 7 ± 7 ± 7 ± 7 ± 7 
Central  Laboratory  Procedures  / Assessments6 <-7 days  
Serum  for PK and/or  ADA Assays   X7 X8 X X7 X8 X X9 X9 X X X X  
Plasma  for Cytokine  Assay   X10 X8  X10 X8         
Blood  for Biomarkers  (whole  blood,  PBMC,  
serum, and/or  plasma)  X X X8 X X X8 X X  X X X   
Local  Laboratory  Procedures  / Assessments11 <-[ADDRESS_491447]  X19      X  X X X   
Study  drug administration20  
AGEN2034   X   X   X X      
ADA: anti -drug antibody; AEs: adverse events; d: day; ECG: electrocardiogram; ECOG: Eastern Cooperative Oncology Group; HPV: human papi [INVESTIGATOR_27509]; 
m: month; PBMC: peripheral blood mononuclear cell; PK: pharmacokinetics; w: week.  
 
Note: Where applic able, assessments performed prior to treatment unless otherwise indicated.  
 
[ADDRESS_491448] one Follow -up Visit at 3 months (± 7 days) from last dose of study drug. Subjects who discontinue 
due to disease progre ssion and/or start of a new line of therapy will then end participation in the trial. Subjects who received the maximum admin istrations of the 
combination of AGEN2034; who have achieved a complete response (CR) according to RECIST 1.1; or who have disconti nued treatment due to reasons other 
than disease progression and/or start of a new line of therapy will be in Follow -up for up to approximately [ADDRESS_491449] dose of study drug or until disease 
progression and/or start of a new line of therapy. Every effort should be made to collect subject information on the start of new antineoplastic therapy, disease 
progression, and death.  
[ADDRESS_491450] dose of study drug or until disease progression and/or initiation of a new line of 
therapy. DLTs will be assessed during the first [ADDRESS_491451] 3  subjects at each dose level. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 66 of 113 4  12-lead ECG on Cycle 1 Day 1, before and 2 hours ( -10 / + 20 min) after AGEN2034 administration; on subsequent cycles as indicated 2 hours ( -10 / 
+ 20 min) after AGEN2034 infusion or as indicated.  
[ADDRESS_491452] dose. Sca ns performed as part of routine clinical management are acceptable for use 
as screening scan if they are of diagnostic quality and < - [ADDRESS_491453] dose; and brain MRI if <- [ADDRESS_491454] dose. For subjects with no previous 
history of brain metastases, screening brain imaging will need to be obtained; except for subjects with cervical cancer, cutaneous squamous -cell carcinoma, 
gastric/gastroesophageal junction cancer, head and neck squamous -cell carcinoma, ovarian cancer, prostate cancer, m esothelioma, or urothelial carcinoma, for 
whom this scan is necessary only if clinically indicated. MRI is the preferred brain imaging modality; however, CT is acceptable if an MRI is clinically 
contraindicated. On -study imaging will be performed every 6 w eeks (+/ - 3 days), or more frequently if clinically indicated. Imaging assessments will continue 
until disease progression per the investigator or until a new line of therapy is initiated. The timing of imaging assessments should follow calendar days and 
should not be adjusted for delays in treatment administration or for visits. The same imaging technique should be used in a s ubject throughout the trial. 
Additional imaging at Discontinuation Visit and Safety Follow -up Visit is not required provided im aging assessments have been performed per schedule.  
6  Unless otherwise specified, samples should be collected before treatment administration. Refer to the Laboratory Manual for i nstructions and additional 
information.  
7  Before administration of AGEN2034, and 30 (± 15) min, 2 hours (± 15 min), and 4 hours (± 15 min) post -administration of AGEN2034.  
8  At 24 (± 2) hours post -infusion of AGEN2034.  
9  Before and 1 hour (± 15 min) post -administration of AGEN2034.  
10  Before and 4 hours (± 15 min) post-administration of AGEN2034.  
[ADDRESS_491455] be available before treatment.  
12  Core serum chemistry: alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitr ogen (BUN)/total urea, 
calcium, chloride, creatinine, glucose, magnes ium, phosphorus/phosphates, potassium, sodium, total bilirubin. Results must be available prior to dosing.  
13  Full serum chemistry: core serum chemistry and albumin, amylase, cholesterol, creatine kinase, C -reactive protein (CRP), gamma glutamyl transfera se 
(GGT), lactate dehydrogenase (LDH), lipase, total protein, triglycerides, uric acid. Results must be available prior to dosin g. 
14  Hematology tests: absolute eosinophil count, absolute lymphocyte count, absolute neutrophil count (ANC), hematocrit, hemo globin, mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet count, red blood cell (RBC), white blood 
cell (WBC) and differential count. Results must be available prior to dosing.  
15  Coagulation tests: activated partial thromboplastin time (aPTT), prothrombin time - international normalized ratio (INR). Results must be available prior to 
dosing.  
16  Endocrine function tests: adrenocorticotropic hormone (ACTH), follicle -stimulating hormone (FSH) (if applicable), free thyroxine (T4), thyroid -stimulating 
hormone (TSH). Results must be available prior to dosing.  
17  Autoimmunity tests: anti -nuclear antibody, rheumatoid factor. 
[ADDRESS_491456] be available prior to dosing.  
19  Serum β -human chorionic gonadotropin (β -HCG) pregnancy test for women of child bearing potential at screening within [ADDRESS_491457] treatment dose (if 
performed earlier  in screening period then a urine pregnancy test may be performed prior to first dose); urine pregnancy test at all other indi cated visits (centers 
where urine pregnancy testing is not routine may substitute with serum β -HCG pregnancy test). Results must b e available prior to dosing.  
20  AGEN2034 should be administered over 60 minutes ( -10/+20 min). Subjects must be observed for [ADDRESS_491458] -infusion for infusion -related reaction. If 
administration of AGEN2034 is delayed due to an AE, treatment visits may b e delayed beyond the window of 3 days and schedules for subsequent visits should 
be adjusted accordingly.  
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 67 of 113 Table 12: Phase  1 Part  A2 — Schedule of Assessments and Procedures  
 Screening  Treatment  Phase  (3-week  cycles)  End of Treatment  Follow -up1 
   
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4 
Visits  Schedule  (days)   [ADDRESS_491459] 
 3 m 
from 
  Schedule  Window  (days)  2  −3/+1    −3/+1    −3/+1 −3/+1 ± 3 ± 3 ± 7 ± 7 ± 7 
Administrative  Procedures  <-42 days  
Informed  consent  X                
Review  of inclusion  / exclusion  criteria  X X               
Issue  Emergency  Medical  Support  and Subject  
Card  X                
Review  of medical  history  and demographics  X                
Review  of baseline  symptoms  X X               
Review  of prior  and concomitant  medications  X X X X X X X X X X X X X X X X 
Cancer  disease  details  and prior  treatment  X                
Subsequent  antineoplastic  therapy  status             X X X X X 
Clinical  Procedures  / Assessments  <-7 days  
Review  AEs3  X X X X X X X X X X X X X X X 
Full Physical  Examination  X           X     
Focused  Physical  Examination   X    X    X X  X X X X 
Vital  Signs  and Weight  X X    X    X X X X X X X 
12-lead ECG4 X X    X    X  X X    
ECOG  Performance  Status  X X X X X X X X X X X X X X X X 
Imaging  Assessments5 <-21 days  
Tumor  Imaging  X Every  6 weeks (±3 days)  from  first dose until discontinuation of study drug . 
Brain  Imaging  X                
Central  Laboratory  Procedures  / Assessments6 <-7 days  
Serum  for PK and/or  ADA Assays   X7 X8 X X X7 X8 X X X9 X9 X X X X  
Plasma  for Cytokine  Assay   X10 X8   X10 X8          
Blood  for Biomarkers  (whole  blood,  PBMC,  
serum,  and/or  plasma)  X X X8 X X X X8 X X X  X X X   
Continued on next page  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 68 of 113  Screening  Treatment  Phase  (3-week  cycles)  End of Treatment  Follow -up1 
   
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4 
Visits  Schedule  (days)   [ADDRESS_491460] 
 3 m 
from 
  Schedule  Window  (days)  2  −3/+1    −3/+1    −3/+1 −3/+1 ± 3 ± 3 ± 7 ± 7 ± 7 
Local  Laboratory  Procedures  / Assessments11 <-[ADDRESS_491461]  X19    X    X X X X X   
Study  drug administration20  
AGEN2034   X    X    X X      
Abbreviations: ADA: anti- drug antibody; AEs: Adverse Events; d: day; ECG: electrocardiogram; ECOG: Eastern Cooperative Oncology Group; HPV: human 
papi[INVESTIGATOR_27509]; m: month; PBMC: peripheral blood mononuclear cell; PK: pharmacokinetics; w: week.  
 
Note:  Where applicable, assessments performed prior to treatment unless otherwise indicated.  
 
[ADDRESS_491462] one Follow -up Visit at 3 months (± 7 days) after last dose of study drug. Subjects who discon tinue 
due to disease progression and/or start of a new line of therapy will then end participation in the trial. Subjects who recei ved the maximum administrations of the 
combination of AGEN2034; who have achieved a complete response (CR) according to RECIS T 1.1; or who have discontinued treatment due to reasons other 
than disease progression and/or start of a new line of therapy will be in Follow -up for up to approximately [ADDRESS_491463] dose of study drug or until disease 
progression and/or start of a new line of therapy. Every effort should be made to collect subject information on the start of new antineoplastic therapy,  disease 
progression, and death.  
[ADDRESS_491464] dose of study drug or until disease progression and/or initiation of a new line of 
therapy. DLTs will be assessed during the first [ADDRESS_491465] 3 subjects at each dose level.  
4  12-lead ECG on Cycle 1 Day 1 and 15, before and 2 hours ( -10 / + 20 min) after AGEN2034 administration; on subsequent cycles as indicated 2 hours (- 10 / 
+ 20 min) after AGEN2034 infusion or as indicated.  
[ADDRESS_491466] dose. Scans performed as part of routine clinical management are acceptable for use 
as screening scan if they are of diagnostic quality and <- [ADDRESS_491467] dose; and brain MRI if < -[ADDRESS_491468] dose. For subjects  with no previous 
history of brain metastases, screening brain imaging will need to be obtained; except for subjects with cervical cancer, cutaneous squamous -cell carcinoma, 
gastric/gastroesophageal junction cancer, head and neck squamous -cell carcinoma, ovarian cancer, prostate cancer, mesothelioma, or urothelial carcinoma, for 
whom this scan is necessary only if clinically indicated. MRI is the preferred brain imaging modality; however, CT is acceptable if an MRI is clinically 
contraindicated. On -study im aging will be performed every 6 weeks (+/ - 3 days), or more frequently if clinically indicated. Imaging assessments will continue 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491469] been performed per schedule.  
6  Unless otherwise specified, samples should be collected before treatment administration. Refer to the Laboratory Manual for i nstructions and additional 
information.  
7  Befor e administration of AGEN2034, and 30 (± 15) minutes, 2 hours (± 15 min), and 4 hours (± 15 min) post -administration of AGEN2034.  
8  At 24 (± 2) hours post -infusion of AGEN2034.  
9  Before and 1 hour (± 15  min) post -administration of AGEN2034.  
10  Before and  4 hours (± 15 min) post -administration of AGEN2034.  
[ADDRESS_491470] be available before treatment.  
12  Core serum chemistry: alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitr ogen (BUN)/total urea, 
calcium, chloride, creatin ine, glucose, magnesium, phosphorus/phosphates, potassium, sodium, total bilirubin. Results must be available prior to dosing . 
13  Full serum chemistry: core serum chemistry and albumin, amylase, cholesterol, creatine kinase, C -reactive protein (CRP), gamm a glutamyl transferase 
(GGT), lactate dehydrogenase (LDH), lipase, total protein, triglycerides, uric acid. Results must be available prior to dosin g. 
14  Hematology tests: absolute eosinophil count, absolute lymphocyte count, absolute neutrophil count (ANC), hematocrit, hemoglobin, mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet count, red blood cell (RBC), white blood 
cell (WBC) and differential count. Results must be av ailable prior to dosing.  
15  Coagulation tests: activated partial thromboplastin time (aPTT), prothrombin time - international normalized ratio (INR). Results must be available prior to 
dosing.  
16  Endocrine function tests: adrenocorticotropic hormone (ACT H), follicle -stimulating hormone (FSH) (if applicable), free thyroxine (T4), thyroid -stimulating 
hormone (TSH). Results must be available prior to dosing.  
17  Autoimmunity tests: anti -nuclear antibody, rheumatoid factor. 
[ADDRESS_491471] be available prior to dosing.  
19  Serum β -human chorionic gonadotropin (β -HCG) pregnancy test for women of child bearing potential at screening within [ADDRESS_491472] treatment dose (if 
performed earlier in screening period then a urine pregnancy test may be performed prior to first dose); urine pregnancy test  at all other indicated visits (centers 
where urine pregnancy testing is not routine may substitute with serum β -HCG pr egnancy test). Results must be available prior to dosing.  
20  AGEN2034 should be administered over 60 minutes ( -10/+20 min). Subjects must be observed for [ADDRESS_491473] -infusion for infusion -related reaction. If 
administration of AGEN2034 is delayed due to an AE, treatment visits may be delayed beyond the window of 3 days and schedules for subsequent visits should 
be adjusted accordingly.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 70 of 113 6.2. Phase 2 Schedule of Assessments and Procedures 
The assessments and procedures for Phase 2 are summarized in  Table 13 for PK, ADA, 
biomarkers, and pharmacogenomics assessments are shown in Table 14.  
 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 71 of 113 Table 13: Phase  2 — Schedule of Assessments and Procedures  
 Screening  Treatment  Phase  (2-week  cycles)  End of Treatment  Follow  Up1 Survival  
Follow  
    
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4  
Telephone  
Visits Schedule  (days)   [ADDRESS_491474] visit Every  2 
months  
Schedule  Window  (days)  3  −3/+1   −3/+1   −3/+1 −3/+1 ≤ 7 ± 7 ± 7 ± 7 ± 7  
Administrative  Procedures  < -42 days  
Informed  consent  X               
Review  of inclusion  / exclusion  criteria  X X              
Issue  Emergency  Medical  Support  and Subject  Card  X               
Review  of medical  history  and demographics  X               
Review  of baseline  symptoms  X X              
Review  of prior  and concomitant  medications  X X X X X X X X X X X X X X  
Cancer  disease  details  and prior  treatment  X               
Subsequent  antineoplastic  therapy  status           X X X X X X 
Survival  status                X 
Clinical  Procedures  / Assessments  < -7 days  
Review  AEs5  X X X X X X X X X X X X X  
Full Physical  Examination  X         X      
Focused  Physical  Examination   X     X X X  X X X X  
Vital  Signs  and Weight  X X     X X X X X X X X  
12-lead ECG6 X X   X   X X X X X    
Expanded ECG Evaluation6a  X X      See 6a       
ECOG  Performance  Status  X X X X X X X X X X X X X X  
Biopsy & Imaging  Assessments  < -21days  
  
Tumor  Biopsy  4 X        See 4       
Tumor  Imaging7 X Every  6 weeks (±  3 days)  from  first dose until discontinuation of study drug   
Brain  Imaging8 X               
Blood Samples for PK, ADA, Biomarkers, and 
  See Table 14 and Laboratory Manual  
Continued on next page  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 72 of 113  Screening  Treatment  Phase  (2-week  cycles)  End of Treatment  Follow  Up1 Survival  
Follow  
    
Cycle  1  
Cycle  2 Every  
Subsequen t 
Odd Cycle  Every  
Subsequen t 
Even  Cycle  Discontinuation  
Visit Safety 
Visit  
Visit 1  
Visit 2 Visits  3 
and 4  
Telephone  
Visits Schedule  (days)   [ADDRESS_491475] visit Every  2 
months  
Schedule  Window  (days)  3  −3/+1   −3/+1   −3/+1 −3/+1 ≤ 7 ± 7 ± 7 ± 7 ± 7  
Local  Laboratory  Procedures  / Assessments14 < -[ADDRESS_491476]  X22      X  X X X    
Study  drug administration23  
AGEN2034   X   X   X X       
Abbreviations: ADA: anti-drug antibody; AEs: Adverse Events; d: day; ECG: electrocardiogram; ECOG: Eastern Cooperative Oncology Group; IERC: Independent Endpoint 
Review Committee; m: month; PBMC: peripheral blood mononuclear cell; PGx: pharmacogenomics; PK: pharmacokinetics; w: week.  
 
Note: Where applicable, assessments performed prior to treatment unless otherwise indicated.  
 
[ADDRESS_491477] one Follow -up Visit at 3 months (± 7 days) after last dose of study drug. Subjects who discontinue due to disease 
progression and/or start of a new line of therapy will then end participation in the trial. Subjects who received the maximum  administrations of the combination of AGEN2034; 
who have achieved a complete response (CR) according to RECIST 1.1; or who have discontinued treatment due to reasons other than disease  progression and/or start of a new 
line of therapy will be in Follow -up for up to approximately [ADDRESS_491478] dose of study drug or until disease progression and/or start of a new line of therapy. Every effort 
should be made to collect subject information on the start of new antineoplastic therapy, disease progression and death.  
[ADDRESS_491479] Follow -up Visit, subjects that present(ed) with progressive disease and/or start new line of therapy will move into Survival Follow -up and should be contact[CONTACT_13104] [ADDRESS_491480]’s response to them will also be 
collected.  
[ADDRESS_491481] be available for PD -L1 expression and HPV evaluation. Only biopsies 
obtained at the time of or after the diagnosis of metastatic disease will be evaluated for PD -L1 expressi on. If a tumor biopsy was obtained from a target lesion during eligibility 
assessment, it is preferred to obtain a new baseline scan. Biopsy of lesions on study should be limited to non- target lesions or new lesions if their pathologic etiology is ambiguous. 
FOR SUBSEQUENT EVEN CYCLES: An optional biopsy  is desired at Cycle [ADDRESS_491482] 
dose of study drug or until disease progression and/or initiation of a new line of therapy.  
6 12-lead ECG on Cycle 1 Day 1, before AGEN2034 infusion starts and 2 hours ( -10/+ 20 min) after infusion ends; on subsequent cycles as indicated 1 hour ( -10 / + 20 min) 
after infusion ends or at visits indicated.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 73 of 113 6a  (At selected sites only) Expanded ECG Evaluation (triplicate tracings; see Section  [IP_ADDRESS] ): 12-lead  ECGs will be taken for Cycles 1 and 4 on Day  1 within 15  min ( ± 10 min) 
before the Predose PK sample and within 15  min ( ± 10 min) before the 30-min -after -end-of-infusion PK sample, and on Day  2 within 15  min ( ± 10 min) before the 24 -h-after -end-
of-infusio n PK sample. ECGs (12 -lead, triplicate tracings) will also be taken for every subsequent 8th cycle for up to 1 year (approximately every 4  mo [in Cycles 12, 20, and 28]) 
on Day  1 within 15  min ( ± 10 min) before the Predose PK sample and within 15 min ( ± 10 min) before the 30-min -after -end-of-infusion PK sample.  
[ADDRESS_491483] dose. Scans performed as part of routine clinical m anagement are acceptable for use as screening scan 
if they are of diagnostic quality and <  [ADDRESS_491484] dose. On-study imaging will be performed every 6 weeks (± 3 days), or more frequently if clinically indicated, and 
submitted for central review. Tumor assessments should be performed every 6 weeks (± 3 days) from first treatment dose until RECIST 1.1-defined disease progression has been 
established by [CONTACT_391486]. Furthermore, if study drug is discontinued as a result of unacceptable toxicity, tumor assessments should continue 
every 6 weeks (± 3 days) until RECIST1.1-defined disease progression has been established by [CONTACT_391486]. Imaging is required eve ry 
6 weeks (± 3 days) for those subjects with  PD who remain on AGEN2034 per protocol exemption ( Section  5.4.5)  until treatment is discontinued.  
8  Screening brain imaging is only necessary if clinically indicated. MRI is the preferred brain imaging modality; however, CT is acceptable if an MRI is clinically 
contraindicated.  
9-[ADDRESS_491485] be available before treatment.  
15  Core serum chemistry: alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN)/total urea, calcium, chloride, 
creatinine, glucose, magnesium, phosphorus/phosphates, potassium, sodium, total bilirubin. Results must be available prior to dosing.  
16  Full serum chemistry: core serum chemistry and albumin, amylase, cholesterol, creatine kinase, C -reactive protein (CRP), gamma glutamyl transferase (GGT), lactate 
dehydrogenase (LDH), lipase, total protein, triglycerides, uric acid. Results must be available prior to dosing.  
17  Hematology Tests: absolute eosinophil count, absolute lymphocyte count, absolute neutrophil count (ANC), hematocrit, hemoglobin, mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet count, red blood cell (RBC), white blood ce ll (WBC) and differential count. 
Results must be available prior to dosing.  
18  Coagulation Tests: activated partial thromboplastin time (aPTT), prothrombin time - international normalized ratio (INR). Results must be available prior to dosing.  
19  Endocri ne function tests: adrenocorticotropic hormone (ACTH), follicle -stimulating hormone (FSH) (for postmenopausal women if applicable), free thyroxine (T4), thyroid-
stimulating hormone (TSH). Results must be available prior to dosing.  
[ADDRESS_491486] be available prior to dosing.  
22  Serum β -human chorionic gonadotropin (β -HCG) pregnancy test for women of child bearing potential at screening within [ADDRESS_491487] treatment dose (if performed earlier 
in screening period then a urine pregnancy test may be performed prior to first dose); urine pregnancy test at all other indi cated visits. Results must be available prior to dosing. 
23  AGEN2034 should be administered over 60 min ( -10/+20 min). For the first [ADDRESS_491488] -infusion for infusion-related reaction; for 
subsequent cycles subjects must be observed for at least [ADDRESS_491489] -infusion for infusion-related reaction. If administration of AGEN2034 is delayed due to an AE, treatment visits 
may be delayed beyond the window of 3 days and schedules for subsequent visits should be adjusted accordingly.  
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 74 of 113 Table 14: Phase  2 — Blood Sampling for Pharmacokinetic, Pharmacodynamic, Genetic, and Other Assessments 
Visit or Cycle  Day For PK  
(see NOTE)  Additional Time 
Points for Rich 
PK Subset  For ADA  For PBMC  For  For PGx  
Screening  — — — — — — X1 
Cycle 1  1 Predose2 
30 min (± 15 
min)3 — Predose2 Predose2 Predose2 — 
2 — 24 h (± 60 min)4 — — — — 
8 — 168 h (± 4 h)4 — — — — 
Cycle 2  1 Predose2 — Predose2 Predose2 Predose2 — 
Cycle 3  1 Predose2 — Predose2 Predose2 — — 
Cycle 4  1 Predose2 
30 min (± 15 
min)3 — Predose2 Predose2 Predose2 — 
2 — 24 h (± 60 min)4 — — — — 
8 — 168 h (± 4 h)4 — — — — 
Cycles 5, 6, 12, 18, 24  1 — — Predose2 — — — 
Discontinuation  — X  — X X X — 
Safety Follow -up Visit  [ADDRESS_491490]  dose X — X — — — 
Follow -up Visit  [ADDRESS_491491] dose X — X — — — 
Abbreviations: ADA: antidrug antibody;  DNA: deoxyribonucleic acid; h: hour(s); mo: month; min: minute(s); PBMC: 
peripheral blood mononuclear cell; PGx: pharmacogenomics(s); PK: pharmacokinetic(s); wk: week(s).  
1 Blood sample for PGx is collected only if an ‘optional’ PGx consent is signed.  
2 Predose samples will be collected within 30 minutes before starting the AGEN2034 infusion.  
3 Blood samples collected on Day  1 at 30 (± 15) minutes after the end of infusion  
4 As of Amendment  5 (27 September 2019), additional rich PK sampling will be collected in a subset of approximately 20 subjects in selected sites . Rich PK 
sampling will occur  on Days 2 and 8  of Cycles 1 and 4  at 24  hours (± 60 min) and 168 (± 4) hours, respectively, af ter the start of the infusion.  
NOTE:  It is important to record all infusion start dates/times, infusion end dates/times, infusion interruption(s) start and end dates/times, infusion flush end 
dates/times, and blood sample dates/times completely and accurat ely (to the nearest minute). Blood for the [ADDRESS_491492] 15 min after the end of infusion.  
 

Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491493] should continue to receive all assessments as defined in the Treatment phase of the 
Schedule of Assessments while they are actively receiving treatment.  
6.3.3. End-of-Treatment Visits  
Visit requirements are outlined for Phase  1 in Section  6.1 and for Phase 2 in Section  6.2. Specific 
procedure- related details are provided in Section  6.4. 
[IP_ADDRESS]. Discontinuation Visit  
The Discontinuation Visit should occur at the time study drug is discontinued for any reason. If the Discontinuation Visit occurs [ADDRESS_491494] ug, at the time of the 
mandatory Safety Follow up Visit, procedures do not need to be repeated. Procedures at the time of discontinuation are detailed in Section  [IP_ADDRESS], Safety Follow up Visit. 
[IP_ADDRESS]. Safety Follow- up Visit  
The mandatory Safety Follow -Up Visit should be conducted for all subjects approximately 
[ADDRESS_491495]. Subjects with an AE of Grade >[ADDRESS_491496]. Subjects with an adverse drug reaction (ADR) ongoing at the Safety 
Follow-up Visit must be followed up until the ADR resolves, becomes stable, or is considered not clinically significant by [CONTACT_093].  
6.3.4. Follow- up Phase  
In Phase 1, subjects who discontinue treatment will be followed for up to [ADDRESS_491497] to follow-up. 
Follow-up visits and survival follow-up requirements are outlined in Section  6.1 and Section  6.2, 
respectively, for Phase 1 and Phase 2. Specific procedure -related details are provided in 
Section  6.4. 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 76 of 113 [IP_ADDRESS]. Follow- up Visits  
All subjects who discontinue treatment will have at least one post- treatment visit at 3 months 
(± 7 days) after last dose of study drug.  
For both study Phases, subjects who received the maximum administrations of AGEN2034, who 
have achieved a complete response (CR) according to RECIST 1.1, or who have discontinued 
treatment due to reasons other than disease progression and/or start of a new line of therapy 
should be have Follow- up Visits eve ry [ADDRESS_491498] dose of study drug 
(see schedules in Section  6.1) or until disease progression and/or start of a new line of therapy.  
For Phase 2 (see schedule in Section  6.2), subjects who present with progressive disease and/or 
start a new line of therapy will move into the Survival Follow -up Phase. Every effort should be 
made to collect subject information on the start of new antineoplastic therapy, disease progression and death.  
[IP_ADDRESS]. Survival Follow-up (Phase 2 only) 
There is no survival follow-up for Phase 1. 
For subjects in Phase 2, after the first Treatment Follow -up Visit, subjects with progressive 
disease and/or who start new line of therapy will move into Survival Follow-up. Subjects should 
be contact[CONTACT_391487] [ADDRESS_491499] dose of study drug. 
6.4. Trial Procedures  
The schedules of events in Section  6.1 and Section  6.2 summarize the trial procedures to be 
performed at each visit in Phase 1 and 2, respectively. Individual trial procedures are described in detail below. It may be necessary to perform these procedures at unscheduled time points if deemed clinically necessary by [CONTACT_093].  
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_391488]. In these cases, such evaluations/testing will be performed in accordance with clinical judgement.  
6.4.1. Administrative Procedures  
[IP_ADDRESS]. Informed Consent  
The investigator or qualified designee must obtain documented consent from each potential 
subject prior to participating in the clinical trial and for optional pharmacogenomics research. 
[IP_ADDRESS]. General Informed Consent  
Consent must be documented by [CONTACT_423]’s dated signature [CONTACT_391527]. A copy of the signed and dated consent form should be given to the subject before participation in the trial. 
The investigator is responsible for ensuring that a careful and thorough informed consent 
procedure is implemented before a subject enters the study and at any time during the study 
should ICF changes be introduced. This includes, but is not limited to: (1) allowing ample time 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491500]; (2) ensuring that qualified medical personnel are available to 
directly answer questions that a subject may have; (3) ensuring that each potential study subject 
understands that his or her medical treatment will not be otherwise affected based on the decision whether or not to participate in the study, that his or her participation is completely voluntary, 
and that he or she can opt to stop participation in the study at any time for any reason; and (4) 
ensuring a full copy of the signed ICF is given to the subject to take home for his or her medical records. The process for obtaining informed consent should also be noted in the subject’s source documentation. 
The initial informed consent form, any subsequent revised written informed consent form, and 
any wri tten information provided to the subject must receive the IRB/ERC’s approval/favorable 
opi[INVESTIGATOR_19349]. The subject should be informed in a timely manner if new information becomes available that may be relevant to the subject’s willingness to co ntinue participation in 
the trial. The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the subject’s dated 
signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable representative’s dated signature.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and Sponsor requirements. 
[IP_ADDRESS]. Consent for Pharmacogenomics Assessment (optional) 
Participation in the pharmacogenomics portion of the trial is optional and requires separate informed consent. Participation in the pharmacogenomics portion of the trial will not affect 
participation in the trial. Subjects may withdraw consent from pharmacogenomics portion of the 
trial without withdrawing from the trial.  
Specimens that may be used for pharmacogenomics testing include: blood and tumor specimens collected during this trial.  
The investigator or qualified designee will explain the optional pharmacogenomics assessment portion of the consent to the subject, answer all of his/her questions, and obtain written informed 
consent before performing any procedure related to pharmacogenomics assessment. A copy of 
the informed consent will be given to the subject. 
[IP_ADDRESS]. Review of Inclusion and Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by [CONTACT_80081].  
[IP_ADDRESS]. Emergency Medical Support and Subject Card  
All subjects will be given an Emergency Medical Support and Subject Card identifying them as 
participants in a research trial. The card will contain trial site contact [CONTACT_3031] (including 
direct telephone numbers) to be utilized in the event of an emergency. The investigator or qualified designee will provide the subject with an Emergency Medical Support and Subject Card immediately after the subject provides written informed consent. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 78 of 113 [IP_ADDRESS]. Medical History  
A medical history will be obtained by [CONTACT_27404]. Medical history will 
include all active cond itions; history of hepatitis B virus (HBV), hepatitis C virus (HCV), HIV 
and/or HPV; and any condition diagnosed within the prior 10 years that are considered to be 
clinically significant by [CONTACT_737]. Medical history will also include an assessment of smoking history.  
History of the cancer under study will be recorded separately  (see Section  [IP_ADDRESS]) ; all other 
cancer history should be captured in the medical history.  
For subjects in Phase 2, in addition, record any prior cancer other than cervical cancer even if 
diagnosed greater than 10 years prior to Visit 1.  
[IP_ADDRESS]. Review of Baseline Symptoms 
Baseline symptoms associated with the disease u nder study will be assessed for each subject at 
screening. Baseline symptoms will be Graded and recorded according to NCI CTCAE Version  4.03. Baseline symptoms will be characterized in terms including seriousness, causality 
to previous treatment, toxicity grading, and action(s) taken if any.  
[IP_ADDRESS]. Review of Prior and Concomitant Medications 
[IP_ADDRESS].1. Prior Medications 
All medication — other than chemotherapy — taken by [CONTACT_2690] 30 days before 
starting the trial will be recorded. In addition, all treatments for a prior cancer other than current 
cancer will be recorded, even if taken greater than 30 days prior to Visit 1.  
Prior treatments for the current cancer will be recorded separately  (see Section  [IP_ADDRESS])  and not 
listed as a prior medication.  
[IP_ADDRESS].2. Concomitant Medications  
Any medication taken by [CONTACT_152462], from the date of consent through the 30- day 
Safety Follow -up Visit, will be recorded. Af ter the Safety Follow -up Visit, record all 
medications related to reportable SAEs and AESIs as defined in Section  [IP_ADDRESS]. 
[IP_ADDRESS]. Cancer Disease Details and  Prior Treatment  
Obtain current cancer disease details and prior treatment for all subjects including:  
• Detailed history of the tumor at diagnosis and study entry including histopathological 
diagnosis, grading, and staging in accordance with the AJCC-8 Tumor Node 
Metastasis (TNM) classification ( Amin et al 2017).  
• All therapy used for prior treatment of the disease under study (including but not limited to surgery, radiotherapy [including total radiation dose received and general 
treatment field], and any systemic treatment) – and for each therapy, complete dosing 
schedule and their corresponding best response. 
• Any other conditions treated with radiation therapy or and any systemic treatment.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 79 of 113 • Current cancer signs and symptoms, and side effects from current and/or previous 
anticancer treatments.  
• Current cancer disease status.  
• Relevant somatic or germline mutations detected.  
• Chronic viral infection status, i f available.  
• Human epi[INVESTIGATOR_3506] 2 (HER2) status, if available. 
• Smoking history. 
• Tumor markers, including but not limited to, molecular/genetic or immunohistochemistry markers (such as PSA, CA125, AFP, BRCA, PD-L1 status, etc.), if applicable and available. 
• HPV status, if available.  
[IP_ADDRESS].1. Subsequent Antineoplastic Therapy 
The investigator or qualified designee will review all new antineoplastic therapy initiated after the last dose of study drug. If a subject initiates a new antineoplastic  therapy within [ADDRESS_491501] dose of the new therapy.  
Subjects in Phase 2 will move into survival follow- up once new antineoplastic therapy has been 
initiated.  
[IP_ADDRESS].2. Survival F ollow -up (Phase 2 only) 
Once a subject in Phase [ADDRESS_491502] dose of study drug. (See also Section  [IP_ADDRESS].) 
[IP_ADDRESS]. Assignment of Subject Trial Number  
After a subject signs an informed consent form, the subject will be assigned a unique, sequential 
subject number. Once a number is assigned, it cannot be reassigned if the original subject is found to be ineligible or withdraws consent. 
[IP_ADDRESS]. Trial Compliance  
Any delay from the protocol-specified AGEN2034 dosing frequency which is due to toxicity and 
which results in >  [ADDRESS_491503] 
management.  
Administration of trial medication will be witnessed by [CONTACT_1755]/or trial staff. The total volume of trial treatment infused will be compared to the total volume prepared to determine compliance with each dose administered.  
Any reason for noncompliance should be documented. Noncompliance is defined as a subject missing >1 cycle of study treatment for non-medical reasons . If 1 cycle was missed and the 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491504] administered treatment cycle is 
longer than 4 weeks for non- medical reasons, criteria for insufficient compliance are met.  
6.4.2. Tissue Collection and Tu mor Biomarker Assessment  
For Phase 2, expression of PD-L1 and HPV status will be among the exploratory biomarkers assessed in tumor samples from archival tissues or biopsies. 
[IP_ADDRESS]. Tissue Collection  
Tumor tissue for biomarker analysis from a biopsy of a tumor lesion not previously irradiated must be available for biomarker assessments including but not limited to PD -L1 expression and 
HPV evaluation. Biomarker assessment will be performed on the most recent FFPE biopsy of a 
tumor lesion, collected either at the time of or after the diagnosis of metastatic disease has been 
made, and from a site not previously irradiated. An optional tumor biopsy will be collected at Cycle  4, Day  1 (-3/+1 day) if clinically feasible to assess pharmacodynamic effects of the drug 
on tumor microenvironment. 
• Tissue from needle or excisional biopsy or from resection is required. 
• An FFPE tumor tissue block that is less than 4 years old should be provided. If an archival tumor-containing FFPE tissue block is not available, freshly cut FFPE s lides 
(within 10 days) are acceptable for submission to the sponsor. If an FFPE tumor tissue block or freshly cut slides are not available, fresh biopsy will be required, and 
an FFPE tumor tissue block should be provided. If a block or freshly cut FFPE sli des 
are not available, discuss with the study Medical Monitor prior to patient enrollment.  
• Fine needle aspi[INVESTIGATOR_4026], endobronchial ultrasound (EBUS), or cell blocks are not 
acceptable.  
If limited tissue is available, preference will be given to PD -L1 assessment.  
If a tumor biopsy was obtained from a target lesion during eligibility assessment, it is preferred to obtain a new baseline scan. Biopsy of lesions on study should be limited to non- target lesions 
or new lesions if their pathologic etiology is ambiguous.  
Tissue processing : The cancer tissues should be fixed in 10% neutral buffered formalin, paraffin 
embedded, and routinely processed for histological evaluation. Formalin substitutes are not suited as fixative.  
Provision of samples :  
1. Priority: tumor -containing FFPE tissue block that is less than 4 years old 
2. If an archival tumor-containing FFPE tissue block is not available, a fresh biopsy will be required , and an FFPE tumor tissue block should be provided. 
3. Priority: 25 freshly cut tumo r tissue FFPE slides (within 10 days) must be provided. 
Minimum [ADDRESS_491505] ensure that the newly 
obtained tissue sample collection data and slide cut date are documented in the 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 81 of 113 requisition forms. Slides submitted more than 10 days after cutting or cut from more than 
one tissue specimen block wil l be rejected , and a new specimen will be required.  
Sample shipment: The tumor blocks should be sent with the next scheduled monthly shipment to 
the central lab at room temperature.  
Sample storage: At the central laboratory, the FFPE tissue blocks shall be stored at room 
temperature in the dark and the FFPE tumor block shall be kept in sealed containers at 2°C to 8°C. 
For additional details and instructions regarding tissue requirements, collection, storage and shipment, refer to the study Laboratory Manual. 
[IP_ADDRESS]. PD-L1 Expression Assessment  
Tumor expression of PD-L1 will be assessed using an FDA- approved test in all subjects in 
Phase 2. 
[IP_ADDRESS]. HPV Assessment  
For subjects with cervical cancer (Phase 2), tissue sample provided at screening will be used for 
HPV assessment.  Should tissue only be sufficient for PD-L1 expression assessment, the subject 
may still be enrolled and HPV status will not be assessed.  
6.4.3. Clinical Assessments and Procedures  
[IP_ADDRESS]. Review of Adverse Events  
The investigator or qualified designee will assess each subject to evaluate for potential new or worsening AEs as specified in the Schedule of Assessments and Procedures and more frequently 
if clinically indicated. Adverse experiences will be Graded and recorded throughout the study and during the follow- up peri od according to NCI CTCAE Version 4.03 (see Section  7). 
Toxicities will be characterized in terms including seriousness, causality, toxicity grading,  and 
action taken with regard to trial treatment.  
Comprehensive assessment of any AE experienced by [CONTACT_391489], from time of the subject’s consent. Trial site personnel will report any AE, 
whether observed by [CONTACT_98138] ( Section  7.2). Given the intended 
mechanism of action, particular attention should be given to AEs that may result from enhanced 
T-cell activation, such as dermatitis, colitis, hepatitis, uveitis, or other immune -related reactions. 
When clinically indicated, ophthalmologic examinations should be considered for signs or 
symptoms of uveitis.  
An irAE may be defined as an AE of unknown etiology, associated with drug exposure and is 
consistent with an immune phenomenon. Efforts should be made to rule out neoplastic, infectious, metabolic, toxin or other etiologic causes prior to labeling an AE immune related. 
Immunological, serological and histological (biopsy) data should be used to support the 
diagnosis of an immune- related toxicity. Following the guidance described in Section  [IP_ADDRESS], 
certain irAEs should also be reported to the Sponsor as AESIs. 
The reporting period for AEs is described in Section  7.2.1. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 82 of 113 [IP_ADDRESS]. Physical Examination 
[IP_ADDRESS].1. Full Physical Examination  
The investigator or qualified designee will perform a complete physical exam during the 
screening period, as per Section  6.1 (Phase 1) or Section  6.2 (Phase 2). Clinically significant 
abnormal findings should be recorded as medical history. After consent, new clinically 
significant abnormal findings should be recorded as AEs. 
[IP_ADDRESS].2. Focused Physical Examination 
For cycles that do not required a full physical exam per Section  6.1 (Phase 1) or Section  6.2 
(Phase 2), the investigator or qualified designee will perform a directed physical exam as clinically indicated prior to trial treatment administration. New clinically significant abnormal findings should be recorded as AEs. 
[IP_ADDRESS]. Vital Signs, Height and Weight 
Vital signs, height, and weight will be measured and recorded as specified in Section  6.1 
(Phase 1, Table 11 or Table  12) or Section  6.2 (Phase 2, Table 13 ). The investigator or qualified 
designee will take vital signs at the specified times including prior to the administration of each dose of trial treatment. Vital signs include temperature, pulse, respi[INVESTIGATOR_697], and blood 
pressure. Weight should be measured prior to dosing. Height will be measured at Visit 1 only. 
[IP_ADDRESS]. 12-lead Electrocardiogram  
A standard 12- lead ECG will be performed using local standard procedures at screening and as 
specified in Section  6.1 (Phase 1, Table 11 or Table 12) or Section  6.2 (Phase  2, Table 13).  
Clinically significant abnormal findings at Screening should be recorded as medical history. 
[IP_ADDRESS]. Expanded Electrocardiogram Evaluation  (in selected sites  only) 
In Phase 2, in addition to the standard 12-lead ECGs, expanded ECG evaluation will occur with 12-lead ECG tracings recorded in triplicate  at selected sites only and on the following schedule 
(see also  Table 13):  
• Cycles 1 and 4: 
− On Day 1 (day of infusion), within 15 min (± 10 min) before the Predose PK 
sample and within 15 min ( ± 10 min) before the 30- min-after-end-of-infusion PK 
sample  
− On Day  2, within 15 min (± 10 min) before 24-h- after-end-of-infusion PK sample 
• Every subsequent 8
th cycle (that is, approximately every 4  months for up to 1 year, in 
Cycles  12, 20, and 28): 
− On Day 1 (day of infusion), within 15 min (± 10 min) before the Predose PK sample and within 15 min ( ± 10 min) before the 30- min-after-end-of-infusion PK 
sample  
Every attempt should be made to use the same ECG machine for all measurements within a subject, and ECG values should be computer -generated.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 83 of 113 [IP_ADDRESS]. Eastern Cooperative Oncology Group Performance 
ECOG status will be assessed (see Appendix II) at screening, prior to the administration of each 
dose of trial treatment and during the Follow-up period as specified in Section  6.1 (Phase 1) or 
Section  6.2 (Phase 2).  
6.4.4. Imaging Assessment s 
[IP_ADDRESS]. Tumor Imaging 
In Phase 1, the initial tumor imaging will be performed within [ADDRESS_491506] dose; 
however, scans performed as part of routine clinical management are acceptable for use as 
screening scan if they are of diagnostic quality and perfo rmed < [ADDRESS_491507] dose. On-
study imaging will be performed every 6 weeks (± 3 days) from first treatment dose (or more frequently if clinically indicated)  until discontinuation of study drug.  
In Phase 2, the initial tumor imaging will be perfo rmed within [ADDRESS_491508] dose; 
however, scans performed as part of routine clinical management are acceptable for use as screening scan if they are of diagnostic quality and performed < [ADDRESS_491509] dose. Subjects without centrally confirmed measurable disease at 
baseline will not be eligible for this trial. On -study imaging will be performed every 6 weeks (± 
3 days) from first dose (or more frequently if clinically indicated) until discontinuation of study drug. Imaging studies will be submitted for central review by [CONTACT_309546].   
The timing of on-study-treatment imaging should follow calendar days and should not be 
adjusted for delays in treatment administration or for visits. Additional imaging at the 
Discontinuation Visit and Safety Follow-up Visit is not required provided imaging assessments 
have been performed per schedule. 
Throughout the trial, the same imaging technique should be used in a subject. In general, lesions 
detected at baseline should be followed using the same imaging methodology and preferably the 
same imaging equipment at subsequent tumor evaluation visits. The investigator may perform scans in  addition to a scheduled trial scan for medical reasons or if progressive disease is 
suspected.  
[IP_ADDRESS]. Brain Imaging 
MRI is the preferred brain imaging modality; however, CT is acceptable if an MRI is clinically contraindicated.  
In Phase 1, subjects with no previous history of brain metastases are required to have brain imaging at screening (within [ADDRESS_491510] treatment dose) unless adequate imaging 
is available for exams within [ADDRESS_491511] dose of trial treatment; except for subjects 
with cervical cancer, cutaneous squamous- cell carcinoma, gastric/gastroesophageal junction 
cancer, head and neck squamous- cell carcinoma, ovarian cancer, prostate cancer, mesothelioma, 
or urothelial carcinoma, for whom brain imaging is necessary only if clinically indicated.  
In Phase 2, brain imaging should only be conducted if clinically indicated. 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491512]/MRI (with contrast if not contraindicated) scans should be conducted 
if clinically indicated by [CONTACT_391490].  
[IP_ADDRESS]. Response Assessment  
Response assessment will be done according to RECIST 1.1 ( Eisenhauer et al 2009) in Phase 1 
and Phase 2. In Phase 1, response will be assessed by [CONTACT_2413]; in Phase [ADDRESS_491513]/abdomen/pelvis (plus other regions as required for specific tumor types) and other 
established assessments of tumor burden if CT/MRI imaging is insufficient for the individual 
subject. All scans performed at baseline and other imaging performed as clinically required (other supportive imaging) will be repeated at subsequent visits. In general, lesions detected at 
baseline should be followed using the same imaging methodology and preferably the same 
imaging equipment at subsequent tumor evaluation visits.  
For each subject, the investigator will designate 1 or more of the following measures of tumor 
status to follow for determining response: CT or MRI images of primary and/or metastatic tumor 
masses, physical examination findings, and results of other assessments. All available images collected during the trial period will be considered. The most appropriate measures to evaluate a 
subject’s tumor status should be used. Measure(s) chosen for sequential evaluation during the 
trial must correspond to measures used to document progressive tumor status that qualifies the subject for enrollment.  
In Phase 2, radiographic images used for local determination of disease progression will be read centrally and reviewed by a blinded IERC. The IERC will make a determination as to whether criteria for tumor response or progression according to RECIST 1.[ADDRESS_491514] 1.1 (all measurements should be recorded in metric notation; see Eisenhauer et al 2009). Assessment of tumor response by [CONTACT_391491]. 
• To assess objective response, tumor burden at baseline will be estimated and used for 
comparison with subsequent measurements. At baseline, tumor lesions will be categorized in target and non- target lesions as described by [CONTACT_221846] ( 2009).  
Results for these evaluations will be recorded with as much specificity as possible so that pre- and post-treatment results will provide the best opportunity for evaluating tumor response. 
Any complete response (CR) or partial response (PR) should be confirmed as des cribed by 
[CONTACT_221846] ( 2009).  
In the case of a PR or CR, a confirmatory CT or MRI scan must be conducted ≥ [ADDRESS_491515] ed. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 85 of 113 6.4.5. Pharmacokinetic, Pharmacodynamic, Genetic, and Other Assessments  
Sample collection, labeling, storage and shipment instructions will be provided in the 
operations/laboratory manual. 
A full chain of custody will be maintained for all samples throughout their lifecycle. Sponsor 
will keep oversight of the entire life cycle through internal procedures, monitoring of study sites, and auditing of external laboratory providers. 
[IP_ADDRESS]. Pharmacokinetic Assessments  
Blood samples will be collected in both study phases for plasma AGEN2034 concentration determinations (for pharmacokinetic evaluation). 
In Phase 1, PK samples will be collected as shown in Table [ADDRESS_491516] all infusion start dates/times, infusion end dates/times, infusion 
interruption(s) start and end dates/times, infusion flush end dates/times, and blood sample 
collection dates/times completely and accurately (and to the nearest minute). 
[IP_ADDRESS]. Immunogenicity Assessment  
Blood samples for assessment of the immunogenicity of AGEN2034 will be collected for all subjects at the time  points described in Section  6.1 (Phase 1).  
In Phase 2, ADA samples will be collected as shown in Table 14. 
The immunogenicity assessment will be conducted to detect and measure ADA (antibody against 
AGEN2034).  
[IP_ADDRESS]. Blood Biomarker Assessments  
To complete all assessments on blood samples (whole blood and plasma), the Sponsor or 
designated contract research organization (CRO) will provide instructions and necessary supplies 
to the site, including shippi[INVESTIGATOR_391452]. Refer to the Laboratory Manual for 
detailed information.  
All proposed biomarker analyses are exploratory objectives and are dependent on the quality and availability of sufficient materials. Collection and storage of samples will be detailed in the Laboratory Manual. The panel of biomarkers might be adjusted based on results from ongoing research related  to anti–PD1/PD- L1 and anti- CTLA -4 therapi[INVESTIGATOR_13265]/or safety. 
[IP_ADDRESS].1. In Phase  1 
[IP_ADDRESS].1.1. R
ECEPTOR OCCUPANCY  
In Phase 1 only, PD-1 receptor occupancy on circulating T cells will be measured as an indication of target engagement.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 86 of 113 [IP_ADDRESS].1.2. IMMUNOPHENOTYPI[INVESTIGATOR_391453]/or transcriptional profiling by [CONTACT_391492]. T cell lymphocytes, B lymphocytes, and natural killer cells (TBNK) profiling will be asses sed by [CONTACT_391493]. All analyses will follow the schedule of 
events shown in Section  6.1. A complete differential blood count will be provided for each time 
point for calculations of absolute lymphocyte counts. As biomarker research is constantly evolving, selection of markers with the highest specificity and relevance to treatment effect may change.  
[IP_ADDRESS].1.3. C
YTOKINE ASSESSMENT  
In Phase 1 only, cytokine profiles will be evaluated at various time points from plasma samples collected according to Section  6.1. 
[IP_ADDRESS].2. In Pha se 2 
 The blood 
collection schedule for biomarker assessments in Phase 2 is detailed in in Table 14. 
[IP_ADDRESS].2.1. 
  
 
 
[IP_ADDRESS].2.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 

Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 87 of 113  
 
 
 
 
 
[IP_ADDRESS]. Ph
armacogenomics Assessments (Optional) 
The Sponsor may conduct research on DNA from blood or tumor tissue specimens collected 
during this trial. This research may include genetic analysis (DNA) and gene expression profiling 
(RNA).  
Germline (inherited) variants will be investigated in DNA extracted from the whole blood. For 
this purpose, an additional 4 mL of whole blood (PGx sample) will be collected at screening. 
Additionally, tumor biopsy samples may be used for the extraction of DNA to study tumor genetics (somatic variations). Participation is optional for subjects being recruited at sites whose 
IEC/IRB has approved pharmacogenomics assessments and a pharmacogenomics ICF (optional) 
is signed.  
All samples collected during the trial will be kept confidential. For this purpose, the samples will 
be given a label connected with a code assigned at the start of the Main Study (coded trial subject 
number). Outside the study center, no one will be able to link the subject’s identity to the subject number. The link between the subject’s identity and the subject number will only be known by a 
limited number of authorized personnel. Information about race, ethnicity, sex, medical history, 
etc, may be available to scientists studying the PGx blood samples. Such information might be impo rtant for research or public health purposes. Genomic analysis results will not be reported 
back to the sites.  
Participation in pharmacogenomics portion of the trial is optional, requires separate informed consent, and will not affect participation in the main trial. Subjects may withdraw consent from 
pharmacogenomics portion of the trial without withdrawing from the trial. Consent and 
withdrawal of consent (if applicable) for pharmacogenomics assessments will be documented in the eCRF.  
6.4.6. Local Laboratory Tes ts 
It is essential that the Sponsor be provided with a list of laboratory normal ranges before shipment of study drug. Any change in laboratory normal ranges during the trial will additionally be forwarded to the CRO and the Sponsor. 
Blood samples will be collected from non -fasted subjects. All routine laboratory analyses will be 
performed at a laboratory facility local to the investigational site.  
The overall amount of blood to be drawn for safety laboratory testing, pregnancy testing, and 
exploratory biom arker investigation from a single subject with a body weight ≤  70 kg (154 lb) 
must not exceed 120 mL/week. 
Laboratory tests for screening should be performed within [ADDRESS_491517] dose of trial 
treatment. After Cycle 1, predose laboratory procedures can be conducted up to 48 hours prior to 
dosing. 

Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491518]’s  medical record or source 
documents. Blood samples for study related tests will be collected at time points specified in per Section  6.1 (Phase 1) or Section  6.2 (Phase 2).  
Laboratory tests are shown in Table 15 . 
Table 15: Required Local Laboratory Panel Tests 
Full Chemistry  
Albumin  
Alkaline  phosphatase1 
ALT  (SGPT) [ADDRESS_491519]  (SGOT) 1 
BUN/total urea1 
Calcium1 
Chloride1 
Cholesterol   
Creatine  kinase   
Creatinine1 
CRP  
GGT  
Glucose1 
LDH  
Lipase  
Magnesium1 
Phosphorus/phosphates1 
Potassium1 
Sodium1 
Total bilirubin1 
Total protein  
Triglycerides  
Uric acid 
 
Pregnancy  Tests  
Serum  pregnancy  test  
Urine  pregnancy test  Hematology 
Absolute  lymphocyte  count  
Absolute neutrophil count  
Hematocrit  
Hemoglobin  
MCH  
MCHC 
MCV  
Platelet count  
RBC  
WBC  and differential count  
 
Coagulation  Studies  
aPTT 
Prothrombin time (INR)  
 
Endo crine Function Te sts 
ACTH  
FSH (for postmenopausal women if  applicable)   
T4 
TSH 
 
Autoimmunity  Tests  
Anti-nuclear  antibody (Phase 1 only)  
Rheumatoid factor (Phase 1 only)  
Abbreviations: ACTH: adrenocorticotropic  hormone;  ALT: alanine  aminotransferase;  aPTT:  activated  partial  
thromboplastin  time; AST:  aspartate aminotransferase;  BUN:  blood urea nitrogen;  CRP:  C-reactive  protein;  
FSH:  follicle -stimulating  hormone;  GGT:  gamma  glutamyl  transferase;  INR:  international normalized  
ratio;  LDH:  lactate  dehydrogenase;  MCH:  mean  corpuscular  hemoglobin;  MCHC:  mean  corpuscular  
hemoglobin  concentration;  MCV:  mean  corpuscular  volume;  RBC:  red blood  cell; SGOT:  serum  glutamic  
oxaloacetic transaminase;  SGPT:  serum  glutamic  pyruvic  transaminase;  T4: free thyroxine;  TSH:  thyroid -
stimulating  hormone; WBC:  white  blood  cell. 
1Core  serum  chemistries.  
 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491520] a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. In cases of surgical or 
diagnostic procedures, the condition/illness leading to such a procedure is considered as the AE 
rather than the procedure itself. 
The investigator is required to Grade the severity/intensity of each AE. Inves tigators will 
reference NCI CTCAE v4.03, which is a descriptive terminology that can be used for AE 
reporting. A general grading (severity/intensity) scale is provided at the beginning of the referenced document, and specific event Grades are also provided. If a particular AE’s 
severity/intensity is not specifically Graded by [CONTACT_43970], the investigator is to 
revert to the general definitions of Grade 1 through Grade 5 and use his/her best medical judgement. 
The 5 general Grades of AE severity are:  
 Grade 1:  Mild  
 Grade 2:  Moderate  
 Grade 3:  Severe  
 Grade 4:  Life-threatening or disabling  
 Grade 5:  Death related to AE  
According to the Sponsor’s convention, if a severity/intensity of Grade [ADDRESS_491521] also report the event as an SAE as per Section  7.2.2. However, a 
laboratory abnormality with a severity/intensity of Grade 4, such as anemia or neutropenia, is considered serious only if the condition meets one of the serious criteria described below. 
In the case of death, the primary cause of death or the event leading to death should be recorded 
and reported as an SAE. “Fatal” will be recorded as the outcome of this respective event; death 
will not be recorded as separate event. Only if no cause of death can be reported (e.g., sudden 
death, unexplained death), might the death per se be reported as an SAE. 
Investigators must also systematically assess the causal relationship of AEs to AGEN2034 using 
the following definitions. Decisive factors for assessment of causal relationship of an AE to 
AGEN2034 include, but may not be limited to, temporal relationship between the AE and AGEN2034, known side effects of AGEN2034, medical history, concomitant medication, course of the underlying disease, and trial procedures. 
Not related:  Not suspected to be reasonably related to AGEN2034. AE could not medically 
(pharmacologically/clinically) be attributed to the AGEN2034 under study in this clinical trial protocol. A reasonable alternative explanation must be available.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 90 of 113 Related:  Suspected to be reasonably related to AGEN2034. AE could medically 
(pharmacologically/clinically) be attributed to the AGEN2034 under study in this clinical 
trial protocol.  
7.1.2. Abnormal Laboratory Findings and Other Abnormal Investigational Findings 
Abnormal laboratory findings and other abnormal investigational findings (e.g., on an ECG 
trace) should not be reported as AEs unless they are associated with clinical signs and symptoms, 
lead to treatment discontinuation, or are considered otherwise medically important by [CONTACT_3170]. If an abnormality fulfills these criteria, the identified medical condition (e.g., 
anemia, increased ALT) must be reported as the AE rather than the abnormal value itself.  
7.1.3. Adverse Drug Reaction  
An ADR is defined in this trial as any AEs suspected to be related to AGEN2034 by [CONTACT_1755]/or Sponsor. 
7.1.4. Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death. 
• Is life -threatening.  
Note:  The term “life -threatening” in this definition refers to an event in which the subject 
is at risk of death at the time of the event; it does not refer to an event that hypothetically 
might cause death if it were more severe.  
• Requires in -patient hospi[INVESTIGATOR_73606] 
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• An overdose of Sponsor's product, as defined in Section  7.5 
• Is otherwise considered as medically important 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_107922], based on appropri ate medical judgement, they 
may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events include allergic bronchospasm requiring intensive treatment in an emerg ency room or at home, blood dyscrasias or convulsions 
that do not result in in subject hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse. 
For purposes of reporting, any suspected transmission of an infectious agent via a study drug is 
also considered a serious adverse reaction, and all such cases should be reported in an expedited manner as described in Section  7.2.2. 
7.1.5. Events That Do Not Meet the Definition of an SAE  
Elective hospi[INVESTIGATOR_391454] (e.g., overnight stay to facilitate chemotherapy and related hydration therapy application) are not 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 91 of 113 considered SAEs. However, all events leading to unplanned hospi[INVESTIGATOR_116891] (e.g., undesirable effects of any administered 
treatment) must be documented and reported as SAEs.  
7.1.6. Events not to be Considered as AEs/SAEs  
Medical conditions present at the initial trial visit that do not worsen in severity or frequency during the trial are defined as baseline medical conditions, and are not to be considered AEs. 
7.1.7. AE/SAEs Observed in Association with Disease Progression  
Disease progression recor ded in the course of efficacy assessments only, but without any adverse 
signs or symptoms, should not be reported as an AE. However, if adverse signs or symptoms 
occur in association with disease progression, these should be recorded as AEs and as SAEs if 
they meet any seriousness criteria.  
7.1.8. Predefined Potential AEs of Special Interest for Safety Monitoring  
Selected non -serious and SAEs defined below are considered AESIs and must be recorded as 
such on the Adverse Event case report forms/worksheets and reported within [ADDRESS_491522] information can be found in the Investigator Trial File Binder (or equivalent). 
Events of clinical interest for this trial include: 
• Infusion-r elated reactions.  
• An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline phos phatase lab value that 
is less than 2X the upper limit of normal, as determined by [CONTACT_13149]- specified 
laboratory testing or unscheduled laboratory testing. 
Note: These criteria are based upon available regulatory guidance documents. The 
purpose of t he criteria is to specify a threshold of abnormal hepatic tests that may 
require an additional evaluation for an underlying etiology. The trial site guidance for assessment and follow up of these criteria can be found in Section  5.6.4. 
• Any AE that is reasonably suspected to be immune- mediated (ie, an irAE).  
AESIs (both non-serious and serious AEs) identified in this guidance document from the date of 
first dose through [ADDRESS_491523] additional testing to rule out other etiologic causes. If lab results or symptoms indicate a possible irAE, then additional testing should be performed to rule out other etiologic causes. If no other cause is found, then it is assumed to be immune- related.  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491524] will be queried on changes in his/her condition. During the reporting period of the trial, any unfavorable changes in the subject’s condition will be r ecorded 
as AEs, whether reported by [CONTACT_280635]. 
Complete, accurate, and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the 
eCRF. Among these AEs, all SAEs and all non-serious AESIs must be additionally documented 
and reported using the appropriate report form as described in Section  7.2.2. 
It is important that each AE report include a description of the event, its duration (onset and 
resolution dates and times to be completed when it is important to assess time of AE onset 
relative to recorded treatment ad ministration time), its severity, causal relationship with trial 
treatment, any other potential causal factors, any treatment administered or other action taken 
(including dose modification or discontinuation of study drug), and outcome. In addition, serious 
cases should be identified and the appropriate seriousness criteria documented. 
Specific guidance can be found in the eCRF Completion and Monitoring Conventions. 
7.2.1. Definition of the Adverse Event Reporting Period  
The AE reporting period for safety surveillance begins when the subject provides written consent 
and continues until either [ADDRESS_491525] dose of study drug or until disease progression and/or initiation of a new line of therapy, whichever comes first. 
Any SAE suspected to be related to trial treatment must be reported whenever it occurs, 
irrespective of time elapsed since last dose of study drug.  
7.2.2. Procedure for Reporting SAEs / AESIs  
All adverse reactions will be reported to the FDA according to 21 Code of Federal Regulations 
(CFR) 312.32 and according to applicable regulatory authorities and institutional ethics 
committees.  
[IP_ADDRESS]. Serious Adverse Events  
In the event of any new SAE (of any Grade) occurring during the reporting period, the 
investigator must immediately (i.e., ≤  24 hours after becoming aware of the event) inform the 
Sponsor or designee by [CONTACT_756], fax, or e- mail. For the following significant SAEs the 
reporting period to the Sponsor is ≤ 8 hours after becoming aware of the event:  
• Drug -related death less than 30 days of dosing 
• Drug-related life -threatening event.  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 93 of 113 When an event (or follow-up information) is reported by [CONTACT_756], a written report must be sent 
immediately thereafter by [CONTACT_3719] e- mail.  
Reporting procedures and timelines are the same for any new information on a previously reported SAE (= follow-up). 
For names, addresses, telephone, and fax numbers for SAE reporting, see information included 
on the SAE report form. 
All written reports should be transmitted using the SAE report form, which must be completed 
by [CONTACT_391494]. The AE section of the eCRF must 
be completed. Relevant pages from the eCRF may be provided in parallel (e.g., medical history, concomitant drugs). 
In all cases, information provided in the SAE report form must be consistent with data on the 
event that is recorded in the corresponding eCRF sections. 
The investigator/reporter must respond to any request for follow-up information (e.g., additional 
information, outcome and final evaluation, specific records where needed) or to any question the 
Sponsor or designee may have regarding the AE within the same timelines as described for initial reports. This is necessary to permit a prompt assessment of the event by [CONTACT_199421] (as applicable) to allow the company to meet strict regulatory timelines associated 
with expedited safety reporting obligations. 
Requests for follow-up will usually be made by [CONTACT_166339], although in exceptional 
circumstances the Sponsor’s global drug safety department may contact [CONTACT_391495] a particularly critical event.  
[IP_ADDRESS]. Adverse Events of Special Interest  
In the event of a non- serious AESI, the investigator must complete the AESI report form and 
send it to the Sponsor/designee immediately, within [ADDRESS_491526] be reported in an expedited manner as SAEs, as outlined above. 
[IP_ADDRESS]. Safety  Reporting  to Health  Authorities,  Independent  Ethics
 Committees/ Institutional Review Boards, and Investigators 
The Sponsor will send appropriate safety notifications to health authorities in accordance with applicable laws and regulations. 
The investigator must comply with any applicable site -specific requirements related to reporting 
of SAEs (and in particular deaths) involving his/her subjects to the IEC/IRB that approved the 
trial. 
In accordance with International Conference on Harmonization Good Clinical Practice ( GCP) 
guidelines, the Sponsor or designee will inform the investigator of “findings that could adversely affect the safety of subjects, impact the conduct of the trial, or alter the IEC’s/IRB’s 
approval/favorable opi[INVESTIGATOR_150831].” In accordanc e with respective regulations, the 
Sponsor or designee will inform the investigator of AEs that are both serious and unexpected, 
and are considered to be related to the administered product (suspected unexpected serious 
adverse reactions [S[LOCATION_003]Rs]). The investigator should place copi[INVESTIGATOR_391455], Inc. C -700-01 Phase 1/[ADDRESS_491527] to safety report notifications to 
investigators will be taken into account.  
When specifically required by [CONTACT_43973], the Sponsor or designee will provide appropriate safety reports directly to the concerned health authority and lead IEC/IRB, and will 
maintain records of these notifications. When direct reporting by [CONTACT_391496] o r site -specific regulations, the investigator will be responsible for 
promptly notifying the concerned IEC/IRB of any safety reports provided by [CONTACT_16015], and for filing copi[INVESTIGATOR_391456]. 
7.3. Mon itoring of Subjects with Adverse Events  
Adverse events are recorded and assessed continuously throughout the trial starting at the time the subject receives his/her first treatment ( Section  7.2.1) and are assessed for final outcome at 
the end -of-treatment visit.  
After the End -of-Treatment Safety Follow -up Visit, only treatment- related AEs will be 
documented through the Treatment Follow-up Period of up to [ADDRESS_491528] dose of study drug or until disease progression and/or initiation of a new line of therapy. 
All SAEs ongoing at the post- treatment safety follow -up visit must be monitored and followed 
by [CONTACT_391497], unless the subject is 
documented as “lost to follow-up.” Reasonable attempts to obtain this information must be made and documented. It is also the 
responsibility of the investigator to ensure that any necessary additional thera peutic measures 
and follow-up procedures are performed. 
7.4. Pregnancy and In Utero Drug Exposure  
Only pregnancies considered by [CONTACT_391498] (e.g., resulting from a drug interaction with a contraceptive medication) are considered as AEs.  
However, all pregnancies with an estimated conception date during the period defined in Section  7.2.[ADDRESS_491529] be recorded by [CONTACT_391499] t he AE page/section of the eCRF.  
The same rule applies to pregnancies in female subjects and in female partners of male subjects. The investigator must notify the Sponsor or designee in an expedited manner of any pregnancy 
using the pregnancy report form, w hich must be transmitted according to the same process as 
described for SAE reporting in Section  7.2.2.  
Investigators must actively follow up, document, and report the outcome of these pregnancies, even if subjects are withdrawn from the trial. A separate consent will be obtained for follow-up 
of these subjects.  
The investigator must notify the Sponsor or designee of these outcomes using the pregnancy 
report form and, in case of abnormal outcome, the SAE report form if the subject sustains an 
event and the parent -child/fetus AE report form when the child/fetus sustains an event). 
Any abnormal outcome must be reported in an expedited manner, as described in Section  7.2.2, 
whereas normal outcomes must be reported within 45 days from delivery. 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491530] be followed as described above. 
7.5. AGEN2034 Overdose  
An overdose is defined as any dose 5% greater than the highest daily dose included in the 
clinical trial protocol. Any overdose must be recorded in the trial medication section of the 
eCRF.  
For monitoring purposes, any case of overdose, whether or not associated with an AE (serious or 
non-serious), must be reported to the Sponsor’s or designated CRO’s global drug safety 
department in an expedited manner using the SAE report form. 
There is no data on AGEN2034 overdose to date. Data available with agents from the same class 
indicate that the correlation between dose and toxicity is relatively flat.  
The investigator should use his or her clinical judgement when treating an overdose of AGEN2034. 
8. STATISTICAL CONSIDERATIONS  
This section outlines the core elements of the planned statistical summaries and analyses for the data collected in this study.  
Detailed methodology for summary and statistical analyses of the data collected in this study will be documented in a Statistical Analysis Plan (SAP), which will be maintained by [CONTACT_1034]. 
The SAP m ay modify the plans outlined in the protocol; however, any major modifications of the 
primary endpoint definition and/or its analysis will also be reflected in a protocol amendment. If, 
after the data are locked, changes are made to the SAP, then these dev iations will be documented 
in the Clinical Study Report (CSR).  
8.1. Sample Size  
The study includes 2 phases: Phase 1: Dose Escalation Phase, and Phase 2: Expansion Phase. The total sample size for both phases is expected to be approximately [ADDRESS_491531] overall response (BOR) of confirmed PR 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 96 of 113 or CR  and reported with 95% Wilson score confidence interval (CI) ; the CI will be interpreted as 
a plausible range for a true (unobserved) ORR. 
Phase 2 is expected to enroll approximately 150 subjects. With 150 subjects  in the final analysis, 
the power to exclude an  ORR of 5% by [CONTACT_391500] 95% Wilson score interval is 
92.2% and 96.2%, assuming a true ORR of 12% and 13%, respectively . The sample size will 
provide ≥ 77% probability to observe an AE with and underlying rate of ≥ 1%. With 100 patients 
in the interim analysis , the power to exclude an ORR of 5% by [CONTACT_391501] -sided 
95% Wilson score interval will be 77.4% and 85.2%, assuming a true ORR of 12% and 13%, 
respectively.  
Historical published data may be used for the interpretation of the clinical significance of the 
study endpoints. 
Interim analys es will be performed  to assess the safety and efficacy (using the ORR and selected 
secondary efficacy endpoints) when (1) data are available for approximately [ADDRESS_491532] 3 months and (2) approximately [ADDRESS_491533] the overall type I error.  A non -binding futility 
analysis may be performed using methods described in the statistical analysis plan. Additional interim analyses for safety and efficacy assessment may performed.   
8.2. Analysis Sets 
The following analysis sets will be defined and used separately for Phase 1 and Phase 2, as applicable:  
• Phase 1 DLT analysis set: All subjects with data used for implementing the confirmation of the safety of the combination. These subjects should have received all 
study treatment administrations in the DLT eva luation period or should have stopped 
treatment because of DLTs in the DLT evaluation period. 
• Safety analysis set: All subjects who have received ≥  1 dose of trial treatment.  
• Pharmacokinetics analysis set: All subjects who have completed ≥  [ADDRESS_491534] provided sufficient concentration measurements. 
• Evaluable efficacy analysis set: All subjects in Phase [ADDRESS_491535] received ≥  [ADDRESS_491536] measurable disease at baseline, according to the IERC 
assessment.  
8.3. Description of Statistical Analyses  
8.3.1. General Considerations  
All data recorded during the study will be presented in individual data listings performed on the safety analysis set. All data will be evaluated as observed, and no imputation method for missing values will be used unless otherwise specified. All data will be presented in a descriptive 
manner. Statistical inference of the primary efficacy endpoint will be performed for the efficacy 
expansion cohort based on the pre- planned significance level.  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491537] deviations, medians, and ranges (min, max). 
Categorical variables will be summarized by [CONTACT_33335]. Unless otherwise specified, calculation of proportions will be based on the number of subjects in the analysis set of interest. 
Counts of missing observations will be included in the denominator and presented as a separate 
category if not otherwise specified in the S AP. 
The DLT analysis set is the underlying dataset for determination of the safety. Safety analyses 
will be performed on the Safety analysis set. Analyses of PK variables will be performed on the 
PK analysis set. The primary analysis of the ORR and other efficacy variables will be based on the evaluable efficacy analysis set, defined as all subjects dosed with study drug who had 
measurable disease at baseline by [CONTACT_391502]. Details of the analysis will be described in the SAP.  
Unless otherwise specifie d, endpoint analyses will be performed separately for Phase 1 and 
Phase 2.  
8.3.2. Analysis of Primary Endpoints 
[IP_ADDRESS]. In Phase  1: Dose- limiting Toxicity  
For determination of safety of AGEN2034, individual subject data from the Phase 1 portion of the trial will be reported. In addition, for final statistical analysis, the following will be summarized: 
• At each dose level, number and proportion of subjects in the DLT analysis set who experience a DLT during the DLT evaluation period. 
• At each dose level, number and proportion of TEAEs experienced by [CONTACT_391503]. 
[IP_ADDRESS]. In Phase 2: Objective Response Rate  
• The primary endpoint for Phase [ADDRESS_491538] 1.1, as 
determined by [CONTACT_391461] . ORR will be estimated as the binomial proportion of patients 
with BOR of PR or CR, taking into account the following requirement for confirmation: for PR or CR, confirmation of the response according to RECIST 1.1 will be required at no sooner than 4 weeks after initial documentation of CR or PR. ORR will be reported with two -sided, 95% Wilson score CI . 
8.3.3. Analysis of Secondary Endpoints  
The following secondary endpoints will be summarized. 
[IP_ADDRESS]. Efficacy Parameters  
Efficacy parameters , including confirmed ORR according to RECIST 1.1, as determined by 
[CONTACT_1697] ; disease control rate (DCR) , defined as proportion of subjects with CR, PR, or SD 
for at least 12 weeks ; duration of response (DOR) according to RECIST 1.1; time to response 
(TTR) ; and duration of stable disease, defined as time from treatment start until documented 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 98 of 113 progression, will be listed and summarized in Phase 2 using both IERC and investigator 
assessments.  
DOR and TTR will be summarized in only a subset of patients with confirmed response using 
the Kaplan -Meier method and displayed graphically, where appropriate. The median event time 
and 95% CI for the median will be provided. Duration of stable disease will also be summarized by [CONTACT_8761] -Meier method.  
In addition, PFS, and OS time will be presented in subject listings, analyzed using Kaplan- Meier 
method and displayed graphically where appropriate. The median event time and 95% CI for the median will be provided. 
[IP_ADDRESS]. Pharmacokinetic Parameters  
Both noncompartmental (NCA) and compartmental modeling (e.g., population PK [PopPK]) techniques will be used to analyze AGEN2034 PK. 
The PK parameters to be estimated and reported may include, but may not be limited to: 
maximum drug concentration observed postdose at steady -state (C
max-ss); minimum observed  
concentration at steady -state (C min-ss); area under the drug  concentration- time curve (AUC) 
within a dosing interval within the time span t1 to t2 at steady -state (AUC (t1-t2)-ss); AUC from 
time of dosing (0 h) to time  t, the time of last observation (calc ulated by [CONTACT_391504]) (AUC 0-t); AUC from time of dosing (0  h) extrapolated to infinity (calculated by 
[CONTACT_391505] C last/λz) (AUC 0-∞); time to 
maximum observed concentration (ie, time at which C max occurs) (t max); terminal disposition rate 
constant, determined from the slope of the regression line of log (concentration) vs. time (λ z); 
terminal elimination half -life, determined as 0.693/ λ z (t½ or HL); systemic clearance (CL); and 
volume of distribution (Vd). 
[IP_ADDRESS]. Immunogenicity  
Antidrug antibody concentrations in correlation with AGEN2034 PK exposure matrix will be summarized.  
[IP_ADDRESS]. Exploratory Biomarkers  
Summary statistics for biomarkers will be provided for all preplanned time points. Changes from baseline for continuous biomarkers may also be presented as applicable and categorical biomarkers will be tabulated.  
Possible relationship of biomarker levels with efficacy may be investigated.  
8.3.4. Safety Analyses 
The extent of exposure to AGEN2034 will be characterized by [CONTACT_24109] (weeks), number of administrations, cumulative dose (mg/kg), dose intensity (mg/kg/week), relative dose intensity (actual dose given/planned dose), number of dose reductions, and number of dose delays. 
Safety analyses will be performed on the safety analysis set. Safety endpoints will be 
summarized by [CONTACT_391506]. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 99 of 113 Safety assessments will be based on incidence of AEs, including AESIs, ADRs, immunogenicity, 
and changes in vital signs (including body weight), ECG, and laboratory values (hematology and 
serum chemistry).  
The on- treatment period is defined as time from first dose of study treatment to last dose of study 
drug plus [ADDRESS_491539]. 
[IP_ADDRESS]. Adverse Events  
Adverse events will be coded according to Medical Dictionary for Regulatory Activities 
(MedDRA) version  21.0. Severity of AEs will be graded using CTCAE (version 4.03) toxicity 
grading scale whenever possible.  
Treatment -emergent AEs are AEs wit h onset dates during the on-treatment period, or the 
worsening of an event during the on- treatment period. Incidence of TEAEs, regardless of 
attribution, and AEs defined as related to AGEN2034 will be summarized by [CONTACT_196209], an d described in terms of severity and relationship to AGEN2034.  
Analysis of AES will be performed for events that are considered as treatment emergent. Adverse events leading to death or discontinuation of trial treatment, events with CTCAE Grade 3 or higher, study drug- related events, and SAEs will be summarized.  
Indications of dose- related ADRs will also be examined.  
[IP_ADDRESS]. Laboratory Variables 
Laboratory results will be classified by [CONTACT_391507]. The worst on- trial 
grades after first trial tre atment will be summarized. Shifts in toxicity grading from first 
treatment to highest grade will be tabulated. Results for variables that are not part of NCI CTCAE will be presented as below, within, or above normal limits. Only subjects with post-baseline laboratory values will be included in these analyses. 
[IP_ADDRESS]. Physical Examination, Vital Signs, and Electrocardiogram 
Physical examination data, vital signs (body temperature, respi[INVESTIGATOR_697], heart rate, and blood pressure), and 12- lead ECG data will be presen ted. 
8.3.5. Interim and Final Analysis  
Phase [ADDRESS_491540] 3 months. The primary analysis of efficacy and safety data will include all 
subjects dosed prior to a borderline date (specified as at least 3 months prior to the data cutoff). 
Another interim analysis will be performed [ADDRESS_491541] approximately 100 subjects dosed. Sensitivity safety analyses 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 100 of 113 will be performed on all subjects in  the s afety analysis set dosed as  of the data cutoff. Details of 
the interim analys es will be provided in a separate SAP. 
Additional interim analyses for safety and efficacy assessment may be performed.  
The f inal analysis will be performed after study completion.  
The primary analysis set for efficacy assessment will be the evaluable e fficacy analysis set. The 
primary analysis set for safety assessment will be the safety analysis set.  
The interim analyses may include PD -1 expression data if available. Details will be provided in a 
separate SAP.  After the interim analyses, subsequent enrollment of subjects may be based on 
biomarker enrichment (includ ing but not limited to PD -L1 expression). In such cases, tumor 
tissue must be positive for th e selected entry biomarker  prior to subject enrollment.  
9. TRIAL GOVERNANCE AND OVERSIGHT 
9.1. Safety Monitoring Committee  
A Safety Monitoring Committee (SMC) will regularly review safety data to ensure subjects’ 
safety throughout the study. 
The SMC will consist of permanent members from the Sponsor and/or CRO: 
• Sponsor: head of development/chief medical officer, pharmacovigilance physician, 
study physician, and Principal Investigator(s). 
• CRO: lead statistician and study physician.  
During the Phase 1 portion of the trial, the SMC asses s safety; decide on dose- escalation and 
opening of backfill enrollment; define the recommended Phase 2 dose (RP2D); and determine opening of the Phase [ADDRESS_491542] been met. The IERC will be 
composed of a minimum of 3 properly qualified members. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 101 of 113 The role of the IERC will be to review radiographic image findings for determination of the t ime 
point for overall response and date of disease progression (per RECIST 1.1) for each subject. 
The full membership, mandate, and processes of the IERC will be detailed in a separate IERC charter.  
9.3. Independent Data Monitoring Committee (IDMC)  
For the Phase [ADDRESS_491543] (e.g., they cannot be trial investigators) and must have no competing interests that could affect their roles with respect to the trial. The IDMC will include 4 oncologists (a minimum of 1 of which is experienced in cervical cance r) and [ADDRESS_491544] safety and the continued ethical integrity of the trial. Also, the IDMC will review interim trial results, consider the overall risk and benefit to trial participants (see Section  8.3.5) and 
recommend to the Sponsor if the trial should continue in accordance with the protocol. 
Speci fic details regarding responsibilities and governance, including the roles and 
responsibilities of the various members and the Sponsor protocol team; meeting facilitation; the 
trial governance structure; and requirements for and proper documentation of IDMC reports, 
minutes, and recommendations will be described in a separate charter that is reviewed and approved by [CONTACT_31849]. The IDMC will monitor the trial at an appropriate frequency, as 
described in the detailed IDMC charter. The IDMC will also make recom mendations to the 
Sponsor protocol team regarding steps to ensure both subject safety and the continued ethical 
integrity of the trial.  
10. ETHICAL AND REGULATORY ASPECTS 
10.1. Ethics Review  
The study protocol, subject information and consent form, Investigator’s Brochures and bridging 
Investigator’s Brochure, any written instructions to be given to the subject, available safety 
information, subject recruitment procedures (e.g., study website), information about payments and compensation available to the subjects and documentation evidencing the investigator’s 
qualifications will be approved by [CONTACT_1201]/EC per local regulations prior to study start. The 
written approval should identify all documents reviewed by [CONTACT_152872]. 
Changes in the conduct of the study or planned analysis will be documented in a protocol 
amendment. The investigator must submit and, where necessary, obtain IRB and/or Sponsor 
approval for all subsequent protocol amendments and changes to the ICF or changes of the investigational site, facilities, or personnel. The investigator should notify the IRB of protocol 
deviations or SAEs occurring at the site and other AE reports received from the Sponsor in 
accordance with local procedures.  
Safety updates for AGEN2034 will be prepared by [CONTACT_171809], for submission to the relevant IRB. 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491545] of the trial at his/her site. He/she will ensure that the 
trial is performed in accordance with the clinic al trial protocol and the approved protocol 
amendments; the current version of the Declaration of Helsinki (Ethical Principles for Medical 
Research Involving Human Subjects), ICH Good Clinical Practice (ICH E6 guideline) as 
adopted by [CONTACT_391508]; and applicable Health Authority requirements and 
national and state laws. In particular, the investigator must ensure that only subjects who have 
given their written informed consent are included into the trial.  
10.3. Subject Information and Informed Consent  
An unconditional prerequisite for a subject’s participation in the trial is his/her written informed 
consent. The subject’s written informed consent to participate in the trial must be given before 
any trial -related activities are carried out. Subjects may also sign a separate, optional section of 
the ICF, related to pharmacogenomics, which refers to extraction and analysis of DNA from 
blood and/or tumor biopsy to better understand how gene(s) may affect the efficacy of 
AGEN2034. 
Adequate i nformation must therefore be given to the subject by [CONTACT_391509]. In addition to providing this written information to a potential subject, the 
investigator will inform the subject verbally of all pertinent aspects of the trial. The language 
used in doing so must be chosen so that the information can be fully and readily understood by [CONTACT_391510]. 
Informed consent will be obtained for participation in the trial and for optional participation in 
pharmacogenomics asses sments. Additionally, should a female subject become pregnant in 
during the study, a separate informed consent for follow-up of the pregnancy will be obtained. 
The ICF must be signed and personally dated by [CONTACT_224092]. The signed and 
dated declaration of informed consent will remain at the investigator’s site, and must be safely 
archived by [CONTACT_391511], 
auditing, and inspection purposes. A copy of the signed and dated information and ICF should be provided to the subject before participation. 
Whenever important new information becomes available that may be relevant to the subject’s 
consent, the written subject information sheet and any other written information provided to subjects will be revised by [CONTACT_391512]/IRB for 
review and favorable opi[INVESTIGATOR_1649]. The agreed upon, revised information will be provided to each 
subject in the trial for signing and dating. The investigator will explain the changes to the previous version. 
10.4. Subject Identification and Privacy  
In compliance with ICH GCP guidelines, it is a requirement that the investigator and institution permit authorized representatives of the Sponsor, regulatory authorities, and IRB direct access to review the subject’s original medical records at the site for verification of trial- related procedures 
and data.  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491546] confidentiality include: only the study number, subject number, subject 
initials, and date of birth will id entify the subject on the electronic case report form (eCRF) or 
other documents submitted to the Sponsor. This information will be used in the database for 
subject identification. Subject names or addresses will not be entered on the eCRF or in the 
databas e. No material bearing a subject’s name [CONTACT_96044] [CONTACT_1034]. Subjects will 
be informed of their rights within the ICF. 
In studies conducted in the [LOCATION_002], confidentiality of subject’s personal data will be 
protected in accordance wit h the Health Insurance Portability and Accountability Act (HIPAA) 
of [ADDRESS_491547] sign an authorization from the trial that he or she has 
been informed of following: 
• What Protected Health Information (PHI) will be collected from subjects in this trial;  
• Who will have access to that information and why; 
• Who will use or disclose that information; 
• That health information may be further disclosed by [CONTACT_1955][INVESTIGATOR_64343], 
and that if the information is disclosed the information may no longer be protected by [CONTACT_96025];  
• The information collected about the research trial will be kept separate from the subject’s medical records, but the subject will be able to obtain the research records after the conclusion of the trial; 
• Whether the authorization contains an expi[INVESTIGATOR_320]; and 
• The rights of a research subject to revoke his or her authorization. 
In the event that a subject revokes authorization to collect or use his or her PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts should 
be made to obtain permission to collect at least vital status (i.e., that the subject is alive) at the end of their scheduled trial period. 
10.5. Emergency Medical Support and Subject Card  
Subjects enrolled in this clinical trial will be provided with emergency medical support cards during their trial participation, which will be furnished by [CONTACT_16015]. The emergency medical support card is based on the need to provide clinical trial subjects with a way 
of identifying themselves as participating in a clinical trial, and subsequently give health care 
providers access to information about this participation that may be needed to determine the 
course of the subject’s medical treatment.  
This service is designed t o provide information to health care providers who are not part of the 
clinical trial. Clinical trial investigators, who are already aware of the clinical trial protocol and treatment, have other means of accessing the necessary medical information for man agement of 
emergencies occurring in their subjects.  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491548] for this purpose. If the investigator is available when an event occurs, he/she will answer any questions. Any subsequent action will follow the standard processes established for the investigators.  
In cases in which the investigator is not available, the site will provide the appropriate means to 
contact a physician. This includes provision of a 24-hour contact [CONTACT_391513], whereby 
[CONTACT_391514] . 
10.6. Clinical Trial Insurance and Compensation to Subjects  
Insurance coverage shall be provided for each country participating to the trial. Insurance conditions shall meet good local standards, as applicable. 
10.7. Health Authorities  
The clinical trial protocol an d any applicable documentation (e.g., investigational medicinal 
product dossier, subject information, and ICF) will be submitted or notified to health authorities by [CONTACT_391515].  
11. TRIAL MANAGEMENT  
11.1. Sponsor and Trial Administrative Structure  
The Sponsor of this study is Agenus Inc. 
In countries where a local sponsor is required a qualified local legal Sponsor will be designated 
by [CONTACT_391516], and will act as the legal Sponsor for the study, and will fulfil the obligations that this 
role entails. In these cases, the local legal Sponsor shall, to the extent required by [CONTACT_122833], interact with regulatory and health authorities on behalf of the Sponsor in connection with this study. 
Details of logistical and administrative structures and associated procedures will be defined in a 
separate manual of operations, which will be prepared by [CONTACT_85328]. 
11.2. Investigational Sites  
The trial will be global, with approximately 10 to 15 enrolling centers participating in Phase 1 
and approximately 60 centers in Phase 2. 
11.3. Trial Coordination/Monitoring  
The Sponsor will coordinate the trial and may delegate certain trial activities to CROs, including  
certain laboratory assessments, safety reporting, biostatistics, etc. The Sponsor’s clinical operations department will oversee activities performed by [CONTACT_23761].  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 105 of 113 11.4. Data Collection  
The eCRF is the primary data collection instrument for the trial. The clinical site will keep 
eCRFs current to enable the monitor to review the subjects’ status throughout the course of the 
trial. To maintain confidentiality, only the study number, subject number, subject initials, and date of birth will identify the subject on the eCR F. All data requested on the eCRF must be 
supported by [CONTACT_391517]’s source documentation. 
Source documents are the original documents, data, records and certified copi[INVESTIGATOR_1930], observations and act ivities from which the subject’s eCRF data are 
obtained. These can include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory, medico- technical department and pharmacy records, diaries, microfiches, ECG 
traces, copi[INVESTIGATOR_10379], photographic negatives, microfilm or magnetic media, X-rays, and correspondence. 
All missing data must be explained. When a required laboratory test, assessment, or evaluation 
has not been done or an “Unknown” box is not an option on the eCRF, a note should be created 
verifying that the field was “Not Done” or “Unknown”. For any entry errors made, the error(s) 
must be corrected, and a note explaining the reason for change should be provided. 
The investigator will sign and date the subject eCRF casebook indicating that the data on the 
eCRF have been assessed. Each completed eCRF will be electronically signed and dated by [CONTACT_1600], once all data for that subject is final.  
11.5. Investigator Site F ile and Archiving 
The investigator will be provided with an investigator site file upon initiation of the trial. This file will contain all documents necessary for the conduct of the trial and will be updated by [CONTACT_391518]. It must be av ailable for review by [CONTACT_2037]; be ready for Sponsor 
audit as well as for inspection by [CONTACT_391519]; and safely archived 
for ≥  15 years (or per local requirements or as otherwise notified by [CONTACT_1034]) after the end o f 
the trial. Documents to be thus archived include the subject identification list and signed subject ICFs. If archiving of the investigator site file is no longer possible at the site, the investigator must notify the Sponsor. 
All original subject files (medical records) must be stored at the site (hospi[INVESTIGATOR_307], research institute, 
or practice) for the longest possible time permitted by [CONTACT_5279], and/or as per ICH GCP guidelines, whichever is longer. In any case, the investigator should ensure that no destruction of medical records is performed without the Sponsor’s written approval. 
11.6. Monitoring, Quality Assurance and Inspection by [CONTACT_391520] (ICH E6). The site monitor will visit the trial site at regular intervals.  
Representatives of the Sponsor’s quality assurance unit or a designated organization, as well as health authorities, must be permitted to inspect all trial- related docu ments and other materials at 
the site, including investigator site file, completed eCRFs, ICFs, and the subjects’ original medical records/files.  
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491549] to independent quality assurance activities. Audits may be conducted 
at any time during or after the trial to ensure the validity and integrity of trial data.  
11.7. Publication Policy  
11.7.1. Clinical Trial Report  
After completion of the trial, a clinical trial report according to ICH E3 guideline will be written 
by [CONTACT_391521]. 
11.7.2. Publications  
All information provided regarding the trial, as well as all information collected/documented 
during the course of the trial, will be regarded as confidential. The Sponsor reserves the right to 
release literature publications based on the results of the trial. Results from the trial will be 
published/presented as per the Sponsor’s publication strategy. 
Inclusion of the Investigator in the authorship of any multi-center publication will be based upon 
substantial contribution to the design, analysis, interpretation of data, drafting and/or critically 
revising any manuscript(s) derived from the trial. The investigator acknowledges that the trial is part of a multi-center trial and agrees that any publication by [CONTACT_391522]/her research site shall not be made before the first multi-center publication. 
In the event, there is no multi-center publication within [ADDRESS_491550] or other 
written or oral material that describes  the results of the trial for the purpose only of determining 
if any confidential or patentable information is disclosed thereby. If the Sponsor requests in 
writing, the investigator shall withhold any publication or presentation an additional 60 days solely to permit the Sponsor to seek patent protection. 
 
 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 107 of 113 12. REFERENCES  
Allie SR, Zhang W, Fuse S, Usherwood EJ. 2011. Programmed death 1 regulates development of 
central memory CD8 T cells after acute viral infection. J Immunol 186(11):6280–6286. 
Amin MB, Edge S, Greene F, et al, eds. 2017. AJCC Cancer Staging Manual . 8th ed. Springer 
International Publishing: American Joint Commission on Cancer. 
Barber DL, Wherry EJ, Masopust D, et al. 2006. Restoring function in exhausted CD8 T cells 
during chronic viral infection. Nature. 439(7077):682–687. 
Borcoman E, Le Tourneau C. 2017. Pembrolizumab in cervical cancer: latest evidence and 
clinical usefulness. Ther Adv Med Oncol. 9(6):431–439. 
Boutros C, Tarhini A, Routier E, et al. 2016. Safety profiles of anti- CTLA -4 and anti- PD-1 
antibodies alone and in combination. Nat Rev Clin Oncol. 13(8):473–486. Opdivo
® (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 
September 2015. 
Opdivo® (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 
December 2017.  
Buchbinder EI, Desai A. 2016. CTLA-4 and PD- 1 pathways: Similarities, differences, and 
implications of their inhibition. Am J Clin Oncol. 39(1):98–106. 
Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP- 2 associate with 
immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell 
stimulation, but only receptor ligation prevents T cell activation. J Immunol. 173(2):945–954. 
Chung HC, Schellens JHM, Delord JP, et al. 2018. Pembrolizumab treatment of advanced 
cervical cancer: Updated results from the phase 2 KEYNOTE -158 study. [ASCO abstract 5522]. 
J Clin Oncol. 36([ADDRESS_491551]):5522. 
Disis ML. 2010. Immune regulation of cancer. J Clin Oncol. 28(29):4531– 4538. 
Drescher C, Moore KN, Liu J, et al. Phase 1/2, open- label, multiple ascending dose trial of 
AGEN2034, an anti–PD -1 monoclonal antibody, in advanced solid malignancies: Results of dose 
escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical 
cancer. Poster presented at European Society for Medical Oncology (ESMO); October 19 -23, 
2018; Munich, [LOCATION_013]. Poster 1158P. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. 2009. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228–247. 
Food and Drug Administration. 2018. FDA approves pembrolizumab for advanced cervical 
cancer with disease progression during or after chemotherapy. 
https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm610572.htm . Accessed 
14 January 2019. 
Frazier KS, Engelhardt JA, Fant P, et al. 2015. Scientific and Regulatory Poli cy Committee 
Points- to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule 
Therapeutics in Preclinical Development: Part I. Biotherapeutics. Toxicol Pathol. 43(7):915–934. 
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 108 of 113 Frenel JS, Le Tourneau C, O'Neil BH, et al., 2016. Pembrolizumab in patients with advanced 
cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE -028 study 
[ASCO abstract  5515]. J Clin Oncol. 34([ADDRESS_491552]):5515. 
Hollebecque A, Meyer T, Moore KN, et al. 2017. An open-label, multicohort, phas e I/II study of 
nivolumab in patients with virus- associated tumors (CheckMate 358): Efficacy and safety in 
recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers [ASCO abstract  5504]. J Clin 
Oncol. 35([ADDRESS_491553]):5504. 
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. 2017. Current diagnosis and 
management of immune related adverse events (irAEs) induced by [CONTACT_391523]. Front Pharmacol. 8:49. 
Latchman Y, Wood CR, Chernova T, et al. 2001. PD- L2 is a second ligan d for PD -1 and inhibits 
T cell activation. Nat Immunol. 2(3):261–268. 
Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. 2015. Enhanced expression of PD L1 in 
cervical intraepi[INVESTIGATOR_391457]. Mod Pathol. 28(12):1594–1602. 
National Comp rehensive Cancer Network. 2016. NCCN Clinical Practice Guidelines in 
Oncology: Cervical Cancer. Version 1.2017. Oken MM, Creech RH, Tormey DC, et al. 1982. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 5(6):649–655. 
Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. 2017. Combination 
immunotherapy: A road map. J Immunother Cancer. 5:16. 
Ponce R, Abad L, Amaravadi L, et al., 2009. Immunogenicity of biologically-derived 
therapeutics: Assessment and interpretati on of nonclinical safety studies. Regul Toxicol 
Pharmacol. 54(2):164–182. 
Postow MA, Callahan MK, Wolchok JD. 2015. Immune checkpoint blockade in cancer therapy. 
J Clin Oncol. 33(17):1974–1982. 
Reagan -Steiner S, Yankey D, Jeyarajah J, et al. 2016. National , Regional, State, and Selected 
Local Area Vaccination Coverage Among Adolescents Aged 13 –17 Years — [LOCATION_002], 
2015. MMWR Morb Mortal Wkly Rep. 65:850–858. Reddy OL, Shintaku PI, Moatamed NA. 2017. Programmed death-ligand 1 (PD- L1) is expressed 
in a s ignificant number of the uterine cervical carcinomas. Diagn Pathol. 12(1):45. 
Rojko JL, Evans MG, Price SA, et al. 2014. Formation, clearance, deposition, pathogenicity, and 
identification of biopharmaceutical- related immune complexes: review and case stud ies. Toxicol 
Pathol. 42(4):725–764. 
Schumacher TN, Schreiber RD. 2015. Neoantigens in cancer immunotherapy. Science. 
348(6230):69–74. 
Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science. 348(6230):56–
61. 
Siegel RL, Miller KD, Jemal A. 2017. Cancer Statistics, 2017. CA Cancer J Clin. 67(1):7–30. 
Agenus, Inc. C -700-01 Phase 1/[ADDRESS_491554]. 2014. Improved survival with bevacizumab in advanced 
cervical cancer. N Engl J Med. 370(8):734–743. 
Topalian SL, Drake CG, Pardoll DM. 2015. Immune checkpoint blockade: A common 
denominator approach to cancer therapy. Cancer Cell. 27(4):450–461. 
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 
2012. CA Cancer J Clin. 65(2):87–108. 
US Department of Health an d Human Services, Food and Drug Administration. 2005. Guidance 
for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy Volunteers. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov- drugs -gen/documents/document/ucm078932.pdf . Accessed 13 Jan 2019. 
US Department of Health and Human Services, Food and Drug Administration. 2010. Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals. https://www.fda.gov/downloads/Drugs/Guidances/ucm085389.pdf . Accessed 13 Jan 2019. 
Weber JS, Kähler KC, Haus child A. 2012. Management of immune- related adverse events and 
kinetics of response with ipi[INVESTIGATOR_125]. J Clin Oncol. 30(21):2691–2697. 
Yang W, Song Y, Lu YL, Sun JZ, Wang HW. 2013. Increased expression of programmed death 
(PD)-1 and its ligand PD- L1 correlat es with impaired cell -mediated immunity in high -risk 
human papi[INVESTIGATOR_28597]-related cervical intraepi[INVESTIGATOR_28601]. Immunology. 139(4):513–522. 
Yokosuka T, Takamatsu M, Kobayashi- Imanishi W, Hashimoto -Tane A, Azuma M, Saito T. 
2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit 
T cell receptor signaling by [CONTACT_391524]2. J Exp Med. 209(6):1201–1217. 
Zha YY, Blank C, Gajewski TF. 2004. Negative regulation of T- cell function by [CONTACT_4002] -1. Crit Rev 
Immunol. 24(4):229–237. 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 110 of 113 APPENDIX 1. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE SCALE  
ECOG  Performance  Status  
Grade  Description  
0 Fully  active, able to carry  on all pre-disease  performance  without  restriction.  
1 Restricted  in physically  strenuous  activity  but ambulatory  and able to carry out work  of a light or 
sedentary  nature,  e.g., light house  work,  office  work.  
2 Ambulatory  and capable  of all self-care but unable  to carry out any work  activities. Up and about  
>50%  of waking hours.  
3 Capable  of only limited  self-care,  confined  to bed or chair  >50%  of waking hours.  
4 Completely  disabled.  Cannot  carry  on any self-care.  Totally  confined  to bed or chair.  
5 Dead.  
Source:  Oken MM, Creech RH, Tormey DC, et al. 1982. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol. 5(6):649– 655. 
  
Agenus, Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 111 of 113 APPENDIX 2. SIGNATURE [CONTACT_391528], Inc. C -700-01 Phase 1/2 Trial of AGEN2034 in Advanced Tumors  
Amendment 5, 27 September 2019  
Confidential  Page 113 of 113 Signature [CONTACT_3490] – Principal Investigator 
[CONTACT_1641]  A Phase 1 / 2, Open -Label, Multiple  Ascending Dose  Trial to 
Investigate the Safety,  Tolerability,  Pharmacokinetics,  
Biological, and Clinical Activity  of AGEN2034 in Subjects  
with Metastatic  or Locally  Advanced  Solid  Tumors,  with  
Expansion to Second Line Cervical Cancer  
Clinical  Trial  Version  / Date  Version  6.0, [ADDRESS_491555] of the trial at this site and affirm that: 
• I understand and will conduct the trial according to the clinical trial protocol, and the 
approved protocol amendments; the current version of the Declaration of Helsinki Ethical 
Principles for Medical Research Involving Human Subjects), ICH Good Clinical Pr actice 
(ICH E6 guideline) as adopted by [CONTACT_391525].  
• I will not deviate from the clinical trial protocol without prior written permission from the Sponsor, and prior review and written approval f rom the Institutional Review Board or 
Independent Ethics Committee, except where necessary to prevent immediate danger to the subject.  
I understand that some regulatory health authorities require the Sponsors of clinical trials to obtain and 
supply, when r equired, details about the investigators’ ownership interests in the Sponsor or 
investigational medicinal product and information regarding any financial ties with the Sponsor. The 
Sponsor will use any such information that is collected solely for the purpose of complying with the 
regulatory requirements. I therefore agree to supply the Sponsor with any necessary information regarding 
ownership interest and financial ties (including those of my spouse and dependent children), and to provide updates as necessary.  
 
   
Signature   [CONTACT_391529], academic degree   
Position (job title)   
Institution   
Address   
Telephone number   
E-mail address   
 